Evaluation of the therapeutic potential of red clover extract and red grape seed extract on human adult malignant brain tumours in vitro by Lall, Satinder
i | P a g e  
 
 
 
 
Evaluation of the Therapeutic Potential of 
Red Clover Extract and Red Grape Seed Extract 
on Human Adult Malignant Brain Tumours 
In Vitro 
 
 
 
 
 
 
 
 
A thesis submitted by 
 
Satinder K Lall BSc MSc 
 
In partial fulfilment of the requirements of Middlesex University  
for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Middlesex University 
The Burroughs 
London 
NW4 4BT 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
For My Nanaji  
Harbhajan Singh Panesar 
 
 
i | P a g e  
 
Abstract 
Gliomas are rare intrinsic brain tumours which account for 2% of all cancers. 
Glioblastoma multiforme is the most malignant malignant glioma form and 
remains incurable. The biological features which preclude successful therapy 
include heterogeneity, diffuse invasive patterns and angiogenesis. Despite, 
advances in current conventional treatments the median survival time is only 
14 months. Hence there is a need to investigate novel therapeutic approaches 
which can be included alongside conventional treatment. One such approach 
is the use of micronutrients in the management of glioblastoma multiforme. 
This study evaluated the affects of two micronutrient extracts, red clover 
extract (RCE) and red grape seed extract (RGSE), on human adult malignant 
brain tumours in vitro.  
Four primary (or short-term) cell cultures derived from human brain tumour 
biopsies, an established cell line and normal human brain cells from an 
epileptic pateint were used to measure the cell viability, anti-invasive, anti-
angiogenic and pro-apoptotic potentials, following 48-hour treatment with the 
IC50s of either micronutrient extract.   
Both RCE and RGSE exhibited similar affects on the glioma cell cultures. 
They both appeared to reduce cell viability, invasive potential and 
angiogenesis potential though did not appear to have any significant affect on 
the apoptotic portential of the glioma cultures. For example, incubation with 
0.007-1ug/ml RCE caused a significant (p<0.05) reduction of in viability of 
glioma cells but did not affect viability of normal astrocytes. Similar results 
were obtained for RGSE. These doses also resulted in a significant decrease 
in invasion and angiogenesis (p<0.05). Effects varied between cell lines but in 
general decreased by 50-60%. 
This suggests that both RCE and RGSE do affect the development of glioma 
cell cultures in vitro and warrant further study into the pathways in which this 
may occur. 
 
 
ii | P a g e  
 
Acknowledgements 
 
First and foremost, I would like to thank all my family, in particular, my late 
Nanaji and my mum and dad, for believing in me, standing by me and 
encouraging me even when times were hard.  
I’d like to thank the following people for their patience, support, help and 
contributions: Manika Choudary and Darshana Yagnik for their friendship, 
support and encouragement. Dr Frank Hills for his time and consideration in 
helping finalise this thesis. Dr Celia Bell for her continuous support and 
positive supervision. I am grateful for the time and effort she has put into my 
supervision. Dr Bali Rooprai for giving me the opportunity to partake in this 
study and her supervision throughout. Professor Ray Iles for his 
encouragement, positive words and help with statistical analysis. Miss Noor 
Azela Thani for looking after my cell cultures when I was away and helping 
me with population doubling times. Miss Sukveer Purewal and Mr Derek 
Davis (Cancer research UK) for allowing me to use the flow cytometer and 
helping me with analysis. I especially appreciate the time and patience 
Sukhveer provided enthusiastically. Mr Richard Selway and Mr K Askhan and 
the Department of Neurosurgy, at King’s College Hospital for providing the 
biopsies. Professor Geoff Pilkington for his input into the microenvironmental 
studies.  
And finally, I would like to thank my husband Mr Jatinder Lall without whose 
support, patience, love and trust I couldn’t have gotten this far. 
iii | P a g e  
 
Contents 
ABSTRACT ...................................................................................... I 
ACKNOWLEDGEMENTS .................................................................. II 
CONTENTS .................................................................................... III 
LIST OF FIGURES ............................................................................ V 
LIST OF TABLES ........................................................................... VIII 
LIST OF ABBREVIATIONS ................................................................ X 
THESIS ........................................................................................... 1 
CHAPTER 1: INTRODUCTION .......................................................... 1 
1.1 EPIDEMIOLOGY OF BRAIN TUMOURS .......................................... 1 
1.2 AETIOLOGY OF BRAIN TUMOURS ............................................... 3 
1.3 CLASSIFICATION OF GLIOMAS ................................................... 7 
1.4 GLIOMAS .............................................................................. 2 
1.5 CLINICAL PRESENTATION OF GLIOMAS ........................................ 7 
1.6 DIAGNOSIS AND CLASSIFICATION OF GLIOMAS ............................. 9 
1.7 BIOLOGICAL FEATURES EVADING TREATMENT ............................ 13 
1.8 APOPTOSIS ......................................................................... 25 
1.9 CONVENTIONAL TREATMENT .................................................. 29 
1.10 CONVENTIONAL MEDICINE CLINICAL TRIALS. ........................... 35 
1.11 REQUIREMENTS OF NEW THERAPIES ...................................... 37 
1.12 USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE............ 37 
1.13 PHYTOCHEMICALS AND CANCER ............................................ 40 
1.14 CAM: A THEARPY FOR GLIOMAS .......................................... 41 
1.15 EVALUATION OF MICRONUTRIENTS IN GLIOMA THERAPY ........... 43 
1.16 RED CLOVER EXTRACT ......................................................... 43 
1.17 RED GRAPE SEED EXTRACT ................................................... 46 
iv | P a g e  
 
1.18 AIMS ............................................................................... 49 
1.19 AN OVERVIEW OF THE THESIS ............................................... 50 
CHAPTER 2: MATERIALS AND METHODS ...................................... 51 
2.1 SOURCE OF CELL CULTURES .................................................... 51 
2.2 MICRONUTRIENTS ................................................................ 52 
2.3 CELL CULTURE TECHNIQUES ................................................... 53 
2.4 CELL VIABILITY TECHNIQUES ................................................... 55 
2.5 CHARCTERISATION OF ASTROCYTIC CELL CULTURES ..................... 57 
2.6 INVASION ASSAYS................................................................. 59 
2.7 DETECTION OF APOPTOSIS ..................................................... 60 
2.8 DETECTION OF ANGIOGENESIS ................................................ 61 
2.9 STATISTICS .......................................................................... 63 
CHAPTER 3: MICROENVIRONMENTAL CHANGES OF GROWTH 
SERA ............................................................................................ 64 
3.1 INTRODUCTION .................................................................... 64 
3.2 MATERIALS AND METHODS .................................................... 68 
3.3 RESULTS ............................................................................. 70 
3.4 DISCUSSION ........................................................................ 77 
3.5 CONCLUSION ....................................................................... 80 
4.3 THE EFFECT OF MICRONUTRIENT EXTRACTS ON CELL VIABILITY ..... 85 
CONCLUSION ............................................................................. 147 
REFERNCES ................................................................................ 148 
REFERENCES .............................................................................. 149 
APPENDIX .................................................................................. 226 
HPLC RED CLOVER EXTRACT ....................................................... 227 
RED GRAPE SEED EXTRACT ......................................................... 227 
v | P a g e  
 
List of Figures 
Figure 1 The approximate percentage incidence of various 
cancers in 2010 ........................................................................................ 1 
 
Figure 2 The incidence of brain tumours over the average adult 
lifespan, in the UK, ................................................................................... 2 
 
Figure 3 Differentiation of progenitor cells in the neural tube .......... 6 
 
Figure 4 Phase contrast micrograph of an anaplastic astrocytoma 
(III) ............................................................................................................ 14 
 
Figure 5 Apoptosis initiation pathways both extrinsic and intrinsic 
including caspases involved................................................................. 28 
 
Figure 6 The isoflavonoids of Red Clover Extract. .......................... 44 
 
Figure 7 The isoflavonoids of Red Grape Seed Extract. ................ 48 
 
Figure 8 MTT structure. ........................................................................ 56 
 
Figure 9 Illustration how coverslips were seeded with both 
HUVECs and brain tumour cells. ......................................................... 62 
 
Figure 10 Phase contrast micrographs of the IPSB-18 cell line 
when cultured in the presence of (a) FCS (b) NCS and (c) HS.. ... 71 
 
Figure 11 Micrographs of the changes in antigenic expression of 
Gal C (red) and GFAP (green) ............................................................. 73 
 
Figure 12 Phase contrast micrographs of the cell lines involved in 
this study including. ............................................................................... 82 
 
Figure 13 Population doubling time of glioma cell lines ................. 84 
 
Figure 14 The mean cell viability of IPSB-18 l . ............................... 86 
 
Figure 15 The mean cell viability of IPSB-18. .................................. 87 
 
Figure 16 Mean percentage viability of MUAB-C ............................ 90 
 
vi | P a g e  
 
Figure 17 Mean percentage viability of IPSB-18 using RCE ......... 91 
 
Figure 18 Mean percentage viability of IPSB-18 using RGSE ...... 92 
 
Figure 19 Absorption spectra of three concentrations read at 
570nm ...................................................................................................... 94 
 
Figure 20 Cell viability of glioma cell cultures .................................. 95 
 
Figure 21 Scatter plot illustrating the cell viability of IPSB-18) ...... 96 
 
Figure 22 Mean percentage cell viability ........................................... 97 
 
Figure 23 Cell viability of glioma cell cultures when treated for 48 
hours with red grape seed extract. ...................................................... 99 
 
Figure 24 Mean percentage cell viability of IPSB-18 following 48 
hr treatment with RGSE. ..................................................................... 100 
 
Figure 25 Mean percentage viability of (a) MUMG-GM, (b) MUIH-
GM (c) MUTC-GM and (d) MUPK-GM. ............................................ 101 
 
Figure 26 Representative plots of the percentage of fluorescent 
cells. ....................................................................................................... 104 
 
Figure 27 Representative micrographs of the expression of (a) 
GFAP, (b) CD44, (c) Eric-1 NCAM, (d) 1 integrin and (e) v 
integrin ................................................................................................... 107 
 
Figure 28 Representative micrographs of the invasive potential of 
GBs ......................................................................................................... 109 
 
Figure 29 The mean number (three repetitions) of MUAB-C control 
cells which have invaded across the ECM in the Boyden chamber.
 ................................................................................................................ 110 
 
Figure 30 The mean number (three repetitions) of glioma cells 
invading across the ECM of the Boyden chamber following 48 hour 
treatment with RCE .............................................................................. 110 
 
Figure 31 The mean number (three repetitions) of glioma cells 
invading across the ECM of the Boyden chamber following 48 hour 
treatment with RGSE, .......................................................................... 111 
 
vii | P a g e  
 
Figure 32 Apoptosis in the IPSB-18 glioma cell culture ............... 112 
 
Figure 33 Micrographs representing apoptosis following the 
TUNEL assay ........................................................................................ 115 
 
Figure 34 Micrograph representing apoptosis using the TUNEL 
assay in untreated MUAB-C control cells ........................................ 116 
 
Figure 35 The average numbers of tubules formed by HUVEC 
cells. ....................................................................................................... 118 
 
Figure 36 Representative micrographs illustrating tubule 
development of HUVEC cells  ........................................................... 119 
 
Figure 37  The average number of tubules counted ..................... 120 
 
Figure 38 Growth Curve..................................................................... 126 
 
Figure 39 The expression of 3 integrin in a) normal brain tissue 
and b) glioma cultures.. ....................................................................... 142 
 
viii | P a g e  
 
List of Tables 
Table 1 Who classification of gliomas adapted from Louis 2007 .... 1 
 
Table 2 Symptoms that can be caused by tumours .......................... 8 
 
Table 3 Some stimulants and inhibitors of angiognenesis. ............ 22 
 
Table 4 A brief summary of the top 10 clinical trials ........................ 36 
 
Table 5 A brief summary of a fraction of clinical trials currently 
being performed for the use of CAM therapy in 2016. ..................... 42 
 
Table 6 Four biopsy-derived malignant cell lines and 1 normal 
astrocytic culture .................................................................................... 51 
 
Table 7 Primary antibodies were used to characterise cell 
cultures.. .................................................................................................. 58 
 
Table 8 Primary antibodies used to characterise cell cultures. ..... 59 
 
Table 9 Summary of the cell cultures used as part of this study 
including the source ............................................................................... 68 
 
Table 10 Primary antibodies used to characterise cell cultures. An 
illustration of the dilutions used and the host species the antibody 
was cultured in........................................................................................ 69 
 
Table 11 Summary population doubling times (PDTs) of the cell 
cultures in this study .............................................................................. 72 
 
Table 12 Summary of the immunocytochemical results ................. 74 
 
Table 13 Summary of the significant difference between the 
median flow cytometry results ............................................................. 76 
 
Table 14 Similarities and differences in three different sera; foetal 
calf serum, newborn calf serum and human serum ......................... 78 
 
Table 15 Population doubling times (PDT) of glioma cell lines and 
the control cell line (MUAB-C) ............................................................. 83 
 
Table 16 Summary of the IC50 of RCE with various cell cultures. . 98 
ix | P a g e  
 
Table 17 Summary of the IC50 of RGSE for various cell cultures 
 ................................................................................................................ 102 
 
Table 18 Mean antigenic expression  .............................................. 105 
Table 19 Antigenic expression in glioma cell lines incubated with 
the respective IC50 of either RCE or RGSE for 48 hours,). ........... 108 
 
Table 20 Summary of the percentage of live, apoptotic and 
necrotic cells. ........................................................................................ 113 
 
Table 21 Mean number of fluorescent cells counted ..................... 117 
 
Table 22 Summary of population doubling times ........................... 127 
 
Table 23 Summary of the IC50s of the micronutrients using various 
cell cultures including primary cultures set up from biopsies, an 
existing low passage cell line. ............................................................ 130 
 
x | P a g e  
 
List of Abbreviations 
 
 
CAM Complementary and alternative medicine 
CD44 Cluster of differentiation 44 
CNS Central nervous system 
DMEM Dulbecco’s modified Eagle’s medium 
ECM Extra celluar matrix 
FCS Foetal calf serum 
GalC Galactocerebroside 
GB Glioblastoma multiforme 
GD3 Ganglioside 
GFAP Glial fibrillary acidic protein 
HS Human serum 
MMP Matrix metalloproteinases 
NCAM Neural cell adhesion molecules 
NCS Newborn calf serum 
NG2 Neural Glial 2 
RCE Red clover extract 
RGSE Red grape seed extract 
  
 
 
 
 
 
 
THESIS 
 
1 | P a g e  
 
CHAPTER 1: Introduction 
1.1 Epidemiology of Brain Tumours 
 
Intrinsic brain tumours account for only 3% of all adult cancers with an 
incidence of approximately 14-15 per 100,000, in each gender. They are rare 
when compared to other somatic cancers such as lung cancer, which is 
almost 11 times more prevalent. However, in the UK alone, 9,365 new 
patients were diagnosed with this fatal disease in 2011 (Fig 1) (Office for 
National Statistics 2012, ISD Scotland 2014, Welsh Cancer Intelligence and 
Surveillance Unit 2014, Northern Ireland Cancer Registry 2012, Cancer 
Research UK 2014) with this number rising each year. 
 
Figure 1 The approximate percentage incidence of various cancers in 2010 including 
the low incidence of brain and CNS tumours. Adapted from cancer research UK 
website (2014) 
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Over the past three decades the incidence in developed countries has rapidly 
risen increasing by between 35% - 45% (Inskip 2010; Hoffman 2006 p27; 
Pilkington 2001 p408; Radhakrishnan 1995 p 67). This is probably due to a 
number of factors including, improved diagnostic and imaging techniques, 
better documentation of diagnosis, environmental factors and an increasingly 
elderly population. Differences in incidence can also be seen across ages, 
gender and ethnic groups in developed countries.  
 
An advanced age positively correlates with a greater risk of being diagnosed 
with a brain tumour (Fig 2). The incidence peaks between six decades of life. 
Beyond this point both the incidence and rate decline, either due to lack of 
investigation and detection of neoplasms in the elderly (McKinney 2004, p12), 
alternatively due to a number of other mortality factors encountered by this 
population. 
 
 
Figure 2 The incidence of brain tumours over the average adult lifespan, in the UK, 
and the rate per 100,000 capita in males and females between 2008 and 2011. 
Adapted from Cancer Research UK website (2014) 
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Figure 2 also illustrates a general male predilection, most significantly beyond 
the fifth decade. Gliomas in particular have a male: female ratio of 1.5:1.0. 
Although this is not representative of the greater tendency of females to be 
diagnosed with meningiomas, it has been suggested that this inclination could 
be a result of socio-economic factors such as occupation (McKinney 2004, 
p12).  
 
As well as a gender partiality, Caucasians have an increased risk of being 
diagnosed with brain tumours compared to Asian or African origins, in the 
same country. Glaser et al. (1996) demonstrated that non-Hispanic whites, in 
the San Francisco Bay Area have a higher frequency of brain malignancies 
than white Hispanics, Japanese, African Americans, Chinese, and Filipinos. 
This data is mimicked when examining global incidences with American 
Indians and Asians being the groups with the lowest risk between 2002 and 
2006 (National Center for Health Statistics). Unfortunately, unlike ethnicity, 
global differences are usually cautiously interpreted, as around, a four-fold 
difference is observed in incidence of malignant brain tumours when 
comparing countries with high incidences such as Australia, Canada, 
Denmark, Finland, New Zealand and the US to countries with a low incidence 
such as the Philippines and India. This difference is probably due to 
inconsistancies in registration and criteria for diagnosis but also too many 
socio-economic factors which result in brain tumours being undiagnosed in 
many patients (Lo 2012; Wiemels 2010, p308; Schwartzbaum 2006, p501).  
1.2 Aetiology of Brain Tumours 
 
Despite improvements in diagnosis and registration, to date, the causes of 
brain tumours remain unknown. Speculation and the current school of thought 
suggests that brain tumour development results from an accumulation of 
genetic alterations which occur as a result of physical, chemical and/or 
biological damage. (McKinney 2004, p14). Very little is known about the 
genetic risk factors for brain tumours, though this may be attributed to the few 
factors identified within this field (Reilly 2009, p2). Of the identified inherited 
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syndromes, brain tumours are associated with several familial cancer 
predispositions including Li-Fraumeni, neurofibromatosis type 1 and 2, 
tuberous sclerosis, and syndromes involving adenomatous polyps lead to a 
genetic predisposition to the occurrence of brain tumours.  This development 
only accounts for around 1-2% of brain tumours. Other genetic abnormalities 
thought to be associated with the development of brain tumours involve 
mutations of genes associated with basic cellular metabolic pathways for 
example pathways involved in DNA repair and stability, immune responses, 
oxidation and detoxification. Published data into the risk associated with 
genetic mutations is very limited and further study is required to identify any 
specific polymorphisms related to brain tumour growth.  
 
This however is not considered the sole causative agent and in addition a 
number of other environmental risk factors are being investigated including 
ionising radiation, extremely low frequency electromagnetic fields, mobile 
phones, infections and chemical agents (McKinney 2004, p14). 
 
High frequency radiation, involved in radiotherapy, can result in the breaking 
of molecular bonds, thus causing DNA damage. Therefore, patients suffering 
from paediatric cancer or leukaemia, receiving radiation therapy, have an 
increased risk of developing brain tumours in adulthood despite radiation 
being administered at therapeutic doses (McKinney 2004, p6). It has also 
been reported that survivors of the Hiroshima atomic bomb have a greater risk 
of developing meningiomas (Shintani 1999) though the radiation did not seem 
to increase the risk of brain tumours to developing foetuses. 
 
Extremely low frequency electromagnetic fields (ELF-EMF) (30-300 Hz) are 
present in domestic and industrial electricity supplies including but not limited 
to pylons, energy plants, radio, TV, public transport vehicles and video 
terminals. The effects of ELF-EMFs depended on their intensity and time of 
exposure. Investigation and published research into the risk of developing 
brain tumours due to ELF is very sparse and methodologies are inconsistent. 
Kheifets et al (2010) suggested inconsistent results may be attributable to 
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numerous shortcomings in the studies, notably assessment of exposure. 
Despite this various in vitro studies have indicated ELF-EMFs lead to DNA 
breaks of double and single strands (Lai 1996), DNA-protein and DNA-DNA 
crosslinks (Singh 1998), and increased apoptosis (Lai 2004) in rat brain cells. 
These effects were reported to be mediated by free radicals (Simko 2007). 
Currently, conclusions concur that ELF-EMF has a weak link to the risk of 
developing brain tumours, though research is still ongoing (Gadhia 2004, p65; 
Kheifets 1995). Conversely, recent studies have investigated the therpeutic 
effects of ELF-EMF such as improvement and facilitation of bone healing, 
increasing neurogenesis and in the treatment of cancer (Cuccurazzu 2010, 
Masutani 1995, p462; Robles 1998, p1113). Due to the inconsistent nature of 
current conclusions the need to better assess exposure, including 
development of a more complete job-exposure matrix combining job title, work 
environment, and exposure to electric fields, magnetic fields, contact current, 
spark discharge, and other chemical and physical agents (Khiefets 2010; Mee 
2009; Estécio 2002) is warranted. 
 
Similarly mobile phone handsets emit radiofrequency signals from the 
microwave spectrum. Though the energy levels of these waves are 
insufficient to damage DNA, public concern over the possible health effects of 
using mobile phones has resulted in various investigations into the 
relationship between mobile phones and brain tumours. Hardell et al. (2013; 
Carlberg 2012) reported an association, clearly indicating an increased risk for 
both malignant brain tumors and acoustic neuroma after long-term use of 
wireless phones and mobile phones. Other studies have shown leakage 
across the blood brain barrier (BBB) (Salford 1994; Persson 1992) and data 
suggesting indirect damage to neurons (Salford 2003; Hassel 1994). Despite 
this, the risk associated with mobile phones is controversial as the studies 
published either reported on small sample numbers or have allowed for short 
latent periods. The general consensus, currently, is that mobile phone use 
presents no risk, but this requires further investigation (Kundi 2010; Lahkola 
2005).   
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A number of viruses, including retroviruses, papovaviruses, and adenoviruses 
have been found to induce brain tumours in experimental animal models. 
However, this has not been shown in humans. Various studies have 
suggested that live polio vaccines contaminated with SV40 might increase the 
risk of brain tumours (Pepper 1996; Martini 1996) though further studies did 
not support this evidence. In contrast atopic diseases, for example asthma 
and eczema, have been found, in a number of independent studies, to be 
‘protective’ against the development of gliomas. Limited research has been 
done to identify possible mechanisms related to how infections may initiate 
alignancy or play a protective role remains unknown and further study is 
required.  
 
A variety of both beneficial and harmful chemicals may be found in various 
foods and within the environment. One such example, found both the 
environment and foods, such as some vegetables and cured meats, are the 
N-nitroso compounds. These compounds are able to cross the blood brain 
barrier (BBB) and have mutagenic tendencies, enabling them to potentiate the 
carcinogenic process. N-nitroso compounds both environmental and dietary 
have been studied as potential carcinogens (Lewin 2006; Tricker 1991). In 
contrast to these studies N-nitroso compounds, are involved in chemotherapy 
regimens given to patients subsequent to diagnosis of any cancer, therefore 
suggesting that some N-nitroso compounds may be protective and not 
harmful.  
 
Another chemical studied for its potential carcinogenic effects is aspartame, a 
low calorie sweetener found in various food products and fizzy drinks like diet 
coke. It was suggested that aspartame might be involved in the aetiology of 
some brain tumours though it was concluded in a study, that aspartame was 
not a risk factor (Mallikarjun 2015). However, if there was a pre-existing 
tumour, it has been suggested that it progresses rapidly in the presence of 
aspartame (Olney 1996; Pilkington and Rooprai personal communication).  
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Tobacco has been found not to cross the BBB and therefore, though 
carcinogenic to other organs of the body, studies are inconsistent with only 
some populations being linked to development of brain tumours (Hou 2015). 
Alcohol similarly does not seem to be related to brain tumour development. 
Other chemicals including hair dyes and hair sprays, pesticides and traffic 
pollution, which have been linked to other cancers, have yielded inconclusive 
results though are all still undergoing further study (Khanolkar 2016). 
 
A variety of occupations have been linked to an increased risk of developing 
brain tumours due to exposure to carcinogenic or neurotoxin compounds such 
as polycyclic aromatic hydrocarbons, phenols, organic solvents, and 
lubricating oils. Farmers, for example, are 30% more prone to brain tumours 
(Khuder 1998, p252) probably due to their exposure of pesticides and other 
specifics related to farming (Viel 1998; Bohnen 1995). Apart from workers 
associated with farming and the petrochemical and oil industries, studies 
within other occupations, investigating this risk factor remains inconsistent 
and no specific chemical has been associated with the risk of petrochemical 
and oil industry workers though multiple exposures have to be considered 
(McKinney 2004, p16).  
 
1.3 Classification of Gliomas 
 
1.3.1 WHO Classification 
 
Today the most widely accepted classification scheme of CNS tumours is that 
of the World Health Organisation (WHO) (Table 1) (Louis 2007; Kleihues 
2002). The WHO system, developed by Zulch, was first published in 1979, as 
a result of a series of meetings over the period of the 1970s between various 
neuropathologists, neuro-oncologists, radiation oncologists and various other 
health professionals. Revision thereafter of this original WHO system, by 
Kleihues and Cavanee, occurred in 1993, 2000 and most recently in 2007 
(Louis 2007; Kleihues 2002; Kleihues 2000; Kleihues 1993). This scheme 
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sought to classify all CNS tumours using a system based on the 
histopathologic features of the tumour, as described in the Daumas-Duport 
scheme, and survival rates. 
 
Daumas-Duport et al. (1988) developed a classification based on the 
presence of cellularity and the presence or absence of four histopathological 
features; presence of mitoses, nuclear atypia, endothelial cell proliferation, 
and the presence and extent of necrosis (Daumas-Duport 1988). In this 
system, one point was given for each malignant feature thus increasing points 
correlated with increasing malignancy accordingly Grade I tumours display 
cellularity only, grade II tumours display mitosis as well, grade III tumours 
display grade II characteristics and nuclear atypia and finally grade IV 
tumours display all 4 histological features including anaplasia and necrosis. 
This scheme is now referred to as the St Anne-Mayo classification system 
(Doolittle 2004). The WHO classification is based on cell of origin, proportion 
of malignant features, and tumour grade (I-IV). A brief description of glial 
tumours is illustrated in Table 1. 
 
1.3.2 The Future of Classification 
 
New techniques of classifying brain tumours may lie in gene expression 
analysis and molecular genetics. Techniques such as these invite the 
possibility of improved tumour classification thus resulting in patient 
stratification for treatment and prognosis (Caskey 2000). An example of such 
a study has profiled the gene expression, using cDNA array technology of 
human primary glioma tissue samples. A good correlation was reported for 
survival against molecular classification (Fuller 2002).  Another new method 
includes the use of support vector machines (SVM), creating a model to 
predict astrocytoma grades following MRI to identify common features of the 
neoplasms (Milchenko 2016). The diagnostic performance of SVM was 
reported to be significantly better than clinician diagnosis for higher grade 
tumours. 
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Table 1 Who classification of gliomas adapted from Louis 2007 
 
Tumour classification Histological grade of malignancy 
Astrocytoma   
         Pilocytic Astrocytoma I 
         Pilomyxoid astrocytoma II 
         Pleomorphic xanthoastrocytoma  I 
         Subependymal giant cell 
astrocytoma 
I 
         Astrocytoma (Low-grade, diffuse) I-II 
         Anaplastic astrocytoma III 
         Glioblastoma multiforme IV 
         Giant cell glioblastoma IV 
         Gliosacrcoma IV 
Oligodendroglioma  
          Oligodendroglioma (low grade) I-II 
          Anaplastic oligodendroglioma III 
Mixed gliomas  
          Oligoastrocytoma 
          Anaplastic oligoastrocytoma                                            
II 
III 
Ependymoma  
          Subependymoma I 
          Myxopapillary ependymoma I 
          Ependymoma II 
          Anaplastic ependymoma III 
Glioblastoma  
          Giant cell glioblastoma IV 
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1.4 Gliomas 
 
Gliomas are thought to be derived from glial cells or neural progenitor cell and 
are the most commonly diagnosed CNS tumour accounting for approximately 
86% of diagnosed tumours (McKinney 2004, p12). Gliomas include 
astrocytomas, oligodendrogliomas, ependymomas and mixed gliomas. 
Astrocytomas are the most commonly occurring glioma with grade IV 
astrocytomas or glioblastoma multiforme being the most difficult neoplasm to 
treat. 
 
1.4.1 Astrocytomas: The Most Common Glioma 
 
Astrocytomas are the most commonly occurring neuroepithelial tumours and 
may be described as well-differentiated diffusely infiltrating tumours 
predominately comprising neoplastic astrocytes. They may be characterised 
into two groups; those that diffusely infiltrate and those that do not. Diffuse 
astrocytomas account for at least 75% of astrocytic tumours. They have a 
poorer prognosis and a higher risk of recurrence as there is no discernible 
boundary between the tumour and the normal tissue, thus during resection 
many residual cells in the brain tissue lead to recurrence.  
Location of the tumours varies greatly and is largely dependent upon age 
though they are most commonly located in the frontal, temporal and parietal 
lobes of the brain.  
 
Low grade tumours are graded WHO grades I or II, thus presenting only one 
or two malignancy features. These tumours exist as either non-diffusely 
infiltrating, such as pilocytic astrocytoma (WHO grade I), pleomorphic 
xanthoastrocytoma (WHO grade II) and subepndymal giant cell astrocytoma 
(WHO grade I), or as diffusely infiltrating tumours. The former tumour type 
occurs in paediatric patients and young adults which, are all generally slow 
growing, well differentiated and circumscribed with a lack of anaplastic 
progression due to slow limited invasion thus the prognosis of these tumours 
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is more favourable. The later tumour types occur mainly in adults and are 
capable of undergoing malignant transformation, therefore carrying a more 
worrying prognosis. These tumours may be categorised into one of three 
variants which are identified upon resection, using histological techniques, in 
accordance to the most predominant cell type, specifically fibrillary 
astrocytomas which are by far the most common, gemistocytic astrocytomas 
and protoplasmic astrocytomas (Kleihues 2000).  
 
Malignant tumours are graded WHO grades III or IV. These tumours display 
three or more histological characteristics and are all poorly differentiated with 
a more marked malignant progression. Unlike most solid tumours, these 
neoplasms rarely metastasize outside the brain instead they undergo a ‘go or 
grow’ phenomemnon (Bolteus 2001). This theory describes the mutually 
exclusive nature of brain tumour cells to either proliferate or diffusely infiltrate 
the contingent brain. Invasion is perhaps the most significant biological 
feature that precludes successful treatment. Other biological features 
exhibited by malignant neoplasms that obstruct treatment are cellular 
heterogeneity and angiogenesis. Evasion of treatment therefore leaves 
patients diagnosed with malignant neoplasms with a bleak prognosis. 
Anaplastic astrocytomas are diffusely infiltrating astrocytomas with 
proliferative potential and either focal or dispersed anaplasia and a display of 
hypercellularity which is often important in diagnosis. They have a tendency to 
infiltrate without tissue destruction thus often leading to enlargement of 
adjacent structures. The tumour mass frequently appears granular and 
opaque with a soft consistency. Anaplastic astrocytomas have a poor 
prognosis with tumours undergoing malignant progression, though 
progression of recurrent tumours is more rapid that those that arise de novo. 
 
Glioblastoma multiforme (GB) is the most malignant form of astrocytoma, at 
WHO grade IV this neoplasm portrays all the features of malignancy and is 
amongst the most difficult of astrocytomas to treat effectively and remains 
incurable. GBs account for approximately 15-20% of all intracranial 
neoplasms and 50% of all gliomas (Glantz 1991, p1741). Morphology of GBs 
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varies greatly, due to its heterogeneous nature. Cells appear a number of 
different shapes with marked invasive cell populations budding of the tumour 
mass thus invading both hemispheres of the brain and characteristically 
displaying the ‘butterfly’ effect. GBs are also associated with oedema, 
degeneration and occasional haemorrhaging. Molecular studies support two 
pathways of occurrence of GBs, they can arise both de novo and as a result 
of malignant progression from anaplastic astrocytomas. Prognosis of GBs is 
poor with most cases leading to mortality with a year of diagnosis (Hottinger 
2014, p32; Stupp 2005, p988; Grossman 2004; McKinney 2004, p13;). 
 
1.4.2 Oligodendrogliomas 
 
Oligodendroglial tumours can be either well-differentiated, low grade tumours 
(WHO grade I or II) or malignant tumours (WHO grade III). Unlike astrocytic 
tumours the incidence for oligodendrogliomas is far less. Traditionally these 
were thought to comprise 2% to 5% of primary brain tumors however recent 
studies have indicated these account for around 4% to 15% of gliomas 
(Engelhard 2003, p444; Paleologos 2001, p59).  Oligodendrogliomas are 
localized to the white matter of the cerebral hemispheres. Macroscopically the 
tumours mass may appear soft and gelatinous and can be associated with 
infiltration of the surrounding cortex and adjacent leptomeninges. The tumour 
cells are monomorphous and in areas of increased cellularity the tumour 
mass may display circumscribed nodules. Morphologically they have uniform 
round nuclei slightly larger than those of normal cells. During degeneration the 
mass creates a distinctive ‘honey-comb’ effect which is used as a useful 
diagnostic feature. Survival rates of oligodendrogliomas are more favourable 
than diffuse astrocytomas specifically post-operative median survival time is 
3-5 years (Chinot 2001, p13; Sun 1998, p886; Shaw 1996, p288). Also, in 
contrast to astrocytomas, recurrence and malignant progression occurs less 
frequently. 
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1.4.3 Progenitor Cells 
 
The presence of a population of cancer stem cells has been discovered, over 
the years, as a result of research into the existence of cancer progenitor cells 
in cancers such as leukemia (Lapidot 2001; Reya 2001; Bonnet 1997). 
Normally progenitor cells or stem cells are cells that indefinitely self-renew 
and give rise to differentiated cells (Watt 2000). Pluripotent stems cells, have 
the ability to give rise to multipotent or tissue-specific stems cells, which in 
turn have been identified in various organs including bone marrow, breast, 
intestine, lung, skin and brain (Shackleton 2006; Dekaney 2005; Kim 2005; 
Alonso 2003; Krause 2001; Uchida 2000). Though dormant under normal 
physiological conditions, these, may also, be stimulated, during homeostasis 
and injury repair, into simultaneous self-renewal, maintaining a stem cell 
population, and differentiation, giving rise to a new population of all the cell 
types of a given tissue (Shackleton 2006; Krause 2001), accountable for 
tissue function and homeostasis (Weissman. 2001) for example stem cells of 
neural tube origin give rise to neurones, astrocytes, oligodendrocytes and 
ependymal cells (Fig 3). Such a phenomenon is known as trans-
differentiation. 
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Figure 3 Differentiation of progenitor cells in the neural tube adapted from Fan et al. 
(2007) 
Cancerous stem cells however continually clone tumour cells thus are 
responsible for maintenance of the tumour mass which ultimately leads to 
increasing malignancy (Singh 2003, p5822).   
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1.5 Clinical Presentation of Gliomas 
 
Patients with primary neoplasms usually present with drowsiness, headaches, 
vomiting/nausea and/or papilloedema as a result of increased pressure and 
neural tissue compression due to small increases in the tumour mass. 
Cerebrospinal fluid (CSF) pathways may also be blocked as a consequence 
of raised pressure preventing drainage thus causing hydroencephalus. 
Personality & cognitive changes, focal neurological deficit or seizures may 
also present if increased compression, direct infiltration or neuronal 
destruction occurs. 
 
Presentation varies according to location of the tumour and whether or not it is 
deep seated. Table 2 illustrates the symptoms associated with some of the 
various regions, of the brain. The most common primary symptoms will be a 
seizure or epileptic fit, upon which hospitalization and emergency surgery is 
required. 
 
8 | P a g e  
 
Table 2 Symptoms that can be caused by tumours in different parts of the brain adapted from Cancer Research UK website 2014 
 
Position of the tumour Symptoms 
Frontal lobe Personality changes 
Loss of inhibitions 
Apathy 
Difficulty with planning and organising 
Being irritable or aggressive 
Weakness in part of the face, or on one side of the body 
Difficulty walking 
Loss of sense of smell 
Problems with your sight or speech 
  
Temporal lobe Forgetting words 
Short term memory loss 
Seizures 
déjà vu or phantom smells 
  
Parietal lobe Speech difficulty 
Problems with reading or writing 
Loss of feeling in part of the body 
  
Occipital lobe Visual impairment 
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1.6 Diagnosis and Classification of Gliomas 
 
Advances in diagnostic tools over the years have lead to successful diagnosis 
of brain tumours. Examples of such include better visualisation of the tumours 
using computed tomography (CT) and magnetic resonance imaging (MRI) 
scanning and better diagnostic conclusions using microscopy and 
Immunohistology.  
 
1.6.1 Imaging 
 
CT scanning was first introduced in the 1970s by Sir Godfrey Hounsfield. This 
technique is an advancement of the X-ray machine though unlike an X-ray 
machine a CT scanner emits multiple beams to examine a cross-sectional 
image of the body thus allowing a 3-dimensional visualisation of the tumour. 
This scan is usually accompanied by iodine based compounds which are 
absorbed by the tissues and detected by the CT scanner. Unfortunately, the 
resolution of soft tissues, compared to bony tissues is poor therefore CT 
scans are better used for bony tissues. McCormack et al. (1992) showed that 
the seven times increase in the risk of recurrence of low grade astrocytomas 
was associated contrast enhancement on a CT scan. Reduced integrity of the 
BBB increases enhancement in CT scans rather than the presence of the 
tumour itself.  
 
MRI uses the presence of strong magnetic fields to visualise the soft tissues 
of the body and is based on the alignment of hydrogen atoms in the body in 
response radio waves of the magnetic fields. Images are produced on a 
computer to visualise not only 2-dimensional slices of a 3-dimensional image 
but also different planes of the image. Contrast enhancements agents or 
paramagnetic compounds, such as gadolinium are not normally required 
though on occasion they are administered intravenously to increase image 
sensitivity. 
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Positron Emission Tomography (PET) measure cerebral blood flow & 
metabolic activity. A variant of PET, Single Photon Emission Computerized 
Tomography (SPECT), also functions using the same principles. PET scans 
are effective in identifying the progression of low grade tumours to high grade 
tumours. They are also able to identify recurrent tumours. PET scans 
visualise the low grade tumours as ‘cold’ as they are hypometabolic and 
malignant areas are perceived as ‘hot’ or hypermetabolic (Francavilla 1989, 
p1). Unfortunately as it is an expensive procedure it is very rarely used except 
in the case of private patients.  
 
1.6.2 Immunohistology 
 
Following initial diagnosis during surgery, a clinical diagnosis is usually 
determined as a result of histological examination of biopsy derived paraffin 
sections. This technique is used to investigate and conclude cell lineage, 
histological type and malignancy. This technique was first discovered in the 
late 1970s when Kohler and Milstein reported immortal/transformed cells 
developed monoclonal antibodies (Kohler 1975). These cells gave rise to cell 
populations that divided indefinitely and secreted the antibody. These 
antibodies were used to identify surface antigens, their receptors or 
cytoplasmic and nuclear antigens of both normal and neoplastic cells. A 
number of antigenic markers may be related to the detection of astrocytic 
tumours some of which include glial fibrillary acidic protein, cluster of 
differentiation 44, neural cell adhesion molecules and integrins. 
 
Glial fibrillary acidic protein (GFAP) is an intermediate filament thought to 
retain the mechanical strength and structure of astrocytes (Eng 1971) it is a 
distinguished marker of normal, reactive and neoplastic astrocytes. Extended 
studies of astrocytomas have proved this marker to be invaluable for both 
diagnosis and research. It is not however, thought to be exclusive to 
astrocytomas alone, instead it is expressed, to some extent, in all gliomas 
apart from meningiomas, medulloblastomas and brain metastasis (Oh 1999; 
Fischer 1989). The origin of such tumours may be misinterpreted as 
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astrocytic. Instead they are more likely to display a plastic phenotype in vitro 
when the microenvironment is changed (Tenenbaum 1996). 
 
Cluster of differentiation 44 (CD44) is an adhesion molecue and a marker of 
invasion and progenitor cells. It is up-regulated in brain tumours as a result of 
involvement of hylauronic acid (HA) expression increasing in the extracellular 
matrix (ECM), during invasion, regardless of tumour grade (Delpech 1993). 
CD44 is involved in this invasive process and is commonly studied as a 
marker of astrocytic invasion. Ranuncolo et al.  (2002) suggested that 
overexpression of CD44 could be relevant in determining the highly invasive 
behaviour of gliomas, though it does not behave as an independent 
prognostic factor for survival 
 
Neural cell adhesion molecules (NCAMs) are members of the immunoglobulin 
super family. They are cell surface glycoproteins that mediate cell-cell 
adhesion independent of Ca2+ (Keilhauer 1985), play an important role in 
neurite outgrowth and fasciculation and are involved in migration/invasion 
(Appel 1993). Expression of NCAM has been shown to reduce 
migration/invasion of glioma cells both in vitro as well as in vivo (Owens 1998; 
Gratsa 1997; Edvardsen 1994; Edvardsen 1993). In addition to cell-cell 
adhesion, signal transduction is induced by hemophilic interaction of NCAM, 
resulting in neuronal differentiation (Kolkova 2000; Walsh 1996) and inhibition 
of cell proliferation (Edvardsen 1993; Edvardsen 1993). Additionally Prag et 
al. (2002) reported exposure to NCAM strongly affected the motile behaviour 
of glioma cells independently of homophilic NCAM interactions, probably 
through interference with factors regulating cellular attachment. 
 
The fundamental cellular function of integrins is their adhesive properties, 
which mediate extensive and important cellular functions by interacting with 
the extracellular matrix (Palecek 1997; Condic 1997; Gumbiner 1996; 
Miyamoto 1995;). The interactions of integrins with the ECM also activate 
signal transduction (Clark 1995; Zachary 1992). Many known ECM molecules 
that interact with integrins, including fibronectin, collagen, and vitronectin, 
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contain an RGD consensus sequence (D'Souza 1988; Ruoslahti 1986). As 
such integrins are an attractive target for the treatment of several cancers 
(Xiao 2016). Several factors expressed in glioma cells have been found to 
regulate integrin expression, particularly, urokinase, a plasminogen activator 
(uPA), secreted by glioma cells. uPA has been shown to upregulate integrin 
v3 expression by autocrine mechanism (Pedroja 2009, p20708). 
 
Galactocerebroside (Gal C) belongs to the family of cerebrosides. It is a 
common cell surface glycolipid marker for mature oligodendrocytes and 
appears to regulate myelin formation (Marcus 2006; Dupree 1998; Bosio 
1996; Coetzee 1996). Tenebaum et al. (1996) identified the loss of this 
marker in their studies, identifying the changes in antigenic expression in the 
presence of different serum supplementation. 
 
Neural glial 2 (NG2) a transmembrane chondroitin sulphate proteoglycan, is 
expressed on oligodendrocyte progenitor cells (OPCs) (Chekenya 2002). 
OPCs or NG2 cells terminally differentiate into oligodendrocytes and NG2 
cells, thus the number of NG2 cells is comparable to the number of mature 
oligodendrocytes in the gray matter (Dawson 2000). Unlike astrocytes and 
oligodendrocytes, mature cell markers such as GFAP and Gal C are not 
expressed on NG2 cells (Butt 1999 Reynolds 1997; Levine 1993; Levine 
1987) demonstrating their distinct nature.  
 
Ganglioside GD3 belongs to a family of complex acidic glycolipids. Despite 
poor documentation it is thought they are functionally diverse in the normal 
brain and are also expressed and play a role in brain tumours (Yates 1995; 
Wikstrand 1994; Fredman 1994; Pilkington 1993; Shinoura 1992). GD3 is not 
specific to oligodendrogliomas it is reported to be down-regulated in gliomas 
(Gratsa 1997). 
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1.7 Biological Features Evading Treatment 
 
1.7.1 Heterogeneity 
 
A predominant challenging feature of astrocytic tumours is their cellular 
heterogeneity or complexity (Fig 4). When compared to the single sub cell 
population of liver cells of a hepatoma, gliomas can result in up to 14 different 
sub populations. Differing processes of differentiation and anaplasia conceive 
a variety of morphologies with cells displaying antigenic difference. This 
therefore results in sub populations which are not only phenotypically different 
but also genotypically different (Marusyk 2010; Pilkington 1992). This 
characteristic cellular heterogeneity is seen in early passages and is important 
in tumour growth and maintainance. Later passages see retention of fewer 
cell sub populations (Pilkington 1992).  
 
Development of cell culture techniques such as cloning individual cell 
populations, in vitro growth of neurospheres and multicellular tumour 
spheroids, and identification of new markers including nestin, Mushashi-1 and 
CD133 confirm the existing heterogeneity of gliomas and are also suggestive 
of the existance of a stem cell population within gliomas. The presence of 
stem cells in the CNS strongly suggests a role for these cells in tumour 
initiation and resistance to current therapeutic strategies. 
 
Differential resistances to radiation and drug therapies makes gliomas more 
complicated to treat. One study cloned 16 sub populations from an early 
passage (P3-10) human glioma cell culture and exposed each to radiation. Of 
the 16 populations two populations remained completely resistant to the 
radiation and were employed for further study (Yang 1992). An eariler study 
reported a similar resistance to chemotherapy (Yung 1982). Identification of 
properties of the individual cell populations opens new and exciting 
paramaeters of study, providing vectors in novel therapeutic strategies for 
these tumours.  
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Figure 4 Phase contrast micrograph of an anaplastic astrocytoma (III) primary cell 
culture IPSB-18. Cells of different morphologies are depicted in particular elongated 
and partial star shapped cells are illustrated. 
 
1.7.2 Invasion 
 
Perhaps the most significant biological feature which precludes successful 
therapy is invasion. Invasion is a complex pathway, which involves the 
interaction of various components (Liotta 1986) including cell adhesion 
molecules (e.g. Cluster of differentiation 44, CD44), proteases (e.g. matrix 
metalloproteinases – MMPS), extracellular matrix (ECM) components and 
growth factors enabling the attachment of invading tumor cells to extracellular 
matrix (ECM), disruption of ECM components, and subsequent cell 
penetration into adjacent brain structures.  
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In non- CNS tumours, metastasis is the major cause of morbidity and death, 
however, in primary brain tumours, there is no metastasis. Invasion allows the 
formation of secondary tumours within the brain. Under normal conditions, a 
negative feedback mechanism may limit the behavior of normal cells, such as 
endothelial cells, and lymphocytes. Although tumor cells use the same 
mechanism as normal cells, they seem to lack the appropriate feed back 
mechanism during invasion. 
 
One of the most plausible reasons for the failure of brain tumours to 
metastasize lies in the interaction of neoplastic glia with the non-brain 
endothelial cells. For extravasation of glioma cells at a distant site they must 
possess the complement of adhesion molecules necessary to facilitate 
adherence to the endothelial wall. Cluster of differentiation 15 (CD15), is an 
adhesive oligosaccharide epitope which facilitates neoplastic cell/endothelial 
cell adhesion and confers high metastatic potential in non-neural tumours 
(Dejana 1992; Matsusako 1992). Human brain tumours show little or no CD15 
expression (Martin 1995; Reifenberger 1992) while the chemically induced rat 
glioma cell lines, A15A5, F98 and C6, show strong expression of the CD15 
antigen (Martin 1995). These latter experimental rat tumours, unlike their 
human counterparts, show a propensity for metastatic behaviour.  
Furthermore, in vitro adhesion of metastatic carcinoma cells and brain tumour 
cells to vascular endothelium correlates with the level of CD15 expression 
(Martin 1995). 
 
Invasive ‘guerrilla’ cells display the ‘go or grow’ theory (Bolteus 2001) 
whereby the cells are either growing and proliferating within the tumour mass 
or the cells enter G0 phase and bud away from the tumour mass and migrate 
across the brain cortex by primarily digesting the ECM with the aid of elevated 
levels of glycosidases, which break down the glycosaminoglycan chains that 
form the mesh of the ECM, and proteases that break down protein structures 
with the ECM. Elevated levels of hyluronic acid (HA) also digest the ECM. It is 
unknown how HA facilitates tumour cell in vitro (Nakagawa 1996) though 
various possibilities have arisen; 1) it may provide a lead for the tumour cells 
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to follow across the ECM 2) it may provide immunity for the cells.  
 
The sequence of events, originally described by Liotta, during tumour cell 
invasion of the extracellular matrix are described as a three-step hypothesis 
(Onishi 2011). The first step is tumour cell detachment from the primary tumor 
mass and attachment via cell surface receptors which specifically bind to 
components of the extra cellular matrix (ECM) such as laminin and 
fibronectin. The anchored tumour cells then secrete hydrolytic enzymes which 
can locally degrade the matrix. And finally tumour cell locomotion into the 
region of the matrix modified by proteolysis. 
 
Detachement of the cells involves various events. Firstly destabilization of 
cadherin-mediated junctions that hold the primary mass together must occur. 
Cadherins (E-, P-, and N-cadherin) form calcium-dependent, transmembrane, 
cell–cell adherent junctions. Cadherins may function as suppressors of tumor 
growth and invasion (Demuth 2004). Decreased cadherin function in 
carcinoma progression, is correlated with poor prognosis (Bremnes 2002).  
 
Subsequently a decline in the expression of connexin 43, a component of gap 
junctions, leads to a reduction in junction formation. Fewer inhibitory signals 
may be resulted due to decreased gap junction formation, facilitating 
uncontrolled cell division and de-differentiation (Ruch 1994). Connexin 43 is 
the most abundant gap junction protein in CNS and is expressed primarily in 
astrocytes (Dermietzel 1993). McDonough et al. (1999) reported that reduced 
gap junction formation correlates with increased motility of glioma cells in 
vitro.  Clevage of CD44, which anchors the primary mass to ECM, by the 
metalloproteinase ADAM is the final part of the process. CD44 is cleaved by 
ADAM 10 and 17. Both the intracellular and extracellular cleaved components 
of CD44 promote cell migration (Okamoto 1999, p 25530). 
 
Adherence to the ECM is most commonly facilitated by integrins. They 
interact with two groups of ligands including a variety of ECM proteins, such 
as fibronectin, fibrinogen and vitronectin, and cell surface molecules, that are 
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members of the immunoglobulin supergene family, such as vascular cell 
adhesion molecule (VCAM-1) and intracellular adhesion molecules (ICAM-1, 
ICAM-2). In particular, the integrin v3, which binds to fibronectin, 
vitronectin, and tenascin-C in ECM, is thought to play a central role in glioma 
invasion (Leavesley 1993, p165). Up regulation of v3 expresion leads to 
increased motility of human glioma cells and a decrease in apoptosis 
sensitivity (Platten 2000).  
 
The most common proteases involved in the degradation of the ECM are 
MMPs. The first experimental evidence for a role of MMPs in tumor 
development was discovered in the 1980s. It was reported that a type IV 
collagenase was demonstrated to be involved in melanoma invasion and 
metastasis (Liotta 1980). These are a family of zinc dependent enzymes 
which all pave a pathway for the malignant tissue to migrate or invade along. 
23 members of the MMP gene family have been identified to date (Nagase 
2006) the most commonly noted in GBs as being up-regulated, are MMP-2, 
MMP-7, MMP-9, MMP-14 and MMP-15, these can be down-regulated in the 
presence of micronutrients such as selenium (Rooprai 2007).  
 
Regulation of MMPs occurs at many levels: transcriptional activation of MMP 
genes can occur in response to agents such as growth factors, oncogene 
expression and phorbol esters (Matrisian 1985; Kerr 1988; Matrisian & Hogan, 
1990). TGFβ upregulates the expression of MMP-2 and MMP-9 (Wick 2001; 
Salo 1991; Overall 1991) while EGF and PDGF were shown to induce 
stromelysin gene expression in fibroblasts (Matrisian 1985). 
  
Integrins have also been shown to induce MMP expression. The ligation α5β1 
integrin, reported by Werb et al. (1997), showed that, very late antigen-5 
(VLA-5) on fibroblasts induced collagenase and stromelysin gene expression. 
Another study reported that binding of the αvβ3 integrin up-regulated the 
expression of MMP-2 in melanoma cells (Seftor 1992, p1557). The αvβ3 
integrin was also capable of directly binding to the active MMP-2 enzyme 
inhibiting adhesion to vitronectin (Brooks 1996, p687). From studies in glioma 
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cells Deryugina et al. (1997, p2474) showed that αvβ3 binding to MMP-2 
occurred through the C-terminal portion of the enzyme. Treatment of GB cell 
lines with α3β1 antibodies increased MMP-2 activity and invasion in matrigel 
assays (Chintala 1996). 
 
Interleukin-1β (IL-1β) has also been shown to induce stromelysin gene 
expression in fibroblasts (Frisch & Ruley, 1987; Quinones 1989).The 
conversion of latent proenzyme to its active form is another level of regulation 
via plasmin or active stromelysin. Although neither plasmin nor stromelysin 
appear to activate MMP-2 (Okada 1990) in vitro, they have been shown to 
activate MMP-2 by means of MMP-14 (MT-MMP) (Strongin 1995).  
 
A variety of zymographic & enzyme-linked immunosorbent assay (ELISA) 
studies have revealed increased activity of MMPs in GBs and anaplastic 
astrocytomas when compared to low grade astrocytomas and normal brain, 
particularly for MMP-9 (Nakagawa, 1994; Rao 1993, 1996). Glioma cells in 
vitro have been shown to secrete many MMPs including MMP-1, MMP-2, 
MMP-9, MMP-3 and MMP-7 (Nakano 1993). The amounts secreted into the 
culture medium are often higher than those extracted from tissue (Woessner, 
1995). In GBs and anaplastic astrocytomas immunoreactivity to MMP-9 and 
MMP-2 has been reported in endothelial and tumour cells (Rao 1996; Sawaya 
1996). 
 
Secreted MMPs, from glioma cells have the ability to degrade the surrounding 
brain tissue (Lund-Johansen 1991; Bjerkvig 1986), and MMP-2 & MMP-9 can 
degrade collagen IV a component of the ECM. Liotta (1986) proposed that 
such proteolytic enzymes were involved in invasion. Indeed, the highly 
invasive astrocytoma cell line, SF-188 expressed MMP-2 & MMP-9 (Rutka, 
1995) also GB cell cultures have been shown to secrete MMP-9 during in vitro 
2-dimensional invasion studies using Matrigel (Rao 1994). Upon treatment 
with the appropriate inhibitors the ability to invade was reduced (Pan 2015).  
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Upregulation of MMP-2, and MMP-9, in particular, has been associated with a 
high degree of maglinancy and enhanced glioma invasion in several in vitro 
and in vivo model systems (Wild-Bode 2001). The transition of tumour cells 
towards the invasive phenotype, involves gene products such as MMP-2, 
though the mechanisms of initiation and maintenance of glioma invasiveness 
remain unknown. 
 
Inhibition of MMPs could aid a reduction in invasion ultimately preventing 
recurrence of tumour growth. The natural tissue inhibitors of MMPs (TIMPS), 
these are currently being studied for their anti-invasive and anti-angiogenic 
properties. The classical notion of TIMPs in tumour biology is rather narrow, 
however, and there is a growing appreciation that these proteins.  
 
In vivo, TIMPs, play a major role in the regulation of MMP activity. (Liotta, 
1986; Ennis & Matrisian, 1994; Matrisian, 1990). TIMPs are secreted proteins 
that consist of a family of inhibitors that is comprised of 4 gene products 
(TIMPs 1–4) which inhibit secreted MMPs with similar potencies (Apte 1995; 
Greene, 1996; Blavier 1999). Individually, TIMPs differ markedly in their 
affinity for MMP interactions and gene regulatory mechanisms. Specifically 
TIMP-1 interacts with pro-gelatinase-B (MMP-9) and is subject to tight control 
at the transcription level (Phillips 1999), whereas TIMP-2 binds pro-gelatinase 
A (MMP-2) and shows constitutive gene expression (Blavier 1999). 
 
Existance of differences also occurs with regard to biochemical properties: 
TIMP-3 is itself an ECM-associated protein but TIMP-1, -2 and -4 are freely 
diffusible (Leco 1994). Moreover, TIMP-1 is ineffective as an inhibitor of MT1-
MMP, whereas TIMP-2 and TIMP-3 are both functional in this regard (Will 
1996). The general notion is that TIMPs act as the ‘brakes’ of the malignant 
process. Thus, antisense-mediated down-regulation of TIMP-1 can induce 
tumorigenic and migratory behavior of cells in mouse fibroblasts (Khokha, 
1989). Overexpressed or exogenous TIMP-1 and TIMP-2 reduce tumour 
invasion and metastasis in vivo (DeClerck 1991; DeClerck 1992). Additionally, 
TIMP-3 down-regulation has been noted at the invasive edge of highly 
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aggressive colorectal carcinomas (Powe 1997), and overexpressed TIMP-4 
resulted in decreased invasive capacity of breast carcinoma cells (Wang 
1997). 
 
The uses of TIMPs lay across a broad spectrum.TIMP-1 can stimulate the 
proliferation of erythroid precursors (Gasson 1985), and alongside TIMP-2 
can positively influence the proliferation of numerous cell types (Hayakawa 
1992; Hayakawa 1994; Wingfield 1999). Additionally, TIMP-2 is able to inhibit 
in vitro proliferation of human microvascular endothelial cells stimulated with 
bFGF (Murphy 1993), and TIMP-3 promotes apoptosis (Ahonen 2003, p2122; 
Baker 1998), possibly through stabilization of TNF alpha receptors (Smith 
1997).  
 
There is a wealth of evidence showing that MMPs are overexpressed in 
malignant gliomas but studies of TIMPs in gliomas give conflicting results. 
High TIMP levels have been linked with increased malignancy. The 
suggestion of a balance between MMPs and TIMPs to increase the activity of 
MMPs in culture may be due to reduced TIMP levels rather than elevated 
enzyme secretion. Notably, lesser amounts of TIMP would be secreted by 
tumour cells having an invasive phenotype compared to tumour cells with a 
non-invasive phenotype (Halaka 1983). Reduced expression of TIMP-1 and -2 
with increasing glioma grade has been reported, suggesting that a lack of 
inhibitor expression may contribute to a more aggressive glioma phenotype 
(Mohanam 1995; Kachra 1999). In contrast other studies have reported an 
upregulation of TIMP-1 or -2 expressions in malignant tumours (Nakano 1995; 
Saxena 1995; Lampert 1998). Recently the expression of TIMP-4 was 
described as a marker of gliomas (Rorive 2010) and has also been shown to 
be upregulated with increasing malignancy. 
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1.7.3 Angiogenesis 
 
Angiogenesis, another hallmark of malignant gliomas, is the formation of new 
blood vessels from the pre-existing microvasculature thus supporting the 
tumour mass (Auerbach 2003). The formation of new blood vessels is 
attributed to either vasculogenesis or arteriogenesis. Vasculogenesis is the 
embryonic process, however was also identified in tumours in the novo 
production of blood vessels from circulating marrow derived endothelial 
progenitor cells. Arteriogenesis refers to enlarged arteriolar networks 
produced to sustain increased oxygen demands and this process doesn’t play 
significant role in tumour biology (Tate 2009). 
 
Angiogenesis is a critical process for cell survival and development (Arias 
2009) in particular during the development events in the female reproductive 
organs and wound healing. However, aberrant angiogenesis in the 
pathogenesis of numerous diseases including rheumatoid arthritis, diabetic 
retinopathy, Parkinson’s disease, Alzheimer disease and cancer is also 
associated with excessive angiogenesis. In contrast, insufficient angiogenesis 
can be linked to stroke, infertility and heart disease. Normally endothelial 
cells, which line all blood vessels and constitute virtually the entirety of 
capillaries, divide rapidly in response to a physiological stimulus like hypoxia. 
 
Tumour blood vessels differ from those formed in wound healing and from 
those in normal organs. The structure of these new blood vessels is abnormal 
with an irregular or increased diameter, thickened basement membrane, 
random branching, elevated permeability, lack the defining structural features 
of arterioles, capillaries or venules, and highly proliferative endothelial cells 
(Tate 2009). Additionally, it has been shown that abnormal blood vessels in 
gliomas create a vascular niche that houses glioma stem cells capable of 
giving rise to an entire tumour (Tate 2009). Unusually, despite the large size 
of some vessels, blood flow is typically poor and can change directions or 
even stop. The ‘leaky’ nature of these tumour vessels allows macromolecules 
to leave and may be the cause of metastasis by facilitating the movement of 
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tumour cells into the bloodstream. Though this is a rare consequence and 
may be attributed to the lack of Cluster of differentiation 15 (CD15). Blood 
vessel permeability can also lead to the accumulation of fibrin in the 
extracellular matrix thus creating a favourable environment for angiogenesis 
(Tuettenberg 2006). 
 
Induced by hypoxia, a cause of oedema, and oncogenic mutations, vascular 
endothelial growth factor (VEGF) is one of the many factors involved in 
angiogenesis and is a primary stimulant (Brekken 2000). Some MMPs are 
thought to be mediators of both invasion and angiogenesis (Nuttall 2003). 
Other stimulants of anigiogenesis are summarised in Table 3. 
 
 
Table 3 Some stimulants and inhibitors of angiognenesis.  
Proteins Inhibitors 
Proteins 
 
Vascular endothelial growth factor 
Angiogenin 
Accidic fibroblast growth factor 
Basic fibroblast growth factor (bFGF) 
Interleukin 8 
Hepatocyte growth factor 
Epidermal growth factor 
Placental growth factor 
Platelet-derived growth factor 
Transforming growth factor alpha 
Tumour necrosis factor alpha 
Scatter factor 
MMPs 
 
Small molecules 
 
Prostaglandins E1 and E2 
1-Butyryl glycerol 
Adenosine 
Nicotinamide 
 
TIMP-1 (tissue inhibitor of 
metalloproteinase-1) 
TIMP-2 (tissue inhibitor of 
metalloproteinase-2) 
TIMP-3 (tissue inhibitor of 
metalloproteinase-3) 
Angiostatin 
Endostatin 
Thrombospondin 
Interferons 
Platelet factor 4 
 
23 | P a g e  
 
 
VEGF increases vascular permeability leading to extravasation of plasma 
proteins and dissociation of pericyte coverage. VEGF is a great deal more 
active than histamine in enhancing vascular permeability (Nagy 1989). 
Studies have shown antibodies specific to VEGF reduced angiogenesis and 
almost completely inhibited the growth of human tumours in mice (Kim 1993; 
Asano 1995). Colorectal cancers have been known to produce VEGF this 
therefore may be an indication that other cancers also secrete the protein 
(Nakata. 1998). Studies have suggested the use of VEGF as a marker of 
tumour growth or recurrence (Fuhrmann-Benzakein 2000). 
 
There are four main steps involved in angiogenesis (Krishna 2016; Paper 
1998; Denekamp 1993) angiogenic factors are secreted by cancer cells (or 
adjacent tissues) which instigates the growth of a bud from the dissolved 
basement membrane. The basement membrane is a layer of specialized 
connective tissue that encircles capillaries and serves as the connection point 
between the extracellular matrix (ECM), it also provides structural support to 
the capillary. Vascular (endothelial) cells proliferate and migrate from the bud 
toward the angiogenic stimulus for example a low-oxygen (hypoxic) 
environment. Finally the sprout eventually forms a hollow tube (lumen) and 
joins its end with another sprout to form a new capillary vessel. 
 
The key components of the first step of angiogenesis, the breaking down of 
existing blood vessels, are the Angiopoietin-1 and its receptor Tie-2, which in 
normal brain are bound together resulting in a close association between 
pericytes and endothelial cells that stabilise the vasculature. In hypoxic 
conditions Ang-2 is up-regulated in endothelial cells whereas Ang-1 is 
increased in tumour cells. Ang-2’s increased expression seems to lead to the 
initial regression of blood vessels seen in early tumour angiogenesis. Tie-2 
signalling up-regulates MMP-2 expression and in conjunction with VEGF 
promotes continuation of angiogenesis (Tate 2009) it is at this stage the 
vessel basement membrane and surrounding ECM are degraded allowing 
endothelial cell migration and proliferation (Tate 2009). Angiogenic stimuli 
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cause increased permeability through dissolution of adherens junctions (Haas 
2012) between endothelial cells. Proliferation of these cells occurs early in 
angiogenesis and continues when the new capillary sprouts elongates. The 
survival and proliferation of endothelial cells is promoted by activation of 
PI3K/Akt through modulation of numerous cell cycle regulators like: cyclin D1, 
p27 and Bcl-X2. The MAPK signalling pathways (ERK1/2, p38 and JNK) 
mediate growth factor and mechanical force-induced proliferation. The 
proteolysis of basement membrane is necessary to promote invasion into the 
surrounding matrix and is controlled by proteolytic enzymes and its inhibitors. 
The MMP-2 and MMP-9 play major synergistic role in basement membrane 
degradation they are also promoting pro-angiogenic signalling by exposing 
endothelial cells to molecules such as VEGF and fibroblast growth factor 
(FGF). (Tate 2009) MMPs have a great affinity for fibronectin, elastin, laminins 
and collagens which are the major extracellular matrix components found in 
endothelial cell basement membrane and interstitial space. Following 
regression of existing vessels and breakdown of the basement membrane, 
endothelial cells proliferate and begin migrating toward tumour cells that 
express pro-angiogenic compounds. Activation of endothelial cells 
upregulates cell surface adhesion and migration molecules such as integrins 
and CD44. Upregulation of cell surface receptors, transmembrane 
heterodimer proteins integrins ανβ3, α5β1 and ανβ5 in addition to cell 
migration increases cell adhesion and survival (Tate 2009) Activated 
endothelial cells secrete platelet-derived growth factor (PDGF) that ‘recruit’ 
smooth muscle cells and pericytes to the site of newly sprouting vessels to aid 
in establishment of a new basement membrane (Tate 2009). Pericytes play a 
major role in vascular stability by inducing the deposit of a matrix and initiating 
signals allowing cell differentiation and quiescence. The complex final steps of 
tumour angiogenesis involve a dramatic changes in extracellular environment 
and are not well understood (Tate 2009). Formation of new blood vessel is 
accomplished by alignment of EC in bipolar mode, then tubular 
morphogenesis and finally the lumen formation. In the following step the 
vascular loops are formed from connected sprouts and blood begin to flow 
through the new vessel loop. 
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Judah Folkman (1971) introduced the concept of angiogenesis in 1971. He 
postulated that if a tumour was deprived of new blood vessel formation the 
tumour would only grow a few centimeters in diameter, thus reducing 
malignant progression and the problems faced by current treatment. 
Consequently an anti-angiogenic therapy would manage tumour development 
and aid current treatment.  
 
1.8 Apoptosis 
 
A high rate of angiogenesis in brain tumours is accompanied by a severe 
reduction in apoptosis (programmed cell death) a pathway which ideally would 
be activated during treatment. However, apoptotic resistance is a classic 
feature of gliomas which result in accumulation of these mutations. Apoptosis 
was discovered in the early seventies, before this necrosis was thought to be 
the only form of cell death. The importance of studying apoptosis in cancer 
remained unappreciated for nearly 2 decades. Now it is well documented that 
most cytotoxic anti-cancer agents induce apoptosis (Boik 2001). Apoptosis is 
mediated by a family of cysteine aspartic acid-specific proteases or caspases 
(Fig 5). Caspases exist within the body, as inactive precursors of their active 
forms (zymogens). Upon activation these zymogens engage in various 
pathways resulting in apoptosis. They are divided into three groups; apoptosis 
effectors (including 3, 6 and 7), apoptosis initiators (including 2, 9, 8 and 10) 
and cytokine maturation (1, 4, 5, 11, 12, 13 and 14) (Strasser 2000; Cryns 
1998). Activation of the apoptosis pathways may be initiated in one of two 
modes; mitochondrion (intrinsic) pathway and Death Receptor (extrinsic) 
pathway (Fig 5).  
 
The intrinsic pathway involves the disruption of the mitochondrial membrane. 
Consequently a number of mitochondrial proteins are released including 
cytochrome c. Cytochrome c in conjunction with apoptotic protease activating 
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factor -1 (Apaf-1) and zymogen procaspase 9, promote the assembly of 
apoptosomes; cytochrome c, Apaf-1 and caspase 9 complex, ensuing the 
activation of caspase 9 which consequently initiates the apoptotic caspase 
cascade.  
 
The extrinsic pathway employs a death receptor; a transmembrane receptor 
(including Fas, TNF and TRAIL) which upon ligation with its respective ligand 
(FasL, TNF and TRAIL) activates caspases 8 and 10. These subsequently 
cleave and activate effector caspases 3 and 7 resulting in apoptosis. Unlike 
the intrinsic pathway the extrinsic pathway is independent of the p53 protein. 
It has been reported that glioma cell cultures do not appear to activate the 
extrinsic apoptotic pathway in response to irradiation or cytotoxic drugs 
(Steinbach 2004), instead they display a high expression of inhibitor proteins, 
which may be responsible for the failure of glioma cells to activate caspases 
in response to apoptotic stimuli.  
 
There have been tremendous advances in the understanding of apoptosis, 
particularly, in the identification of molecules involved and understanding of 
function and pathways (Bogler, 2002; Lowe, 2000). The protein p53, is 
commonly associated with defects in cancerous tissue. It is an example of a 
molecule implicated in regulation of apoptosis (Pucci, 2000; Smith 2000). p53 
acts as a scanner for proliferating cells. Minor damage to DNA is repaired and 
cells with major DNA destruction are destroyed by apoptosis. It also facilitates 
the process of differentiating cells to leaving the cell cycle. Many brain and 
systemic tumours have shown mutation and/or loss of the p53 gene 
suggesting that cycling cells accumulate defective DNA material. p53 is 
implicated in the intrinsic pathway of apoptosis. Increasing activation of the 
p53 molecule could induce a pro-apoptotic effect. 
It has been reported that the protective gene p53 is activated by progesterone 
therefore redudcing the risk of cancer. As RCE mimics the structure of 
progesterone it would be assumed to induce activation of p53 and as such 
apoptosis 
 
27 | P a g e  
 
Tumour cell death by cytotoxic approaches such as anticancer drugs, 
irradiation, suicide genes or immunotherapy, is predominantly mediated 
through induction of apoptosis (Boik 2001; Fulda 1998; 2001; 2002; 
Hengartner 2000; Kaufmann 2000; Herr 2001; Debatin 2002; Johnstone 
2002). Despite the concept that anticancer drugs act by inducing cell death, 
defects in apoptosis programs may contribute to tumour progression and 
treatment resistance (Cory 2002; Igney 2002).  
 
Resistance to apoptosis is seen in the normal brain, where differential 
resistances exist (Salgado 2007) and increases during malignancy. Migrating 
cells in the marginal zones of the GBs do appear to be more sensitive to 
apoptosis (Lefranc 2005) illustrating an inverse correllation between 
resistance to apoptosis and migration (Sarafian 2009). Such a phenomenon is 
attributed to the increased expression of V3 in the marginal infiltrating 
zones where it acts as a regulator of invasion, proliferation and angiogenesis 
(Bogler 2005), confirming the inverse relationship between apoptosis and 
angiogenesis. 
 
There is little evidence that the current modes of coventional treatment 
mediate their effects via induction of apoptosis (Steinbach 2004). Thus pro-
apoptotic novel therapies are increasingly studied. One such therapy is 
Clomipramine Hydrochloride (CLOM), a tricyclic antidepressant. In use for 
over thirty years, it has the ability to induce apoptosis in malignant glioma 
cells in vitro (Daley 2005). The induction of apoptosis when using CLOM is 
associated with the intrinsic pathway (Daley 2005; Levkovitz 2005; Ekert 
2004). 
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Figure 5: Apoptosis initiation pathways both extrinsic and intrinsic including 
caspases involved. 
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1.9 Conventional Treatment 
 
Current conventional therapies for malignant gliomas include neurosurgery 
followed by radiotherapy. Previously, chemotherapy was only offered to these 
patients at recurrence to provide adjuvant and palliative support (Grant 2004; 
Grossman 2004; Rampling 2004), though it is now offerefed concomitantly 
with radiotherapy. Provided as a combination these therapies are known as 
the gold standard treatment. 
 
1.9.1 Neurosurgery  
 
Neurosurgery is not curative as local recurrence occurs due to the ability of 
such tumours to invade the contiguous nervous tissue instead surgery aims to 
histologically diagnose, debulk or resect as much of the tumour mass as 
possible to relieve symptoms created by the presence of the tumour. Risks 
associated with neurosurgery include post operative paralysis, brain damage, 
infection, psychosis and even death. 
 
However, over the years new sophisticated developments in surgery have 
reduced the potential risks associated with neurosurgery. For example, the 
availability of corticosteroids in the 1960s reduced pressure in the brain thus 
easing the debulking process. Sterotactic frames (Kelly 1986) allowed a 
greater precision in locating exact sites of tumours thus reducing the space 
operated on. Stereotactic surgery is commonly used to operate of ill-defined 
tumours, small tumours or those that exist in locations which are difficult to 
operate in and to map and define expressive tissue (Salcman 1990; Moore 
1989). Stereotactic surgery is also favoured when deriving biopsies for 
diagnosis purposes. 
 
The use of real time MRI (RT-MRI) and micro cameras have allowed greater 
precision allowing the surgeon to identify not just the location of the tumour 
but also the quantity of tumour mass removed thus avoiding unnecessary 
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removal of brain tissue (Carpentier 2008). The invention of microsurgical tools 
have also allowed for greater accuracy at the tumour border. Various other 
surgical techniques using laser beams have recently been produced these are 
less invasive processes.  
 
Complete surgical resection of the tumour with sufficient margins of adjacent 
normal tissue cannot be achieved due to the diffuse mode of local spread so 
most gliomas are reported to re-grow (Berger 1996). As such radiotherapy is 
considered. 
 
1.9.2. Radiotherapy 
 
Radiotherapy, although considered to be aggressive, is the most effective of 
the three therapies. It is give to patients with malignant brain tumours, when 
the cels are rapidly dividing. Though it is most commonly administered in 
conjunction with neurosurgery with the intention of killing any residual cells, it 
is only admistered once, due to the resitrait of the body against radiation. 
Radiotherapy damages the DNA using the cytotoxic affects of X-rays or 
rays, produced by megavoltage linear accelerators or nuclear particles such 
as cobalt60 and caesium137.  
 
Randomized studies have shown 50 to 60 Gy post operative radiation of the 
whole brain increases median survival time from 14 weeks to 36 weeks 
(Shapiro 1976; Walker 1980; Walker 1978) however these quantities have 
been associated with radiation injury (Walker 1979; Bleehen 1980; Chang 
1983) various studies are continually being carried out to reduce radiation 
injury and neurotoxicity however results represent selected patients with local 
diseases have a significant impact as shown in a study by Sarkaria et al 
(1995) who underwent a clinical trial of a novel interstitial radiation device 
placed after debulking. Further studies in this field are required to reduce 
toxicity and unnecessary necrosis. Also, new approaches to improve 
treatment of brain tumours, incorporating radio-chemotherapy after surgery 
are being investigated. 
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1.9.3 Chemotherapy 
 
Chemotherapy is an adjuvant therapy which was given to patients with high 
risk of recurrence, though now is commonly concomitant with radiotherapy. 
Chemotherapy may improve survival albeit slightly, but is associated with 
significant toxicity, however important advances in the development and use 
of cytotoxic drugs have been made recently including the use of 
Temozolomide (an oral alkylating agent) (Gilbert 2013; Stupp 2005), 
carmustine (gliadel wafers) (Westphal 2003; Westphal 2003) and Avastin 
(Junck 2011). The advantage of chemotherapy over other therapies is that it 
is administered when the cells are at their most vulnerable; after surgery.  
Success with chemotherapy relies on three fundamentals; debulking must 
have occurred, the chemotherapy agent should be available and 
chemotherapy should be administered immediately after surgery at the 
maximum dose tolerated and for a limited time only (Grossman 2004). 
Unfortunately, these prerequisites are not always achieved. For example, 
during the therapy of brain tumours, patients are put on adjuvant trials after 
partial resections and stereotactic biopsies the cytotoxic drug is required to 
act upon a larger number of impervious cells. Chemotherapy can be 
administered either individually or as a combination of cytotoxic drugs. Some 
of which include carmustine, lomustine, Irinotecan, Methotrexate, Carboplatin, 
Vincristine, Procarbazine and the newly developed Temozolomide. 
 
Having demonstrated the ability to cross the blood-brain barrier (Ostermann 
2004; Patel 2003), temozolomide, was considered for glioma therapy, after 
phase I and II clinical trials indicated that temozolomide has considerable 
potential in treating gliomas and improving the quality of life of patients (Bower 
1997; Newlands 1996; Paulsen 1999). Professor Malcolm Stevens et al. 
introduced this novel molecule in the late 1980s.  
 
Temozolomide, is a new class of second-generation imidazotetrazine 
prodrugs, it undergos spontaneous conversion under physiological conditions 
to the active alkylating metabolite methyltriazeno-imidazole-arboxamide 
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(MTIC) (Stevens 1987) and as such, does not require hepatic metabolism for 
activation (Clark 1995). These agents are structurally unique as they contain 
three adjacent nitrogen atoms that confer unique physicochemical properties 
and much greater antitumor activity (Stevens 1987). The principle mechanism 
responsible for temozolomide cytotoxicity seems to be the methylation of 
DNA. The active alkylating agent MTIC, degrades to the methyldiazonium 
cation, and transfers the methyl group to DNA (Spassova 1985; Denny 1994). 
The methylation of the O6 position of GMP in DNA, although relatively 
infrequent (6-7%), is usually regarded as the lethal lesion (Zhang 2006; 
Danson 2001; Newlands 1996; Friedman. 2002; Nagasubramanian. 2003). 
Hegi et al. (2005) did a correlative study on specimens from EORTC 
26981/NCIC CE.3 to examine the association of O6-methylguanine-DNA 
methyltransferase (MGMT) gene promoter methylation status with survival. 
MGMT is cytoprotective, it repairs methyl adducts at the O6 position on 
guanine in DNA, and transfers the methyl group to an internal cysteine 
acceptor residue. This reaction results in irreversible inactivation of MGMT, 
requiring increased de novo protein synthesis to restore repair activity. 
Restoration of MGMT activity is a relatively rapid event, usually occurring 
within several hours, in human malignant brain tumors (Schold 2004). The 
effectiveness of temozolomide, therefore, is only assumed to be significant 
with daily repetitive dosing schedules predicted to be most successful at 
depleting MGMT and thereby enhancing its cytotoxicity. As such it was 
reported the effect on survival of combining radiation and temozolomide was 
most marked in glioblastoma patients whose tumors had MGMT promoter 
methylation, those without did not appear to receive significant benefits of the 
combined therapy.  
 
The methyldiazonium cation can also react with RNA and with soluble and 
cellular protein (Bull 1987). However, the methylation of RNA and the 
methylation or carbamoylation of protein do not appear to have any known 
significant role in the antitumor activity of temozolomide (Friedman. 2000). 
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Studies into the efficacy of temozolomide as an adjuvant to radiotherapy 
(Stupp 2005; Stupp 2002) to improve survival time by 14.6 months after 
primary surgical resection. When comparing the effects of temozolomide as 
adjuvant therapy with radiation and radiation alone, adjuvant therapy 
improved survival rates with approximately 9 % of patients surviving 5 years 
(Stupp 2009). In addition, temozolmide taken with other chemotherapies has 
been shown to be efficacious (Vredenburgh 2009), however may also exhibit 
increased adverse effects (Saran 2016). 
 
Studies into administrating the chemotherapy systemically has led to the 
production of carmustine (1,3-bis(2-chloroethyl)-1-nitrosourea) wafers or 
Gliadel wafers which are inserted after debulking into the surgical bed with the 
aim of destroying any residual cells in the vicinity of the surgical bed. Gliadel 
wafers are increasingly a popular approach for delivery of chemotherapy. 
These biodegradable, impregnated polymers are implanted in the tumor bed 
at the time of resection, providing a controlled release of local chemotherapy 
for approximately 3 weeks (Brem 1996), while minimizing systemic adverse 
effects (Tamargo 1989; Fung 1998; Ewend 1996; Ewend 1998; Brem 1992; 
Withrow 2004). Many studies on the use of Gliadel wafers for the treatment of 
both primary and recurrent gliomas have shown improved survival with no 
marked increase in adverse effects (Brem 1991; Brem 1995; Sipos 1997; Olivi 
2003; Westphal 2003), though concern about associated complications have 
arisen, both in published case reports and in a small case series (Weber 
2005; McGirt 2002;  Engelhard 2000; Subach 1999) . These reported 
complications include malignant cerebral edema, resection cavity cyst 
formation, cerebrospinal fluid (CSF) leak, wound healing abnormalities, and 
increased perioperative seizure activity (Engelhard 2000). Gliadel wafers were 
reported to increase median survival of >13 months in primary malignant 
glioma patients (Westphal 2003). Recent studies reported Gliadel wafers with 
concomitant temozolomide was not only well tolerated by patients but also 
resulted in a median survival of >18 months (McGirt 2009; Larocca 2005).  
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1.9.4 Avastin: An Anti-Angiogenic Treatment 
 
Another mode, of increasing interest within the field of conventional therapy, 
are molecular targets, in particular the drug Avastin (Bevacizumab). Avastin 
targets the molecule vascular endothelial growth factor A (VEGF-A). 
Malignant gliomas are highly vascularized tumors. Angiogenesisis is one of 
the pathological hallmarks of GBs. One of the difficulties of developing 
effective treatments for gliomas has been poor drug penetration through the 
blood-brain barrier. By targeting tumor vasculature, theoretically it may be 
possible to bypass this dependence of drugs to cross the blood-brain barrier 
to reach their target. Both experimental (Kamoun 2009; Wong 2010) and 
clinical (Friedman 2009; Kreisl 2009) evidence have reported anti-angiogenic 
drugs decrease vasogenic edema and patients' requirement for 
corticosteroids which are a significant cause of morbidity. 
 
Avastin is a humanized monoclonal antibody that binds to, a stimulant of 
angiogenesis, VEGF-A, and stops tumor growth by preventing the formation 
of new blood vessels. Avastin may work by causing regression of existing 
microvessels, helping arrest tumor growth and reduce tumor size, 
‘normalization’ of surviving mature vasculature, making the tumor vasculature 
more conducive to effective anti-cancer therapy and inhibition of 
neovascularization (Mukherji 2010). 
 
Avastin was first approved in combination with chemotherapy in the treatment 
of lung (Johnson 2004), breast (Miller 2007), renal (Yang 2003) and colorectal 
cancers (Berretta 2008; Hurwitz 2004). Investigation into the use of Avastin in 
the treatment of GBs has yielded positive results and in 2009 the FDA granted 
approval for Avastin to be used in the treatment of GBs following prior therapy 
(Cohen 2009). Studies combining Avastin and chemotherapy drugs, in 
particular irinotecan and temozolomide reported improved overall survival 
times. 
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Despite initial reluctance to investigate Avastin in patients with brain tumors 
owing to concerns of intracranial haemorrhage, a series of 29 patients with 
recurrent malignant gliomas treated with Avastin and irinotecan showed no 
significant haemorrhage (Stark-Vance 2005). Schiff et al. (2008) reported 
Avastin in combination with irinotecan, when compared to Avastin alone not 
only reduced progression but also improved survival rates. However, 
irinotecan had been previously tested as a single agent in phase 2 trials and 
was found to have low levels of progression free survival. These results led to 
investigation of the use of Avastin alongside temozolomide. Although this 
combination was also well tolerated, it did not improve median overall survival 
or progression free survival (Verhoeff 2010, p1723). Investigation into 
combinations with Avastin and other chemotherapy drugs is on-going. 
 
1.10 Conventional Medicine Clinical Trials. 
 
Conventional medicine is continually being investigated and evaluated. 
Globablly clinical trials into the efficacy of various drug combinations are being 
performed. Currently in the UK alone there are approximately 20 clinical trials 
recruiting adults for glioma therapy research. Table 4 summaries a few of the 
trials currently recruiting. 
 
Gliomas display several biological features that succesfully evade 
conventional therapy. Due to these complications, despite continuing clinical 
trials and experimentation, conventional medicine has only made two novel 
advances in the past three decades, namely Temozolomide and Avastin. 
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Table 4 A brief summary of the top 10 clinical trials being performed for the use of conventional medicine as treatment for brain tumours, in the UK in 2016 
(Clinicaltrials.gov). 
Trial therapy Phase  
Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma I 
Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma II 
Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme II 
Acridine Carboxamide in Treating Patients With Recurrent Glioblastoma Multiforme II 
Bevacizumab in Recurrent Grade II and III Glioma II 
Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma III 
Imatinib Mesylate in Treating Patients With Gliomas II 
Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas I 
Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, 
a Malignant Brain Cancer) 
III 
Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma 
(GBM, a Malignant Brain Cancer). 
II 
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1.11 Requirements of New Therapies 
 
Treatment for GBs to date, regrettably has not been successful in curing 
these debilitating neoplasms, though a number of possible therapies have 
been investigated, for their management, in both the conventional (including 
temozolomide, gene therapy and stem cells) and complementary (including 
flavonoids) fields. For an agent to be of therapeutic value for brain tumour 
management it should not only be cytotoxic, anti-invasive, anti-angiogenic or 
pro-apoptotic but most importantly it should be able to cross the blood-brain 
barrier (BBB).  
 
1.12 Use of Complementary and Alternative Medicine 
 
Complementary and alternative medicine refers to those health care practices 
and products that are not considered part of conventional medicine. The 
words 'complementary' and 'alternative' are used in conjuction, suggesting 
they mean the same thing. Although they are a combined phrase i.e. 
complementary and alternative therapies' (CAM), but there is an important 
difference. It is not always easy to decide whether something is a 
complementary or alternative therapy.  
 
Originally described by Eisenberg et al. (1998) as interventions neither taught 
widely in medical schools nor generally available in US hospitals, CAM has 
undergone a radical change of thought and has recently been described by 
Ernst et al (2008) as diagnosis, treatment and/or prevention which 
complements mainstream medicine by contributing to a common whole, by 
satisfying a demand not met by orthodoxy or by diversifying the conceptual 
frameworks of medicine. 
 
A complementary therapy is a therapy which can be used alongside 
conventional medical treatment. They aim to decrease morbidity and help 
cope with treatment. An alternative therapy is generally used instead of 
conventional medical treatment. The main difference between alternative and 
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conventional treatments is all conventional cancer treatments have to go 
through rigorous testing by law in order to prove that they work though most 
alternative therapies have not been through such testing. As such it some 
alternative therapies may cause previously unknown side effects. 
 
There are many different types of complementary therapy, including 
aromatherapy, acupuncture, massage therapy, visualization, yoga and herbal 
medicines. Health care professionals are generally supportive of the use of 
complementary therapies, though some can be reluctant of their use as many 
have not been scientifically tested in the same way as conventional 
treatments. Various research trials have been performed though more studies 
and consistency of testing is needed to help develop knowledge on the 
optimum function and use of complementary therapies. Unlike complementary 
therapies, alternative therapies are used instead of conventional medical 
treatment. People with cancer have various reasons for wanting to try 
alternative therapies, some may not start conventional treatment and may 
choose to use an alternative therapy instead and others stop conventional 
cancer treatment and switch to an alternative therapy. Currently investigation 
on complementary and alternative medicines (CAM) in the 
management/treatment of, not only brain tumours but also many other 
aliments including other cancers, heart disease, asthma and many more, is 
actively being performed. 
 
The prevalence of CAM is increasing every year; one or more CAM therapies 
are used by 46% of the UK population in their lifetime and 10% annually visit 
a CAM practitioner (Thomas. 2004; Thomas 2001). CAM, in the UK, has been 
divided into three groups by the government; professionally organised 
alternative therapies, complementary therapies and alternative disciplines 
which is sub divided into; Long-established and traditional systems of 
healthcare and other alternative (House of Lords; Science and Technology, 
sixth report, 2001). 
CAM has widely been investigated as part of a therapeutic regime against 
cancer.  Up to 90% of cancer patients use one or more forms of CAM, 
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including relaxation and meditative techniques, vitamins and herbal medicines 
and physical or movement therapies (Shen 2002; Richardson 2000; Navo 
2004; Swarup 2006; Vapiwala 2006). Specifically, evaluation of the primary 
brain tumour patients found that approximately 40% use one or more forms of 
CAM (Armstrong 2006; Heese 2010)  in particular 39% of patients chose to 
employ homeopathy (Heese 2010). Another common CAM modality, chosen 
by patients, is Chinese herbal medicine. Chinese herbal medicine has long 
been used for treating malignancies, side effects of conventional treatment 
and as adjuvant therapies (Hedigan 2010; Chiaramonte 2010). 
 
Despite the current popularity of CAM, most mainstream oncologists have 
very little understanding of the therapies (Newell 2000). CAM is also not 
aways encouraged due to a lack of herbal standardization, quality control 
issues, safety and toxicity concerns, interactions with existing therapeutic 
modalities, a lack of proven efficacy by standard clinical trials and a lack of 
mechanistic details, to name a few (Azaizeh 2006) this therefore disheartens 
patients who believe a greater interest and understanding, in CAM, should be 
offered by doctors (Gray 2002).  
The increased interest in CAM can be attributed to several factors including 
the suggested benefits of CAM for cancer patients, the desire to take control 
of their illness and feel hopeful, the notion that CAM modalities are safe and 
nontoxic, the ease with which they may be obtained and the decreased faith 
in conventional medicine to meet patient needs. (Balneaves 1999; Henderson 
2004; Munstedt 1996; Navo 2004; Ponholzer 2003; Richardson 2000; 
Richardson 2002; Sparber 2000; Verhoef 1999; Verhoeff 2010; Hilsden 1999; 
White 2002). Expectations for CAM are quite high with patients expecting 
CAM to improve their quality of life, alleviate symptoms, prolong life and cure 
their disease. Those with incurable diseases, particularly value CAM for its 
medicinal potential (Richardson 2000; Ernst 1998; Eisenberg 1998; Kaptchuk 
1998).  
 
Health professionals in general do express positive views when CAM is used 
complementarily and not as an alternative. Results so far published have 
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shown that CAM can play a role in improving the quality of life and general 
well-being  (Adams 2004; Adams 2011). CAM modalities are also involved in 
supportive care (Leis 2007). In recent years, naturally occurring compounds 
present in diet and beverages, known as nutraceuticals, have gained 
considerable attention because of their beneficial effects on health as cancer 
chemopreventive or cardioprotective agents. Nutraceuticals play an important 
role, in CAM, as a source of effective anti-cancer agents currently over 62% of 
currently used anti-cancer agents are derived in one way or another from 
natural sources (Gonzales 2006), including phytochemicals 
 
1.13 Phytochemicals and Cancer 
 
Phytochemicals are nutraceuticals which derive from plants products. 
Successful studies are being conducted in vitro to show a wide range of 
antioxidant phytochemicals, (including flavonoids, polyphenols and 
carotenoids) are radioprotective in experimental systems (Paul 2010; Weiss 
2003; Borek 2001). Some phytochemicals induce apoptosis in cancer cells 
(Banjerdpongchai 2016; Mehdinezhad 2016) such as, including prostate 
cancer cells and breast cancer cells (Pinto 2001), colon cancer cells (Zheng. 
2003) and ovarian cancer (Zhang 2016). Additional research is needed to 
establish the role of phytochemicals in conjunction with cancer treatment by 
radiation as antioxidant supplementation during radiation therapy may protect 
cancer cells, in conjunction to normal cells, and reduce the efficacy of 
treatment (Borek 2004). 
There are also reasons for thinking that some herbal supplements might 
biochemically interfere with chemotherapy as well as radiation treatments, 
(Labriola 1999) alter treatment compliance (Durant 1998). Patients taking 
chemotherapeutic drugs and CAM are at least 27% at risk of developing 
clinically relevant CAM–drug interactions (Welder 2006). As such health 
professionals are reluctant to recommend CAM. An increasing number of 
CAM practitioners, though, aid understanding and knowledge of any drug 
interactions between CAM and conventional therapies. 
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1.13.1 Flavonoids 
 
Flavonoids are commonly found in foodstuffs including vegetables, fruit, nuts, 
seeds, wine and tea, and it is estimated that the daily intake in the western diet 
ranges from 200mg/day to 1gram (Hertog 1995; Pierpoint 1990).  
 
The basic structure comprises two benzene rings linked by heterocyclic pyran or 
pyrone ring in the middle. These agents display many therapeutic properties 
including anti-inflammatory, antioxidant, antiviral, and anticarcinogenic activity. 
Certain flavonoids have been found to exhibit anti-proliferative properties against 
some cancers and are known to cross the BBB (Zbarsky 2005; Datla 2001). 
1.14 CAM: A Thearpy for Gliomas 
 
1.14.1 CAM in clinical trials 
 
The rising use of CAM has also had an impact on the number of clinical trials 
performed. Clinical studies can provide CAM modalities the necessary scientific 
accreditation for use as therapies. Table 5 summaries the limited clinical trials 
currently being performed in brain related therapies. 
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Table 5 A brief summary of a fraction of clinical trials currently being performed for the use of CAM in oncology and brain related 
therapy in 2016. 
 
 
Trial Phase 
Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology 
Clinical Trials 
I 
Measuring Concerns of Cancer Patients Referred to Complementary Medicine Treatment Integrated 
Within Oncology Service 
 
Oregon Center for Complementary and Alternative Medicine in Neurological Disorders  
Improving Hand Use in Multiple Sclerosis II 
Nutritional Supplements & Complementary/Alternative Medicine by Prostate & Breast Cancer Patients  
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme II 
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1.15 Evaluation of Micronutrients in Glioma Therapy 
 
The current study is part of a clinical trial which involves the use of 
micronutrients (vitamins, minerals, flavonoids and other agents found in food), 
in brain tumour management (Rooprai 2003). The research is based upon the 
original hypothesis and studies within other groups, which was that naturally 
occurring compounds such as flavonoids may effectively serve as anti-glioma 
agents (Dissanayake 2016; Li 2016; Kiekow 2016; Aroui 2016; Wang 2015). 
This efficacy is based on the ability of citrus flavonoids (particularly tangeretin) 
to interfere with underlying mechanisms of tumour invasion in vitro (Rooprai 
2001). The clinical trial involves a combination of 7 micronutrients; tangeretin, 
chokeberry extract, lycopene, selenium, turmeric, red grape seed extract and 
red clover extract. Earlier in vitro studies have indicated that chokeberry 
extract, tangeretin and selenium have promising therapeutic potential for 
malignant gliomas in vitro. 
 
1.16 Red Clover Extract 
 
Red clover extract is a green powder extracted from the red clover plant 
(appendix). Its two main constitutes are the isoflavonoids, commonly also 
found in soya are genistein and daidzein. In addition, red clover extract also 
contains the precursors of the above named isoflavonoids; Biochanin A and 
formononetin respectively. The two precursors have a methylated structure, 
which must be demethylated to become the active forms. This is a successful 
process, in vivo, as demonstrated by Setchell et al (2001).  
Genistein and daidzein mimic oestrogen by binding to the oestrogen receptor 
in cells (Adams 2012) and been shown not only have ability to cross the blood 
brain barrier (Moskot 2014; Upadhyay 2014) but also to exhibit the same the 
neuroprotective actions and functions in the brain (Kostelac 2003).  
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Figure 6 The isoflavonoids of Red Clover Extract. Genistein and Daidzein are the 
active components and Formononetin and Biochainin A are their respective 
precursors. 
In addition to affecting the pathways effected by activation of the oestrogen 
recepetor, genistein in particular, has been shown to inhibit the nuclear 
protein topoisomerase II (Okura 1988), platelet-activating factor- and 
epidermal growth factor-induced expression of c-fos (Tripathi 1992), 
diacylglycerol synthesis (Akiyama 1987), and tyrosine kinases (Dean 1989). 
Additionally, it inhibits microsomal lipid peroxidation (Jha 1985) and 
angiogenesis (Fotsis 1993). 
  
1.16.1 Red Clover Extract and Cancer 
 
Due to the isoflavonoids being structurally related to oestrogenic steroids and 
thus having the ability to mimic oestrogen and bind to its receptor sites, this 
provide the rationale for lower rates of hormone related cancers such as 
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breast, prostate and ovarian cancers(Zhao 2016; Marcela 2016; Yang 2016; 
Kang 2016; Wang 2015)..  
The active isofalonioids found in red clover extract have also been shown in a 
vast number of studies to inhibit a number of non-hormone dependent 
cancers including leukaemia (Zhang 2012), liver cancer (Zhou 2016), lung 
cancer (Yang 2016) and stomach cancer (Huang 2014). 
Kang et al (2016), demonstrated that the consumution of genistein, through 
soy milk, decreased the proliferation of human prostate cancer cells by 
regulating p21 (component of cell cycle regulation). Other studies like Shen et 
al (2000) also found that genistein was also anti-proliferative in prostate 
cancer. The study found the cells became arrested in the G1 phase of the cell 
cycle thus ceasing proliferation, however unlike in breast cancer; it did not 
promote a pro-apoptotic effect in prostate cancer. 
Similar effects on cancer cell proliferation have also been noted in non-
hormone related cancers in humans such as osteosarcomas (Hu 2015), lung 
cancer (Liu 2015), pancreatic cancer (Han 2012) and colon cancer (Yoo 
2015). 
 
In a 2008 study, Li et al (2008) illustrated that genistein inhibits cell 
proliferation and promotes apoptosis via the intrinsic pathway in breast 
cancer. An earlier study carried out in 2003 by Gong et al. noted a similar 
finding. A study analyzing testicular cancer cells demonstrated an enhanced 
expression of caspase 8, caspase 3 and PARP, suggesting genistein 
exhibited a pro-apoptotic effect on these cells (Al-Maghrebi 2016). Laryngeal 
cancer cell lines have also exhibited pro-apoptotic effects when treated with 
genistein (Du 2016). 
Fortunately, in 2008, Zhang et al, found that genistein was anti-invasive, on 
prostate cancer. Genistein has also been found to induce apoptosis via the 
extrinsic pathway in ovarian cancer cells (Thasni 2008).  
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As the effects of the isoflavonoids, found in RCE, have been increasingly 
positive when looking the anti-invasive and pro-apoptotic properties in other 
cancers, though few studies have been carried out on the effects of genistein 
or daidzein on brain tumours and no studies have been performed on the 
effect of red clover extract on brain tumours this warrants further investigation. 
 
1.17 Red Grape Seed Extract 
 
Red grape seed extract is a red powder (appendix) containing a number of 
active flavonoids including catechins, epicatechins and epicatechin (-3-0-) 
gallate or collectively polyphenols (Polyphenolics.com). In vivo these 
flavonoids exist as monomers, dimmers and/or oligomers. They are active in 
conjunction with one another rather than as separate entities i.e. in oligomeric 
form. 
 
Polyphenols are important components of dietary agents that have been 
demonstrated by epidemiological, preclinical, and clinical studies to have 
various health promoting benefits, including neuroprotective (Malhotra 2016), 
cardioprotective (Zhang 2015), and chemopreventive effects. These regulate 
various cellular processes, such as cell proliferation, cell cycle, cell survival, 
and apoptosis that have been implicated in cancer prevention and treatment. 
 
1.17.1 Red Grape Seed Extract and Cancer 
 
Its active ingredients, oligomeric proantho-cyanidins (OPCs) are known to be 
anti-angiogenic (Boik 2001) and have also been shown to inhibit growth of 
cancerous cells.  
Eng et al (2003) suggested the use of RGSE as a chemo protective agent for 
breast cancer as it arrests the cells in the G1 phase of the cell cycle. Similarly 
prostate cancer also undergoes a block in tumour cell growth when treated 
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with RGSE (Singh 2003). Yao et al (2016) analyzed the effect of proantho-
cyanidins in nasopharyngeal carcinoma. This study found not only a reduction 
in the viability of cells but also the induction of cell cycle arrest at the G2/M 
phase causing apoptosis. Furthermore, upon examination of the mechanism 
of apoptosis they noted a increased expression of the pro-apoptotic protein 
Bax, cleaved caspase-3 and cleaved poly(ADP-ribose) polymerase (PRAP) 
protein, along with a decrease expression of the anti-apoptotic proteins Bcl-2 
and Bcl-xL. Other examples of studies with demonstrate the increase in 
apoptotic potential following treatment with either grape seed extract or 
proantho-cyanidins (Zhou 2016; Kumar 2015; Chen 2014;Parsad 2012) 
illustrated similar mechanisms of action in other cancer types.  
In 2004 Singh et al also found that grape seed extract induced apoptosis and 
reduced angiogenesis in prostate cancer cell. Much like Singh et al, Zheng et 
al (2015) demonstrated a reduction in angiogenesis following rtreatement with 
an OPC. They looked at human astrocytoma cells and human hepatoma cells 
following treatment with oligomer procyanidins (F2), a fraction extracted from 
grape seeds. They noted that EGFR-PI3K-AKT-mTOR and MAPK-ERK1/2 
pathways were inactivated and vascular endothelial growth factor (VEGF) and 
matrix metalloproteinases (MMP)-2 expressions were supressed, ultimately 
reducing the presence of angiogenesis.  Other studies also demonstrated a 
reduction in the expression of VEGF and MMPs (Stagos 2015; Kanavi 2014; 
Kuroyanagi 2014).  
Metastatic cancers, when treated with a form of grape seed extract also tend 
to have similar outcomes; anti-proliferative effects and pro-apoptotic effects 
(Rivera 2016; Martinez 2005).  
Much like RCE, although components of grape seeds have been reviewed for 
their effects on brain tumours, RGSE has not yet been investigated for its anti-
glioma effects. As grape seed extracts and their components have anti-cancer 
effects RGSE warrants investigation into it’s anti-glioma effects. Preliminary 
studies have indicated that this extract has got anti-invasive potential in brain 
tumours (Rooprai et al. personal communication). 
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Figure 7 The isoflavonoids of Red Grape Seed Extract. 
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1.18 Aims 
The current study is part of a clinical trial which involves the use of 
micronutrients (vitamins, minerals, flavonoids and other agents found in food), 
in brain tumour management (Rooprai 2003). The research is based upon the 
original hypothesis which was that naturally occurring compounds such as 
flavonoids may effectively serve as anti-glioma agents. This efficacy is based 
on the ability of citrus flavonoids (particularly tangeretin) to interfere with 
underlying mechanisms of tumour invasion in vitro (Rooprai 2001). The 
clinical trial involves a combination of 7 micronutrients; tangeretin, chokeberry 
extract, lycopene, selenium, turmeric, red grape seed extract and red clover 
extract. Earlier in vitro studies have indicated that chokeberry extract, 
tangeretin and selenium have promising therapeutic potential for malignant 
gliomas in vitro (Personal communication; Rooprai 2001). 
The aims of the proposal are to evaluate the anti-invasive, pro-apoptotic and 
anti-angiogenic potential of red clover extract and red grape seed extract on a 
number of biopsy-derived GBs by answering the following questions; 
 
 At what concentration is the viability of the cells affected? 
 Do the micronutrients affect cell invasion? 
 Is the expression of cell adhesion molecules impacted by the 
micronutrients? 
 Do the micronutrients affect apoptosis? 
 Can changes in microenvironment affect antigenic expression?  
 Do the micronutrients affect angiogenesis? 
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1.19 An Overview of the Thesis  
 
Chapter 2 outlines the methods used as part of this study to address the 
research questions set out. Chapter 3 is a small study undertaken to 
determine if changing the microenvironment, in which the cells are cultured, 
changes the phenotypic properties of glioma cells. The phenotypic changes of 
these cells were determined by investigating their antigenic expression. 
Results of experimentation are highlighted in chapter 4 and are discussed in 
chapter 5. Following this are the references and appendicies. 
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CHAPTER 2: Materials and Methods 
2.1 Source of Cell Cultures  
 
Specimens provided from the Neurosurgical staff at King’s College Hospital, 
London, obtained from epileptic patients at temporal lobectomy, served as 
normal astrocytic cultures and four biopsy-derived malignant cell lines at low 
passages were also studied. Ethical approval for this study has been granted 
by King’s; LREC protocols 02-056 (Do flavonoids cross the human Blood 
brain barrier) and 00-173 (Brain tumour invasion: in vitro studies). Table 6 
summaries all the biopsy cultures used as part of this study. 
 
Table 6 Four biopsy-derived malignant cell lines and 1 normal astrocytic culture  
 
Cell line Sex of Patient Passage 
number 
Biopsy grade 
MUAB-C F 4-6 Normal astrocytic cell line 
MUMG-GM M 4-6 Grade IV GBM 
MUTC-GM M 5-7 Grade IV GBM 
MUIH-GM M 4-6 Grade IV GBM 
MUPK-GM M 3-5 Grade IV GBM 
Biopsies provided by staff at King’s College Hospital. Following initial culture, these cultures 
were investigated at low passage. 
Human umbilical vein endothelial cells (HUVECs), used as part of 
angiogenesis assays, were provided by Dr Alan Cooper, University of 
Portsmouth. The passage of these cells is unknown, though experimentation 
was carried out after 3-5 passages. Existing cultures of IPSB-18 (P26-30), for 
all other studies were provided by Dr Timothy van Meter, Virginia 
Commonwealth University, though were originally cultured from biopsy by 
other members of the neuro-oncology group. Cell lines employed for micro-
environment studies were provided by collaborators in Ireland and Norway.  
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2.2 Micronutrients  
 
The red clover extract (RCE), donated by Linnea, in Switzerland is a green 
coloured powder constituting a mixture of four isoflavones of which 
Formononetin and Biochanin A are precursors of Genistein and Daidzien, 
respectively. Linnea performed HPLC yielding a total quantity of isoflavones 
found in the extract, to be 40.4%, specifically 17.8% biochanin A, 22.1% 
formononetin, 0.4% genistein and 0.1% daidzein (appendix). 
 
The red grape seed extract (RGSE) supplied by Polyphenolics, USA is a fine 
red/brown coloured powder. The main constituents of the red grape seed 
extract are; catechin, epicatechin and epicatehin (-3-0-) gallate, of which 10% 
(min) are monomers, 60-80% oligomers and 25% (max) polymers as 
illustrated by HPLC analysis by Polyphenolics (appendix). These individual 
constituents undergo condensation reactions thus elongating to form 
oligomeric proanthocyanidins (personal communication) 
 
Initially the micronutrients were dissolved in Dimethyl sulfoxide (DMSO – 
Acros Organics 414885000) (100mg/ml), and filtered. Though further dilutions 
employed Dulbecco’s modified Eagle’s medium without phenol red (clear 
DMEM – GIBCO 31053-028). A working solution of 1mg/ml was prepared, 
from which subsequent dilutions were formulated. At a later date it was 
discovered that the DMSO had a direct effect on the cells, resulting in 
anomulus results. Subsequent adaptation of the methodology meant the 
micronutrients were dissolved in clear DMEM instead, before being filtered 
and diluting further. 
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2.3 Cell Culture techniques 
 
2.3.1 Setting up Primary Human Astrocytic Culture 
 
Upon resection the neurosurgeon immediately placed the biopsy into DMEM 
supplemented with 1% antibiotic/antimycotic solution and then treated as 
Freshney et al. (2006, p 5; 2005) describe in the protocol for setting up a 
primary explants culture. The tissue was rinsed in Hanks balanced salt 
solution (HBSS – GIBCO 14170070) in a petri dish and unwanted tissue, such 
as blood vessels or necrotic areas were dissected and removed. Remaining 
tissue was finely chopped with scalpels into pieces, approximately < 1mm3. 
This was diluted in DMEM supplemented with 10% heat-inactivated foetal calf 
serum (FCS) and 1% antibiotic/antimycotic solution (complete medium). The 
mixture was transferred to culture flasks, which were placed in the incubator 
at 37oC and 5% CO2. The cultures were maintained for 1-2months (dependent 
upon the individual cultures) to achieve confluence. 
 
2.3.2 Maintenance of Glioblastoma and Astrocytic Cultures 
 
The astrocytic cultures were routinely cultured as monolayers at physiological 
pH by equilibration with 5% CO2 in air in a standard humidified incubator at 
37oC, in either 25cm2 or 75cm2 culture flasks using complete media; 
constituting 10% foetal calf serum (FCS – Sigma F-7524), unless stated 
otherwise and 1% antibiotic/antimycotic solution (penicillin/ streptomycin – 
GIBCO 15240-062) in Dulbecco’s modified Eagle’s medium (DMEM – GIBCO 
61965-026), unless otherwise stated. Prior to use the FCS was heat 
inactivated a procedure which involves immersing the serum into a 60oC 
waterbath for five minutes, to inactivate the complement. The medium was 
changed whenever it was required, usually between 3-4 days, dependent 
upon the culture. Once confluent cells were passaged or harvested for 
experimentation. 
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Cells involved in the evaluation of microenvironment changes (chapter 3) 
were cultured for 48hr in complete medium supplemented with 10% FCS, 
newborn calf serum (NCS – Biowest S0450) or human serum (HS – Biowest 
S4190), as required. 
Cultures involved with all other experiments were treated with the 
micronutrients 48hrs prior to experimentation unless stated otherwise. 
 
2.3.3 Maintenance of HUVEC Cultures 
 
HUVEC cultures were maintained in a similar manner to the astrocytic 
cultures with the exception of the media used. Prior to culture the 25 mm2 
flasks were coated in 1% gelatin for 1 hour and the excess removed the cells 
were then seeded in a media specific to HUVEC cells; large vessel 
endothelial cell basal medium (TCS cellworks) constitutes 10% foetal calf 
serum, 0.1% antibiotic supplement (Gentamicin/Amphotericin), and 0.1% of 
each of the following beta fibroblast growth factor (bFGF), epidermal growth 
factor (EGF) and hydrocortisone. 
 
2.3.4 Mycoplasma Testing 
 
Mycoplasma staining is important in the use of cell culture, as contamination 
of cultures is unaffected by ordinary antibiotics (Hay 1989; Harlin 2008). The 
procedure was followed in accordance to the instructions of the mycoplasma 
kit (GIBCO M7006).  
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2.4 Cell Viability Techniques 
 
2.4.1 Phase Contrast Microscopy 
 
Phase contrast microscopy is a technique to obtain micrographs of the 
morphology of the cells. Briefly cultures were maintained to around 80% 
confluence upon which they were examined under a phase contrast 
microscope. Micrographs were also taken after treatment of flasks with 
concentrations of the micronutrients to observe any cell death, if any, and to 
what extent angiogenesis occurred during experiments involving HUVEC 
cultures. 
 
2.4.2 Population Doubling Time 
 
Population doubling time (PDT) is important to measure, to determine whether 
any abnormalities in growth periods occur at any point during 
experimentation. For example as mycoplasma contamination is undetectable 
to the naked eye, contamination may be detected indirectly via the culture 
growth patterns.  
To calculate the population doubling time, the cells were harvested and 
counted, in order that a population of 100,000 cells could be seeded into a 6 
well plate. Cell count was achieved using the trypan blue method. Cells were 
initially harvested and resuspended in 1ml of complete media, from which 
20l was combined with 20l of trypan blue stain. 20l of this were then 
placed on a haemocytometer. Live cells, those that were not stained blue, 
were counted in the central square. Both chambers of the haemocytometer 
were counted and the cell count deduced by inserting the two counts ( and 
β) into the below equation: 
 
Number of cells/ml = ( + β) x 2 x 10,000 
       2 
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Each cultured well was counted at timed intervals and the total number of 
cells, plotted against time.  
 
The lag phase of this curve may be due to a period of adaptation to the in vitro 
environment thus there are only a few cells present. As the cells enter the log 
phase they begin to replicate and grow. It is from this region of the graph that 
we may calculate population doubling time. The plateau phase represents 
depletion in environmental conditions such as space and nutrients and 
therefore the number of cells begin to settle and die.  
 
2.4.3 MTT cytotoxicity assay  
 
 
 
 
 
 
 
 
Figure 8 MTT structure which reacts with active mitochondrial proteins to form a 
soluble blue/purple salt which may be dissolved. 
 
 
MTT, a quantitative, colorimetric assay for mammalian cell survival and 
proliferation, is a tetrazolium salt, which is converted from yellow and soluble 
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to a blue/purple, insoluble formazan salt, by the succinate-tetrazolium system 
active only in viable cells. This insoluble compound is unable to be measured 
by normal absorbance methods; therefore it must be solubilised using DMSO. 
The intensity of the colour change indicates the enzymatic activity of viable 
cells. Optimized for glioma cells this protocol is based on the experiment 
described by Nikkah et al (1992) and adapted due to apparent biphasic 
results. 
 
Cell were harvested and plated in 96 microtitre plates in clear complete 
medium, as the phenol red may interfere with the final reading. They were 
plated at a density of 10,000 cells per plate in 200µl clear complete medium. 
Cells were left overnight to adhere after which the medium was replaced with 
fresh medium (without foetal calf serum) containing a range of concentrations 
of the micronutrients dissolved in clear DMEM (initially DMSO) and incubated 
for 48hr at 37oC and 5% CO2. To ensure consitancy between experimentation 
and indication of inconsistencies, a positive and negative control were 
concurrently observed in each plate.  
 
Subsequent to incubation the media was replaced with 100 µl MTT solution 
(1mg/ml) for 4 hours after which it was discarded and the formazan crystals 
dissolved in 200 l DMSO. The solution was gently pipetted up and down to 
attain homogeneity and then placed in an incubator at 37°C for 5 minutes to 
let the air bubbles that may have been generated disappear. Absorbance was 
measured at 570 nm on a FLUOstar Optima plate reader. 
 
2.5 Charcterisation of Astrocytic Cell Cultures 
 
2.5.1 Analysis of Antigenic Expression Using Flow Cytometry  
 
This semi-quantitative method characterises the antigenic expression of cells 
using fluorescently labelled antibodies. This procedure will allow for the 
comparison of untreated tumour cells against either untreated normal 
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astrocytes or tumour cells treated with micronutrients. Once confluent the 
cells were harvested from flasks using tryple express (trypsin) for 10min. The 
cells were then neutralised and washed with phosphate buffer solution (PBS) 
supplemented with 5% FCS.  All washes were performed using PBS 
supplemented with 5% FCS and then centrifuged for 5 mins at 1000rpm. The 
cells were resuspended in 200l of for 10 mins the appropriate primary 
antibody (Table 7) washed and resuspended in the appropriate secondary 
streptavidin fluorescein (FITC); for example, if the host species was mouse 
the secondary adopted would be anti-mouse.  
 
Table 7 Primary antibodies were used to characterise cell cultures. An illustration of 
the dilutions used and the host species the antibody was cultured in. 
 
Antibody Dilution Host species Monoclonal or Polyclonal Source 
GFAP Neat Mouse Monoclonal CRUK 
CD44 1:100 Mouse Monoclonal CRUK 
1 Neat Mouse Monoclonal CRUK 
V Neat Mouse Monoclonal CRUK 
NCAM 1.1000 Mouse Monoclonal Abcam 
 
The cells were then washed and resuspended in PBS (2% FCS). Prior to 
analysis 5l of propidium iodide (PI) was added and analysis was performed 
using a FACs Calibur against a suitable control. 
 
2.5.2 Immunocytochemistry  
 
Complementing flow cytometry, this qualitative method of characterisation will 
allow for the detection of the antigens GFAP, CD44, 1, v, and Eric-1 
(NCAM) using the biotin streptavidin FITC protocol. Cells were harvested and 
resuspended in either complete medium or various concentrations of the 
micronutrient, onto 24x24 mm glass coverslips, previously autoclaved, and 
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placed inside 35mm sterile plastic petri dishes. These were then incubated for 
48hrs. The cells were then rinsed in PBS and incubated for one hour with the 
primary antibody at the appropriate dilution (Table 8).  
 
Table 8 Primary antibodies used to characterise cell cultures. An illustration of the 
dilutions used and the host species the antibody was cultured in. 
 
Antibody Dilution Host species Monoclonal or 
Polyclonal 
Source 
GFAP Neat Mouse Monoclonal CRUK/Abcam 
CD44 1:100 Mouse Monoclonal CRUK/Abcam 
1 Neat Mouse Monoclonal CRUK 
V Neat Mouse Monoclonal CRUK 
NCAM 1.1000 Mouse Monoclonal Abcam 
 
 
Coverslips were washed three times in PBS and incubated with biotinylated 
secondary antibody specific to the host species of the primary antibody 
(DAKO monoclonal (anti-mouse) - F0313 polyclonal (anti-rabbit) - E0354) for 
30 mins. Consequently the coverslips were washed in HBSS and incubated in 
the dark with fluorescein-streptavidin conjugate (FITC). The cells were 
washed, again, three times and fixed with acid alcohol (1ml concentrated HCl 
in 90 ml of 70% ethanol) for two mins after which they were rinsed three times 
in HBSS or until discolouration of the phenol red indicator ceases. It is 
important to remember, for internal antigen detection such as GFAP fixation 
occurs prior to incubation with primary antibody. Counterstaining with 
propidium iodide (PI) followed for 10 sec, only, then immediately flushed with 
HBSS. The coverslips were rinsed in HBSS and then mounted on to glass 
slides in Citiflour anti-fadent.  
 
2.6 Invasion Assays 
2.6.1 2-dimesional Invasion Assay using Boyden Chambers  
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Boyden or Transwell TM chambers measure the ability of the cells to invade 
the surrounding matrix. Prior to performing the invasion assay, cells were 
required to be gradually weaned down to serum free media as abruptly 
depriving cells of serum is not always well received by many cell types. To 
achieve this, cells were first cultured in the presence of 10% FCS and 1% 
antibiotic for approximately 24hrs or until the cells were sub-confluent, after 
which, the medium was replaced with complete media supplemented with 5% 
FCS and antibiotic and incubated for a further 24 hrs. Subsequent to this 
incubation the serum supplemented media was once again decreased this 
time to 2.5% FCS for 24 hrs. Finally the media was replaced after 24hrs with 
serum free media. 
 
Four hours prior to seeding, the chamber is coated in 100l of ECM 
component proteins routinely human placental collagen type IV (10g/ml. 
Sigma no. C5533). The polycarbonate filter divides the well into an upper and 
lower compartment, the cells are seeded on the upper surface of the filter in 
serum-free medium and the lower chamber is filled with complete medium, a 
chemo attractant. Upon incubation at 37oC for 48hrs the cells were washed 
and stained with a crystal violet stain diluted 1:100. The cells were then 
counted in both the upper and lower chambers and the percentage invasion is 
calculated using the equation below; 
Percent invasion = mean cells in the lower compartment  x 100 
mean total cell number 
 
2.7 Detection of Apoptosis  
2.7.1 Annexin V Assay  
 
Cells were plated in 25 cm2 tissue culture flasks at 1 × 105 cells per flask, 
incubated overnight, and treated with micronutrients or DMSO control for 
48hr. Subsequent to incubation, media from the flasks wasa collected as they 
could contain dead or dying cells that had detached from the flasks. Adherent 
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cells were harvested and added to the respective media. Cells, at a 
concentration of 1 × 105 cells per 100 μl, were washed with ice cold 
phosphate-buffered saline and resuspended in binding buffer (140 mM NaCl, 
10 mM HEPES, 2.5 mM CaCl, pH 7.4) and stained using annexin V-FITC 
followed by  incubation at room temperature in the dark 15 min. Before 
analysis a few drops of PI was added and measured by flow cytometry on a 
Beckman Coulter Epics XL-MCL Flow Cytometer within one hour of annexin 
V/PI staining. A minimum of 10,000 events was collected for each sample. 
 
2.7.2 TUNEL Assay 
 
The terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling 
(TUNEL) assay was performed in order to detect apoptotic cells to confirm 
annexin V results. Beyond treatment of cells with the micronutrients, the cells 
were fixed in 4% paraformaldehyde for 10 min. TUNEL staining for detection 
of apoptotic cells was done using the TUNEL Apoptotic Detection kit 
(Promega) as per the manufacturer's instructions. Briefly, the fixed cells were 
washed in PBS and then incubated with 0.2% Triton x 100 in PBS for 5 min at 
room temperature. After washing the cells were then incubated in 50 µL of 
terminal deoxynucleotidyl transferase end-labeling cocktail with FITC for 60 
min in the dark at room temperature. The reaction was terminated, with 2% 
SSC solution for 15min and washed in PBS. The cells were then mounted 
with antifading DAPI mount (Vecter Labs). Slides were allowed to dry in the 
dark, observed under a fluorescent microscope. 
 
2.8 Detection of Angiogenesis  
2.8.1 Tubule formation assay 
 
HUVEC cells were cultured in the presence of the IC50 of the micronutrients or 
in complete media in 24 well plates coated in 1% gelatine. These were then 
incubated for 48hrs. Assessment of tubule formation involved fixing the cell 
preparation in 70% ethanol at 4°C for 15 min, rinsing in PBS, and staining with 
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calcein. Tubule formation was assessed by counting the number of tubule 
branches. 
Upon reduction of tubule formation in the presence of the micronutrients, 
tumour cells will undergo experimentation further angiogenesis experiments. 
 
2.8.2 Co-Culture: Glioma Cells and HUVEC 
 
Initially 10,000 HUVECs were seeded on one half a sterile coverslip and left 
overnight. Subsequent to this 5000 tumour cells were seeded on the other 
half of the coverslip and left to incubate for four hours (Fig 11). Subsequently 
the coverslips were treated with IC50s of RCE or RGSE and micrographs were 
taken at 6, 24 and 48 hours respectively and the number of tubules counted. 
  
 
 
 
                                            HUVEC        Tumour cells 
 
 
 
 
 
Figure 9 Illustration how coverslips were seeded with both HUVECs and brain 
tumour cells. 5000 cells of each, HUVECS and glioma cells were seeded on either 
side of the cover slip and cultured together. 
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2.9 Statistics 
 
All studies analysed were performed in triplicate with the average of three 
experiments being statistically analysed as required. In particular statistical 
analyses were carried out on the MTT results using Stats direct software, to 
determine the mean and standard deviation. Any outliers, outside three 
standard deviations, were excluded.  
Analysis on the flow cytochemical data was examined using ANOVA analysis. 
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CHAPTER 3: Microenvironmental 
Changes of Growth Sera 
 
Preliminary investigations into the effects of microenvironmental changes, of 
growth sera, on astrocytic cultures were performed. This was achieved 
through the evaluation of antigenic expression, commonly associated with 
gliomas.  
 
3.1 Introduction 
 
Heterogeneity is regarded as a prominent feature of gliomas due to the 
divergent processes of differentiation and anaplasia giving rise to a mixture of 
different cellular appearances. It is likely that this phenomenon may give rise 
to differing degrees of malignancy being manifest in different regions of the 
same tumour. The cellular heterogeneity seen histologically is, to some 
extent, retained in vitro during early passages. Histological recognition in vitro 
generally includes the expression of common differentiation markers such as 
glial fibrillary acidic protein (GFAP) for astrocytes and galactocerobroside (Gal 
C) for oligodendrocytes. Indeed glioblastoma (GB) is generally believed to 
arise from cells of astrocytic lineage, although oligodendroglial or progenitor 
cell derivation is also possible (Pilkigton 2001). It has also been proposed that 
a rare sub-population of cells within the tumour mass has the ability to self re-
new, differentiate and sustain tumour growth (Bruce 1963).  
 
Recent studies have shown that individual cells within these tumors are 
capable of giving rise to cells of multiple lineages (Hemmati 2003; Ignatova 
2002; Kukekov 1997). This could be explained by cells undergoing trans-
differentiation; manipulation of tissue-specific stem cells into tissue specific 
cells that they would not normally develop into (Fan 2007) for example 
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hematopoietic stem cells giving rise to neural cells or neural stem cells giving 
rise to blood cells (Mezey 2000; Bjornson 1999). Another example of this was 
seen when dorsal domains of the spinal cord and telencephalon, which were 
thought to give rise to astrocytes, were also found to produce 
oligodendrocytes (Kessaris 2006; Richardson 2006; Cai 2005; Fogarty 2005; 
Vallstedt 2005). One study reported that glia that express NG2, which have 
been shown previously to be progenitor cells for glia during development, in 
the adult mouse are capable of producing both oligodendrocytes and 
protoplasmic astrocytes in vivo (Zhu 2012). However, two independent 
studies found that adult NG2-positive glia gave rise to oligodendrocytes and 
neurons, but not astrocytes, in vivo (Rivers 2008; Menn 2006). Despite 
controversy, positive evidence surrounds the study of manipulation of tissue-
specific stem cells into tissue specific cells that they would not develop into 
(Fan 2007). 
 
A similar phenomenon was reported in earlier studies by Raff et al. (1983) 
who explored the influences of external factors the cellular environment, such 
as the presence or absence of foetal calf serum in the culture medium, on the 
developmental pathways of astrocytes and oligodendrocytes. They assessed 
morphological and imunocytochemical criteria of the divergent pathways of 
cell development in the immature glia of the rat optic nerve. They used A2B5 
antibody for the detection of Type 2 astrocytes (fibrous) in this study and 
proposed that both fibrous astrocytes and oligodendrocytes may be derived 
from a primitive precursor cell (the so-called “O-2A” or oligodendrocyte Type 2 
astrocyte progenitor cell), dependent upon the influence of the environment 
(Temple 1985; Raff 1984; Raff 1983). This observation provided the first 
evidence for developmental plasticity and environmental influence in the 
differentiation of glial cells in the central nervous system (CNS). Subsequent 
studies showed that the presence of GFAP-negative, A2B5-positive cells and 
GFAP-positive, A2B5-positive cells in a malignant astrocytoma culture (IPSB-
18) which provided evidence that the O-2A progenitor and Type 2 astrocyte 
phenotypes occur both in vitro in human neoplastic as well as  in normal 
developing rat neural tissue (Pilkington 1992; Knott 1990). 
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Furthermore, Tenebaum et al. (1996) identified the plasticity of 
oligodendroglioma cells by successfully showing that when taken from a rat 
brain, they could be manipulated in the presence of serum supplementation, 
into losing the expression of oligodendrocytic antigenic markers and acquiring 
astrocytic markers. Upon re-introduction into the rat, these cells were able to 
revert back to their original antigenic expression. They also confirmed that 
human oligodendroglioma cells had a similar culmination being induced, by 
the absence or presence of serum, into oligodendrocytes or Type 2 
astrocytes, respectively.  
 
Various antigenic markers characteristically expressed by gliomas, aid 
identification of tumour phenotypes in vitro. Such markers include cluster of 
differentiation 44 (CD44), neural cell adhesion molecules (NCAM), GFAP, 
ganglioside (GD3), Gal C and Neuron-Glial 2 (NG2).  
 
Astrocytic marker CD44 is a cell surface adhesion molecule (Ariza 1995; Li 
1995; Radotra 1994; Pilkington 1993) and a principal receptor for hyaluronan 
(HA) (Aruffo 1990), a glycosaminoglycan found to be highly expressed in the 
extra cellular matrix (ECM). Brian tumours are highly diffuse and are difficult 
to target because of this invasive behaviour. Involvement of HA in this 
invasive process results in its increased ECM expression, regardless of 
tumour grade (Delpech 1993). CD44 is as a result also up-regulated in brain 
tumours. As CD44 is involved in this invasive process and is commonly 
studied as a marker of astrocytic invasion. 
 
Members of the immunoglobulin super family, NCAMs are cell surface 
glycoproteins that mediate cell-cell adhesion independent of Ca2+ (Keilhauer 
1985), play an important role in neurite outgrowth and fasciculation (Appel 
1993) and are involved in migration/invasion (Gratsa 1997). Gratsa et al 
(1997) showed that during migration the NCAM expression is down-regulated. 
 
67 | P a g e  
 
GFAP an intermediate filament protein constituent thought to retain the 
mechanical strength and structure of astrocytes (Eng 1971) and is a valuable 
marker of normal, reactive and neoplastic astrocytes (Pilkington 2001). 
 
GD3 is a ganglioside belonging to a family of complex acidic glycolipids. It is 
thought they are functionally diverse in the normal brain and are also 
expressed and play a role in brain tumours (Yates 1995; Fredman 1994, 
Wikstrand 1994; Pilkington 1993; Shinoura 1992). Earlier studies have 
reported that malignant gliomas contain a higher concentration of GD3. Its 
expression has been shown to correlate with the degree of malignancy (Berra 
1985). 
 
Gal C belongs to the family of cerebrosides. It is a common cell surface 
glycolipid marker for mature oligodendrocytes and appears to regulate myelin 
formation (Marcus 2006; Dupree 1998; Bosio 1996; Coetzee 1996). 
Tenebaum et al. (1996) identified the loss of this marker in their studies when 
the microenvironment was altered.  
 
NG2 a transmembrane chondroitin sulphate proteoglycan, is expressed on 
oligodendrocyte progenitor cells (OPCs) (Chekenya 2002; Chekenya 2007) 
though it is not expressed by multipotent stem cells. It is however up 
regulated once stem cells begin to differentiate. NG2 is then strongly 
expressed whilst cells undergo proliferation and retain a certain degree of 
developmental plasticity. Upon termination of this, NG2 expression is down 
regulated. However NG2 remains up regulated in tumours, due to continual 
proliferative activity (Stallcup 2008). 
 
CD73 is known to be expressed in oligodendrocytes (Maienschein 1996), its 
function. It is known to be involved in various signalling pathways in the body 
including extracellular dephosphorylation of nucleoside monophosphates to 
their corresponding nucleosides and cell– matrix interactions (Stochaj 1992). 
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As an extension of previous work performed by both Raff et al. (1983) and 
Tenenbaum et al. (1996), and with the aim to investigate the currently 
debated use of sera to supplement growth media, this study will aim to identify 
if both astrocytic and oligodendrocytic cultures are influenced by a change in 
microenvironment by a change in antigenic expression.  
 
It is hypothesized that despite the general consensus, it may be advised to 
supplement growth sera with human serum to best mimic in vivo conditions. 
 
3.2 Materials and Methods 
 
3.2.1 Cell Cultures 
 
Established glioma cells (Table 9) were cultured as monolayers in plastic 
culture flasks, in a standard humidified incubator at 37oC and 5% CO2. Cells 
were grown in Dulbecco’s modified eagles medium (DMEM) supplemented 
with 10% inactivated foetal calf serum (FCS), new born calf serum (NCS) and 
1% AB or 10% Human serum (HS) and 1% AB (pen/strep) for 48hr. 
 
Table 9 Summary of the cell cultures used as part of this study including the source
  
 
 
 
Cell line Tumour type 
IPSB-18 Astrocytoma III 
U251 
Glioblastoma 
multiforme 
A172 
Glioblastoma 
multiforme 
HF66 
Glioblastoma 
multiforme 
U373 
Glioblastoma 
multiforme 
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3.2.2 Population Doubling Time 
 
A population of 100,000 cells was seeded into a six well plates and 
maintained in DMEM supplemented with the appropriate medium. At timed 
intervals namely 4hr, 6hr, 12hr, and every six hours subsequent until a 
population doubling time could be achieved. 
 
The cell count was achieved using the trypan blue method. Cells were initially 
harvested and resuspended in 1ml of complete media, from which 20l was 
combined with trypan blue stain.and counted using a haemocytometer.  
 
3.2.3 Immunocytochemistry (ICC) 
 
Cells were maintained on sterile microscope glass cover slips in DMEM 
supplemented with the appropriate serum, as described above. Once 
confluent, the cells were washed in Hank’s balanced salt solution (HBSS). 
Qualitative analysis of the antigens NG2, GD3, NCAM, CD44, CD73, Gal C 
and GFAP was carried out.  
 
Table 10 Primary antibodies used to characterise cell cultures. An illustration of the 
dilutions used and the host species the antibody was cultured in. 
 
Antibody Dilution Host species Monoclonal or Polyclonal Source 
GFAP Neat Mouse Monoclonal CRUK 
CD44 1:100 Mouse Monoclonal CRUK 
NCAM 1.1000 Mouse Monoclonal Abcam 
Gal C Neat Rabbit Polyclonal Millipore 
GD3 Neat Mouse Monoclonal CRUK 
CD73 1.1000 Mouse Monoclonal Abcam 
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For cell surface staining fixation was performed after incubation with the 
primary and secondary antibodies for two mins with acid alcohol (1 vol 1% 
HCL: 99 vol 70% ethanol), whereas fixation for cytoplasmic staining was 
carried out with acid alcohol for one min prior to incubating with the primary 
antibody. Upon incubation with both antibodies the cells were washed and 
counterstained with Hoechst Blue. The monolayer of cells were then mounted 
in Citifluor and analysed with a confocal microscope. 
 
Each micrograph was scored by identifying the intensity/quantity of 
fluorescence. An average score of three micrographs was taken. 
 
3.2.4 Flow Cytometry 
 
When confluent the cells were harvested from flaks using cell dissociation 
solution (GIBCO) for 10min. The cells were then neutralised with phosphate 
buffer solution (PBS) supplemented with 5% appropriate serum and washed. 
All washes were performed using PBS supplemented with 5% appropriate 
serum and then centrifuged for 5 mins at 1000rpm. The cells were 
resuspended in 200l of for 10 mins the appropriate primary antibody (NG2, 
GD3, NCAM, CD44, GalC, GFAP and CD73) washed and resuspended in 
streptavidin fluorescin (FITC). The cells were then washed and resuspended 
in PBS (2% appropriate serum). Prior to analysis 5l of propidium iodide (PI) 
was added and analysis was performed using a Beckton-Dickenson FACS 
Calibur against a suitable control. 
 
3.3 Results 
 
The standard morphology of malignant glioma cells cultured in different 
microenvironments, exhibit differing growth patterns. Illustrated here, the 
IPSB-18 cell line (Fig 12) develops in a monolayer formation in the presence 
of FCS though when cultured in NCS and HS the pattern becomes ‘patchy’ 
and the cells begin to grow as clumps.  
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       (c) 
 
 
Figure 10 Phase contrast micrographs of the IPSB-18 cell line when cultured in the 
presence of (a) FCS (b) NCS and (c) HS. Cells grown in the presence of FCS grew in 
a consistant monolayer, whereas in the presence of NCS or HS the cells grew in 
patches and the morphology of the cells differed in each microenvironment.  
FCS NCS 
HS 
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The population doubling times (PDTs) supported the growth rates seen in the 
micrographs of the indiviual cultures when grown in the presence of differing 
growth media. 
 
Table 11 Summary population doubling times (PDTs) of the cell cultures in this study 
 
Cell line PDT 
FCS NCS HS 
IPSB-18 48 72 102 
U251 26 29 63 
A172 37 49 76 
HF66 32 56 93 
U373 20 42 72 
 
Table 11 summarises the PDTs of all the cultures. When the 
microenvironment was supplemented with NCS, in all cultures, the PDT was 
approximately double that of cultures grown in FCS. Cultures supplemented 
with HS grew slower still with most PDTs being more than double those 
cultured in FCS. This initial morphological change is mimicked in the apparent 
phenotypical change of antigenic expression.  
 
Representative micrographs depict dual staining of the changes seen in Gal C 
and GFAP when cultured in differing serum supplementation (Fig 11). 
Evaluation of the antigenic expression of Gal C and GFAP, the two prominent 
markers for olidendrocytes and astrocytes respectively illustrated  staining 
intensity of glioma cell cultures varies when the serum supplementation is 
altered, when the microenvironment is changed such that there is no antigenic 
expression of Gal C seen when the cells are cultured in FCS. However when 
cultured in NCS or HS there is a slight indication of fluorescence. 
 
Table 12 and 13 summarise the expression of GFAP is down regulated, in 
cultures grown in FCS compared to those grown in NCS and HS. This is 
commonly seen across the remaining cell cultures also.  
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Figure 11 Micrographs of the changes in antigenic expression of Gal C (red) and GFAP (green) when cultured in the in the presence of (a) 
FCS (b) NCS and (c) HS for the cell line IPSB-18 (an established anaplastic astrocytoma). The nuclei are counterstained with DAPI (blue). 
(a) (b) (c) 
HS FCS NCS 
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Table 12 Summary of the immunocytochemical results of the presence of six prominent markers found in oligodendrogliomas and 
astrocytomas when grown in media supplemented with foetal calf serum (FCS), Newborn calf serum (NCS) and Human serum (HS) 
 
Cell line Serum used to 
culture 
Antibody Expression % 
  CD44 NCAM  GFAP GD3 Gal C NG2 CD73 
IPSB-18         
 FCS +++ + +++ +++ ± - + 
 NCS + ± + ± - - + 
 HS ± ± + ± + ++ + 
U251         
 FCS +++ + +++ +++ - + - 
 NCS + + ++ ++ ++ + - 
 HS - ± + + ++ + - 
A172         
 FCS +++ + +++ +++ - ± + 
 NCS + ± ++ + ± + - 
 HS + - ++ ± + ++ + 
HF66         
 FCS +++ + +++ +++ - ± + 
 NCS ++ ± ++ + ± + + 
 HS + ± ++ ± + + + 
U373         
 FCS +++ + +++ +++ - ± - 
 NCS ++ ± ++ + + + + 
 HS ± ± ++ ± ± ++ + 
Where + = positive expression ± = some expression and - = little or no expression 
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When investigating Gal C an opposite phenomenon occurred namely when 
the microenvironment was changed from FCS to NCS or HS, in all the cell 
lines Gal C appeared to be up regulated. The down regulation of Gal C 
expression in the IPSB-18 cell line when cultured in NCS could be assume an 
anomaly (Table 12), as Fig 11 clearly depicts the presence of Gal C 
expression. Table 12 also illustrated an apparent down regulation of CD44, 
NCAM, GD3 and NG2. The expression of CD73 remained fairly consistent.  
 
Flow cytometry semi-quantitatively compliments the immunocytochemical 
data. The plots illustrated fluorescent intensity against cell count and all plots 
are compared to the no primary antibody, negative control. The significance of 
the variation in expression of the different antigens after flow cytometry, as 
calculated by the t-test when compared back to cells cultured in FCS, is 
summarised in Table 13.  
 
The t-test confirmed significant changes in expression of the antigenic 
markers across all the cell line for CD44, NCAM, GFAP and NG2. Gal C and 
CD73 were only depicted to illustrate significant changes in cultures grown in 
HS not those in NCS.  
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Table 13 Summary of the significant difference between the median flow cytometry results of the presence of prominent markers when 
grown in media supplemented with Newborn calf serum (NCS) and Human serum (HS) compared with foetal calf serum (FCS 
 
Cell line Serum 
used to 
culture 
P value of t-test  
  CD44 NCAM  GFAP GD3 Gal C NG2 CD73 
IPSB-18         
 NCS 0.14 0.006* 0.07 0.048* 0.08 0.4 0.13 
 HS 0.013* 0.006* 0.06 0.0005** 0.02* 0.02* 0.06 
U251         
 NCS 0.6 0.05* 0.64 0.01* 0.1 0.01* 0.006* 
 HS 0.3 0.0068* 0.3 0.5 0.004* 0.003* 0.09 
A172         
 NCS 0.21 0.07 0.04* 0.09 0.9 0.01* 0.29 
 HS 0.5 0.089 0.09 0.08 0.06 0.5 0.002* 
HF66         
 NCS 0.002* 0.001** 0.048* 0.01* 0.0009** 0.000** 0.003* 
 HS 0.009* 0.008* 0.029* 0.11 0.0001** 0.000** 0.005* 
U373         
 NCS 0.006* 0.37 0.02* 0.11 0.13 0.001** 0.009* 
 HS 0.025* 0.49 0.02* 0.5 0.01* 0.000** 0.001** 
                 * < 0.05, ** <0.001 A p value of below 0.05 is significant.
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3.4 Discussion 
 
A change in serum supplementation impacted antigenic expression in both 
original studies performed by Tenenbaum et al (1996) and Raff et al (1983). 
More recent studies (Brewer 2007) also depicted similar variations in cell 
differentiation under different serum supplements. Serum supplementation of 
the culture media is required to provide the cells with basic nutrients, 
hormones and growth factors. These constituents promote growth and 
potentiate specialised cellular functions. Although different sera constitute 
similar components, differences are identified in the percentage of these 
constituents as in the comparison of foetal calf serum, newborn calf serum 
and human, particularly in the protein content. Serum supplementation of the 
culture media is required to provide the cells with basic nutrients, hormones 
and growth factors. These constituents promote growth and potentiate 
specialised cellular functions. Although different sera constitute similar 
components differences are identified in the percentage of these constituents 
as Table 14 illustrates in the comparison of foetal calf serum, newborn calf 
serum and human serum.  
 
The major differences between the three sera are the percentages of 
haemoglobin and total protein. Previous studies have found haemoglobin had 
no effect on cell growth (Rooprai et al. personal communication), therefore the 
key to trans-differentiation suggestively lies in the differing content of the total 
protein. The choice of sera used in this study was initially based on previous 
studies in Norway where normally newborn calf serum is used to supplement 
media (personal communication).  
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Table 14 Similarities and differences in three different sera; foetal calf serum, 
newborn calf serum and human serum 
Component 
Foetal calf 
serum 
Newborn calf 
serum 
Human serum 
Total protein 
(g/100ml) 
3 - 4.5 4.5 – 6.0 5.7 
Haemoglobin 
(mg/100ml) 
< 25 20 6.21 
pH 6.8 – 8.1 7 – 8 7.62 
Osmolarity 
(mOsm/kg) 
260 - 330 240 – 340 325 
Endotoxin (EU/ml) < 10.0 100 9 
Mycoplasma none none none 
 
 
The results of this study found that there were differences in the antigenic 
expression using both flow cytometry and immunocytochemistry as a result it 
was suggested cells should be cultured in media supplemented with human 
serum. However, due to the cost and impracticality of obtaining human serum 
it was suggested use of foetal calf serum as a media supplement should 
continue until such time, human serum becomes readily available. 
 
Such differences may be responsible for the differing growth patterns 
exhibited by the IPSB-18 culture (Fig 10), specifically the difference in 
percentage protein content. This most immediate difference illustrated, upon 
changing the microenvironment, cells cultured in foetal calf serum normally 
grow as a monolayer, however on changing to human sera the cells began to 
grow in patches. We may therefore assume the ability to manipulate 
characteristically astrocytic cultures, to differentiate away from the norm 
resulting trans-differentiation. This does suggest the presence of a potential 
cell type with the ability to become manipulated by varying the 
microenvironment.  
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In introducing changes in the growth sera, a phenotypic change was not just 
illustrated in the morphological growth patterns but also in the antigenic 
expression of characteristic markers. Clear distinctions in change of antigenic 
expression were predominately seen when investigating GFAP, for all the cell 
lines. Normally associated with astrocytic cultures, the expression of this 
antigen was markedly down regulated in immunocytochemical micrographs, 
when cells cultured in the presence of FCS were compared to those cultured 
in the presence of NCS or HS (Table 12). Upon comparison of this data to 
flow data the t-test analysis showed significant differences in the data (Table 
13). 
 
Similarly Gal C, which is specifically, associated with oligodendrocytes, in the 
presence of NCS and HS, the astrocytic glioma cultures were seen to express 
Gal C (Fig 11). The differences in this data however were only noted as 
significant when comparing the FCS cultures to the HS cultures (Table 13). 
 
CD44 was another antigen which showed significant changes in the 
differences between antigenic expressions in the cultures. CD44 is normally 
up-regulated in astrocytomas as a result of involvement of hylauronic acid 
(HA) expression increasing in the extracellular matrix (ECM), during invasion, 
regardless of tumour grade (Delpech 1993). Hagel et al (1999) showed in 
characterisation of CD44 positive cells in oligodendrogliomas, reactive 
astrocytes were revealed, at the invasive margin of the tumour. Therefore a 
down regulation of CD44 could indicate a change in the phenotype, from 
astrocytic to another.  
 
NG2 was found to be up regulated in the cell cultures. This marker is 
associated with an up-regulation during proliferation and differentiation. As 
such the significant differences depicted could indicate a change in 
differentiation and indeed increased proliferation. This may also offer an 
explanation for why differences are seen in growth patterns, the cultures 
grown in HS grew in clumps.  
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NCAM also showed significant differences in expression (Table 13) depicting 
an up regulation upon change. This supports the changes seen in NG2 as the 
change in proliferation and differentiation may also be associated with there 
invasive potential. NCAMs are also seen to be up regulated in cultures grown 
in HS where the cells grew in clumps. 
 
A consistency in GD3 expression suggests the malignancy of the tumours did 
not vary. Though a significant difference in CD73 when cells were cultured in 
HS compared to cells cultured in FCS, did suggest a greater presence of 
oligodendrocytic phenotypes. 
 
Additional experimentation was also carried out on some cell lines using 
serum free medium (SFM) with and without platelet derived growth factor 
(PDGF). This data showed a similar occurrence. The Gal C expression of two 
established oligodendrogliomas cell lines was down-regulated in the presence 
of NCS and HS and the GFAP expression was up-regulated. 
 
These dramatic indications, suggested trans-differentiation in astrocytic 
glioma cultures when their microenvironment is altered. As such, a cell type 
with the ability to change phenotypically.  
 
3.5 Conclusion 
 
The suggestion of trans-differentiation indicates the importance of the 
microenvironment in which the cells are cultured. Whilst evaluation of the 
changing environments would suggest the optimum serum supplement is 
human serum, it is not readily available. It is therefore favourable to continue 
using FCS as the chosen serum supplement.  
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CHAPTER 4: Results 
4.1 Morphology 
 
Heterogeneity is a feature of malignant brain tumours, each unique in 
morphology with up to 14 different sub populations of cells, including 
progenitor cells. The classic shape associated with astrocytic cells, ‘star’ or 
‘spindle’, was seen in micrographs of the control cell cultures (MUAB-C) (Fig 
12f). When compared to the control culture the glioma cells illustrated a 
differing morphology, with large spindle like extensions, each cell growing 
separately from one another and consistently across a monolayer.  The cell 
shape seen in IPSB-18, (Fig 12a) however, were smaller in size and initially 
grew in small patches, overlapping one another, eventually spreading across, 
and growing as a consistent monolayer. 
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Figure 12 Phase contrast micrographs of the cell lines involved in this study including (a) IPSB-18, (b) MUMG-GM, (c) MUIH-GM, 
(d) MUTC-GM, (e) MUPK-GM and (f) control cell line MUAB-C (where possible arrows indicate examples of individual cell 
morphologies). Magnification x 40. Differences between the cell cultures are clearly visible. The most noted difference includes, that 
between MUAB-C, (f) the control cell culture with clear star shaped cells and the remaining cultures which have spindle shaped 
cells.
(a)                                                                             (b)                                                                          (c) 
 
 
  (d)                                                                          (e)                                                                                (f) 
IPSB-18 MUMG-GM MUIH-GM 
MUTC-GM MUPK-GM MUAB-C 
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4.2 Population Doubling Times of Giloma Cultures  
 
Table 15 Population doubling times (PDT) of glioma cell lines and the control cell line 
(MUAB-C)  
 
Cell Line Average PDT (hr) SD Tukey’s HSD (p) 
IPSB-18 36 5.57 <0.01 
MUMG-GM 165 7.81 <0.01 
MUIH-GM 210 7.81 <0.01 
MUTC-GM 197 2.65 <0.01 
MUPK-GM 347 9.54 <0.01 
MUAB-C* 72 2 N/A 
* Control astrocytic cells 
Cultured in DMEM culture media supplemented with 10% inactivated foetal calf serum and 1% antibiotics. The PDT 
results of the glioma cultures were statistically different to one another and to the control culture MUAB-C with a 
p<0.05 (ANOVA and Tukeys HSD). 
 
Summarised in Table 15, the IPSB-18 glioma cell culture was observed to 
have the shortest PDT (Fig 13). Within as little as six hours this population 
increased from 10,000 cells to approximately 12,000 cells with a doubling time 
of around 36 hours.  The remaining glioma cultures had a much longer PDT 
with MUPK-GM having the longest time of approximately two weeks (Fig 13). 
The control cell line (MUAB-C) had a PDT of around 72 hours. This remained 
fairly consistent with increasing passages. The rate at which the glioma cell 
cultures doubled, however, decreased with increasing passage. 
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Figure 13 Population doubling time of glioma cell line IPSB-18 (a), MUMG-GM (b), MUIH-GM (c) MUTC-GM (d) and MUPK-GM (e). Readings 
were taken wherever possible at least at 12 hourly intervals. Identification of the population doubling time (i.e. increase from 10,000 cells to 
20,000 cells) has been indicated by the black line.
(a) 
(b) (c) 
(d) (e) 
IPSB-18 
MUMG-GM MUIH-GM 
MUTC-GM MUPK-GM 
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4.3 The Effect of Micronutrient Extracts on Cell Viability 
 
4.3.1 The Toxic Effects of DMSO 
 
Optimized for glioma cells the MTT protocol is based on the experiment 
described by Nikkah et al (1992), this protocol was adapted due to apparent 
biphasic results.  Despite being a simple, well documented and widely used 
assay, errors of analysis have been reported as a result of various problems 
ranging from differing responses within various cell lines (Nikkhah 1992; 
Nikkhah 1992; Chen 1990) to interactions with various compounds (Wang 
2010; Young 2005; Ngai 1998), the use of micronutrients being one such 
hindrance.  Undesirably the use of micronutrients has been shown to reduce 
the MTT salt in the absence of cells (Peng 2005; Bruggisser 2002) at fairly 
high concentrations. 
 
Initial experiments using the IPSB-18 primary cell culture (grade III) yielded 
inconsistent and rarely reproducible results with large standard deviations.  
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Figure 14 The mean cell viability of IPSB-18 (an established anaplastic astrocytoma cell line), as a percentage of the positive control 
(clear DMEM) against the concentration of (a) RCE dissolved in clear DMEM, (b) RCE dissolved in DMSO and (c) DMSO only on a log 
scale. Indicated is a decrease in cell viability upon treatment of cell cultures with DMSO thus impacting the cell viability of the treated 
cells. The inserted absorbance spectra indicate upon a concentration of RCE greater than 1g/ml (blue and red) the colour of the 
micronutrient affects the absorbance reading at 570nm. 
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Figure 15 The mean cell viability of IPSB-18 (an established anaplastic astrocytoma cell line), as a percentage of the positive control 
(clear DMEM) against the concentration of (a) RGSE dissolved in clear DMEM, (b) RGSE dissolved in DMSO and (c) DMSO only on a 
log scale. The insert represents the absorbance spectra of three concentrations of RGSE dissolved in clear media ; 10g/ml (blue), 
1g/ml (red) and 0.1g/ml (green) upon a concentration of RGSE greater than 1g/ml (blue and red) the colour of the micronutrient 
affects the absorbance reading at 570nm. 
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DMSO, often used to aid solubilisation of micronutrient extract, has a 
significant toxic effect on the IPSB-18 astrocytoma cell line (Fig 14). Results 
using the MTT viability assay on glioma cells exposed to DMSO used to 
dissolve the micronutrients showed at least a 20% decrease in viability when 
compared to cells treated with micronutrient extracts dissolved in clear DMEM 
only. When this DMSO toxicity his combined with high concentration 
deposition of RCE, evaluation of cel viability is anomulus. An almost identical 
pattern is seen with RGSE treatment of the IPSB-18 as RGSE also has a 
significant absorption at 570nm (Fig 38). This suggested the DMSO used to 
dissolve the micronutrient extracts may be having a toxic effect on the delicate 
brain tumour cells. This affect may be attributed to the mode of action of 
DMSO. 
 
4.3.2 Cell viability following treatment with micronutrient 
extracts 
 
Initial studies treated glioma cell cultures with RCE and RGSE over a wide 
range of concentrations. In particular the IPSB-18 cell line was treated using a 
range of concentrations between 250mg/ml to 0.04g/ml. When performing 
the MTT assay, concentrations <20g/ml appeared to decrease cell viability of 
glioma cultures, whereas concentrations >20g/ml appeared to increase 
viability. Each of the assays was compared with phase contrast micrography. 
The reduction in cell viability was seen in all the respective analyses.  
 
However, following further investigation it was found that the pigmentation of 
the micronutrients at higher concentrations was interfering with the 
absorbance reading of the assay. Therefore, subsequent evaluation of the cell 
viability of RCE and RGSE was carried out with micronutrient concentrations 
below 10g/ml and 20g/ml, respectively. These analyses suggested that 
both micronutrient extracts had an effect on cell viability. To ensure the effect 
of the micronutrient extracts was specific to glioma cells, experimentation on 
the control culture (MUAB-C) was performed. Neither micronutrient appeared 
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to affect the viability of normal brain tissue following 48 hours of treatment at 
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concentrations of between 0.001g/ml and 10g/ml. These were the same concentrations at which the glioma cells were 
investigated to determine the IC50 (Fig 16). 
 
 
  
         (a)                                                                                                   (b)        
 
Figure 16 Mean percentage viability of MUAB-C using a) RCE and b) RGSE. The percentage viability was calculated as a percentage of the 
positive control (point 0 – assumed100% viability). The standard deviation is displayed as error bars. No significant differences were noted in 
the viability of MUAB-C following ANOVA analysis (p= 0.13 and 0.33 respectively)
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4.3.3 Interference of Micronutrient Pigments on Cell Viability Assay 
 
Initial studies on the IPSB-18 glioma cell culture found that, at concentrations 
of between 20g/ml and 250g/ml, incubation with RCE resulted in an initial 
decrease in cell viability at the lower concentrations of the micronutrient, 
followed by an apparent increase at the highest concentrations (Fig 17). This 
apparent increase in viability was also seen when IPSB-18 was treated with 
the same concentrations of RGSE (Fig 18).  
  
 
Figure 17 Mean percentage viability of IPSB-18 using RCE at concentrations 
between 250g/ml to 20g/ml. The percentage viability was calculated as a 
percentage of the positive control (untreated cells - point 0 is assumed 100% 
viability). The standard deviation is displayed as error bars. Significant difference 
between untreated and treated cells, following a Tukey’s HSD test is displayed (* 
p<0.01) 
* 
* 
* 
* 
* 
* 
* 
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Figure 18 Mean percentage viability of IPSB-18 using RGSE at concentrations 
between 10g/ml to 250g/ml. The percentage viability was calculated as a 
percentage of the positive control (point 0 – assumed 100% viability). The standard 
deviation is displayed as error bars. Significant difference between untreated and 
treated cells, following a Tukey’s HSD test are displayed (* p<0.01) 
 
The apparent increase in cell viability of the glioma culture, IPSB-18, was 
more prominent at the highest concentrations. However, phase contrast 
micrographs showed no viable glioma cells following treatment with 
concentrations of >60g/ml of either micronutrient extract. This suggested an 
anomalous result and therefore warranted further investigation. 
 
* 
* * 
* 
* 
* 
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The mean viability, as a percentage of the positive control, of the IPSB-18 
(astrocytoma) cell line when treated with RCE shows a dose dependant 
decrease up to approximately 1g/ml of RCE. Beyond this a variable and 
general increase in viability appears. Following washing of the wells during 
viability assays, it was noted that, despite copious washing, it was not 
possible to remove all of the extract. The absorbance of treated plates without 
the presence of the MTT assay components added was examined to 
determine whether any residual extract may be contributing to the unusual 
result found with increasing concentration of the micronutrients. Despite 
increased washing of the wells (> 4 times) it was confirmed that the extract 
was resulting in the biphasic anomaly. 
Supplementary studies confirmed that the natural colour of the extracts 
interfered with the optical density/absorbance readings (Fig 19). Although 
RCE and RGSE has absorption maxima at between 200 and 400nm it still has 
significant absorption at 570nm which rises dramatically as we move to 
concentrations greater than 0.1g/ml. Thus, any deposited RCE at such 
concentration can significantly contribute to absorption at this wavelength. 
making, concentrations of >1g/ml of both micronutrients were unsuitable for 
use in the MTT viability assay.  
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(a)                                                                       (b)        
 
 
Figure 19 Absorption spectra of three concentrations read at 570nm; 10g/ml (blue), 
1g/ml (red) and 0.1g/ml (green) for (a) RCE and (b) RGSE. Both RCE and RGSE 
indicate an absorbance at 570nm (vertical black line), the absorbance at which the 
MTT assay is read.  
 
4.3.4 Red Clover Extract and Cell Viability 
 
The IC50 of RCE was found to be in the g/ml range for all of the glioma cell 
cultures. The MUTC-GM and IPSB-18 cultures were more sensitive to the 
micronutrient, with a lower IC50 (Fig 20). 
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Figure 20 Cell viability of glioma cell cultures when treated for 48 hours with red 
clover extract (n=3). The three primary glioma cultures namely, MUMG-GM, MUIH-
GM and MUTC-GM depicted IC50s in the g/ml range. MUPK-GM and IPSB-18 
illustrated much lower IC50s. Error bars are illustrated in Figures 22 and 23 
 
 
IPSB-18 was the only established cell culture to be used in the evaluation of 
the affects of RCE and RGSE on human adult glioma cells. The increased 
passage number of the IPSB-18 is suggestive of decreased heterogeneity of 
the cells (Pilkington 2001), as such the IC50 was expected to be lower than the 
other glioma cultures. 
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Figure 21 Scatter plot illustrating the cell viability of IPSB-18 (an established 
anaplastic astrocytoma cell line) as a percentage of the positive control (clear 
DMEM) against the concentration of RCE on a log scale. The error bars represent 
the standard deviation. A significant difference is seen in the change in viability of 
treated cells when compared to untreated (*p <0.001 following Tukey’s HSD test) 
 
The IC50 of RCE on IPSB-18 was found to be 400ng/ml (Fig 21). Due to the 
increased heterogeneity indicated in low passage cultures, the IC50s of the 
other glioma cultures were expected to be higher than 0.001g/ml.  The IC50 
of RCE for MUMG-GM (p5) was found to lie around 1g/ml (Fig 22). 
 
* * 
* 
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Figure 22 Mean percentage cell viability of (a) MUMG-GM, (b) MUIH-GM (c) MUTC-GM and (d) MUPK-GM following incubation with RCE for 48hrs at 
concentrations between 0 and 1g/ml. The percentage viability was calculated as a percentage of the positive control (point 0 – assumed 100% viability). 
The standard deviation is displayed as error bars. A significant difference is seen in the change in viability (*p <0.001 following Tukey’s HSD test for all 
glioma cell lines)
(a) (b) 
(c) (d) 
* 
* 
* * * 
* 
* 
* 
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Similarly, to MUMG-GM, the remaining primary cultures, MUIH-GM, MUTC-
GM and MUPK-GM (p4), were also investigated following incubation with 
RCE at concentrations below 1g/ml. The IC50 values illustrated in figure 22 
have been summarised in Table 16. The IC50 of MUTC-GM was found to be 
the lowest, followed by IPSB-18. The other glioma cultures indicated higher 
IC50 values when compared to IPSB-18, as expected. 
 
Table 16 Summary of the IC50 of RCE with various cell cultures including biopsy 
derived primary cultures (MUMG, MUTC, MUIH and MUPK) and an existing low 
passage cell line (IPSB-18). 
 
 
Cell Culture Passage 
Number 
IC50 
  RCE 
IPSB-18 29-30 0.4g/ml 
MUMG-GM 4-5 1 g/ml 
MUTC-GM 3-4 0.007g/ml 
MUIH-GM 3-4 0.98g/ml 
MUPK-GM 3-4 0.80g/ml 
 
99 | P a g e  
 
4.3.5 Red grape seed extract 
 
 
 
 
Figure 23 Cell viability of glioma cell cultures when treated for 48 hours with red 
grape seed extract (n=3). The IC50 for red grape seed extract was at a low 
concentration (ng/ml) for all cell cultures. 
 
Incubation with red grape seed extract resulted in a similar reduction in 
viability of the glioma cell cultures as that seen in response to incubation with 
RCE. Figure 24 illustrates the mean percentage cell viability of IPSB-18 
following 48 hr treatment with RGSE and the IC50 for RGSE was found to be 
0.0008g/ml, lower than the IC50 of RCE (0.4g/ml).   The remaining glioma 
cultures were also found to be more sensitive to RGSE (Figure 25 and Table 
17). 
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Figure 24 Mean percentage cell viability of IPSB-18 following 48 hr treatment with 
RGSE. The percentage viability was calculated as a percentage of the positive 
control (point 0 – assumed 100% viability). The standard deviation is displayed as 
error bars. A significant difference is seen in the change in viability of treated cells 
when compared to untreated (*p <0.001 following Tukey’s HSD test)
* 
* 
* 
* 
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Figure 25 Mean percentage viability of (a) MUMG-GM, (b) MUIH-GM (c) MUTC-GM and (d) MUPK-GM following incubation for 48hrs with RGSE. The 
percentage viability was calculated as a percentage of the positive control (point 0 – assumed100% viability). The standard deviation is displayed as error 
bars. A significant difference is seen in the change in viability when compared to the untreated control (*p <0.001 following Tukey’s HSD test for all glioma cell 
lines).
(a) (b) 
(c) 
(d) 
* * 
* * 
* 
* * 
* 
* * * * 
* 
* * 
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The IC50 of RGSE for the biopsy derived primary cell cultures was generally 
lower than those of RCE. The IC50 values for MUIH-GM, MUTC-GM and 
MUPK-GM (p4) are shown in Table 17.  
 
Table 17 Summary of the IC50 of RGSE for various cell cultures including biopsy 
derived primary cultures and an existing low passage cell line (ISPB-18). 
 
Cell Culture Passage 
Number 
IC50 
  RGSE 
IPSB-18 29-30 0.001g/ml 
MUMG-GM 4-5 0.0001g/ml 
MUTC-GM 3-4 0.5g/ml 
MUIH-GM 3-4 0.4g/ml 
MUPK-GM 3-4 0.0000001g/ml 
 
4.4 Antigenic Expression of Glioma Cultures using Flow 
Cytometry  
 
Following the suggestion of a reduction in glioma cell viability, the evaluation 
of RCE and RGSE was extended to determine whether other characteristic 
biologic features of glioma cells, including invasion and angiogenesis, were 
affected following 48-hour treatment in vitro with the respective IC50 of either 
micronutrient. The antigenic expression of a cell can provide an indication of 
the possible biologic features affected within the cell cultures. The antigens 
chosen for investigation, therefore, are those involved in the pathways that 
govern invasion, and/or angiogenesis. 
  
Cells were investigated for changes in expression of six antigens namely 
GFAP, CD44, Eric-1 NCAM, 1 integrin and v integrin. Representative plots 
are shown in Figure 26.  Statistical analysis of all the plots is illustrated in 
Table 18.  
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Plots were produced showing only cells which were PI negative and FITC 
positive; these are live cells expressing the antigen.  Cells were excluded if 
propidium iodide (PI) positive (indicating a permeable nuclear membrane and 
therefore dead) and if PI negative but also FITC negative (indicating no 
expression of the antigen).  
 
The expression of GFAP in the IPSB-18 culture was found to be as high as 
that of the biopsies in this study, in particular MUTC-GM (Table 18). When 
compared to the untreated cells GFAP did not appear to change in the 
micrographs. CD44 did not exhibit a significant up or down regulation in any of 
the cultures. Though a slight up regulation was illustrated following treatment 
with RCE, when compared with the untreated culture, this was not marked 
enough to be statistically significant. Eric-1 NCAM did not indicate a 
significant difference in expression following treatment with either 
micronutrient extract when compared to the untreated cultures. Both 1 and 
v integrins demonstrated marked up regulation in the flow plots and a 
significant difference was found between the treated and untreated cultures 
suggesting an effect of RCE and RGSE on the invasive properties of the 
glioma cells. 
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                                (a)                                                 (b)                                                     
 
                                    (c)                                              (d) 
 
(e) 
Figure 26 Representative plots of the percentage of fluorescent cells, indicating the 
median expression (FL-1H-FITC – intensity of fluorescence) of (a) GFAP, (b) CD44, 
(c) Eric-1 NCAM, (d) 1 integrin and (e) v integrin in a treated glioma cell culture 
(IPSB-18), following 48 hour treatment with the IC50 of RCE. The expression of 
CD44, Eric-1 NCAM and both integrins was expected to be up or down regulated 
upon treatment with the IC50 of RCE. The median percentage expression is indicated 
on the plot.
GFAP CD44 
Eric-1 1 integrin 
V integrin 
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Table 18 Mean antigenic expression (%), standard deviation (SD) and p values (calculated using a unpaired t-test) of GB cell lines following 
48hr treatment with RCE or RGSE at the respective  IC50, when compared to the antigenic expression of the respective untreated glioma 
culture. 
 
 
 
CELL LINE RCE RGSE 
GFAP CD44 Eric-1 NCAM 1 integrin v integrin GFAP CD44 Eric-1 
NCAM 
1 integrin v integrin 
IPSB-18           
mean 83.6 1.88 4.39 86.2 87.2 79.1 3.24 5.67 98.2 72.4 
SD 11.3 7.5 7.9 4.5 5.5 13.4 5.3 8.2 7.6 2.8 
p 0.015 0.109 0.98 0.0007 0.0008 0.0439 0.08 0.89 0.0006 0.0017 
MUMG-GM           
mean 61.2 5.76 23.6 78.6 51.2 85.6 4.30 28.9 69.1 76.5 
SD 2.6 5.2 6.7 7.9 6.4 2.1 2.5 1.2 8.88 8.4 
p 0.003 0.23 0.068 0.0006 0.0006 0.00002 0.073 0.097 0.0013 0.0008 
MUIH-GM           
mean 75.3 2.98 16.5 65.3 65.8 83.4 2.57 11.9 64.8 61.9 
SD 5.3 7.8 5.9 7.4 9.2 2.1 6.1 2.3 6.6 8.7 
p 0.008 0.093 0.07 0.0012 0.0005 0.0013 0.059 0.11 0.001 0.0005 
MUTC-GM           
mean 83.9 4.15 6.34 96.8 53.8 87.9 7.27 4.59 95.4 69.8 
SD 3.6 10.8 3.4 2.9 7.4 7.5 6.9 8.7 1.5 8.9 
p 0.0002 0.192 0.0693 0.0001 0.0019 0.062 0.175 0.078 0.0001 0.0009 
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4.6 Analysis of Antigenic Expression using 
Immunocytochemistry 
 
To verify flow cytometry data, the expression of the same six antigens was 
investigated using immunocytochemistry. Upon comparing the 
immunocytochemical micrographs against the flow cytometry plots, it was 
found that the same trends in antigenic expression changes were seen. Of the 
six antigens measured on the IPSB-18 glioma cell culture, the most 
discernable differences in expression, following treatment with either RCE or 
RGSE, were seen with the  and  integrins (Fig 27). The change in 
expression of GFAP, following treatment, was not as clearly seen in the 
micrographs (Fig 27a). Table 19 summaries the intensity of fluorescence 
visualized following 48hr treatment of the glioma cell cultures with the IC50 of 
RCE or RGSE. The expression was measured over three fields under the 
microscope. 
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Figure 27 Representative micrographs of the expression of (a) GFAP, (b) CD44, (c) Eric-1 NCAM, (d) 1 integrin and (e) v integrin, without 
treatment of RCE (1) and following 48 hr treatment of the IC50 of RCE on IPSB-18 cells (2). Magnification x40
(a) (e) (d) (c) (b) 
2 
After RCE 
 
1 
Before RCE 
GFAP CD44 Eric -1 1 integrin v integrin 
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Table 19 Antigenic expression in glioma cell lines incubated with the respective IC50 of either RCE or RGSE for 48 hours, of five antigens were 
visualized over three fields and compared to an untreated control (assumed 100%) (+ = positive expression, ± = some expression and – little to 
no perceived expression). 
 
 
CELL LINE 
RCE RGSE 
GFAP CD44 Eric-1 NCAM 1 integrin v integrin GFAP CD44 Eric-1 NCAM 1 integrin v integrin 
MUAB-C +++ ± ± ++ ± +++ ± - ++ ± 
IPSB-18 +++ ± ++ ± - +++ ± ± ± - 
MUMG-GM +++ - ++ ± - +++ ± ± ± - 
MUIH-GM ++ - ++ ± - ++ - + ± - 
MUTC-GM +++ - + ± - +++ - ++ - - 
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4.5 2D Change in Invasive Potential of Glioma Cell Cultures 
 
Significant changes in the expression of the integrins suggested that there 
would be a change in the invasive potential of the glioma cells subsequent to 
treatment with either micronutrient. All the cultures were analysed in transwell 
chambers (Chapter 2.7) after treatment with either micronutrient extract (at 
the IC50), for 48 hours, including the control cell culture (MUAB-C). Three 
fields were counted using a haemocytometer and each analysis was repeated 
three times, resulting in a total of nine field counts per experiment.  
 
       
      
                
 
Figure 28 Representative micrographs of the invasive potential of GBs (IPSB-18) 
untreated (a) and after treatment with the respective IC50 of micronutrient extracts; (b) 
RCE and (c) RGSE. Following treatment in the presence of either micronutrient fewer 
cells diffused across the chamber indicating a reduction in invasive potential. 
Micrographs illustrate cells which have invaded. Magnification x40 
 
(a) 
(b) (c) 
Untreated 
IPSB-18 
IPSB-18 after RCE 
treatment 
IPSB-18 after RGSE 
treatment 
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Figure 29 The mean number (three repetitions) of MUAB-C control cells which have 
invaded across the ECM in the Boyden chamber. Invasion of cells treated with the 
IC50 of RCE or RGSE were compared to untreated cells. The standard deviation is 
displayed as error bars. Following an ANOVA analysis no significant difference was 
found between the untreated and treated cultures  
 
 
 
 
Figure 30 The mean number (three repetitions) of glioma cells invading across the 
ECM of the Boyden chamber following 48 hour treatment with RCE as a percentage 
of the positive control (clear DMEM). The standard deviation is displayed as error 
bars. Significant differences calculated using Tukey HSD test are indicated (* p<0.05,  
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Figure 31 The mean number (three repetitions) of glioma cells invading across the 
ECM of the Boyden chamber following 48 hour treatment with RGSE as a 
percentage of the positive control clear DMEM. The standard deviation is displayed 
as error bars. Significant differences calculated using Tukey HSD test are indicated (* 
p< 0.05,  
 
4.6 Apoptosis Assays – Annexin V 
 
The reduction of cell viability as a result of exposure to the micronutrients 
seen earlier (section 4.3) could also be attributed to a pro-apoptotic effect. 
Two assays were used to investigate the apoptotic potential of the two 
micronutrients; the annexin V assay and Terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL). 
 
Annexin V flow plots distinguish between live, dead and apoptotic cells. Figure 
33 represents data for the IPSB-18 cell culture, an established glioma cell 
line, prior to any treatment and following treatment with either RCE or RGSE. 
The plots illustrate three foci; live cells on the lower left, apoptotic cells on the 
lower right and necrotic cells at the top.  While a small number of apoptotic 
cells can be seen in the untreated samples, upon treatment with either RCE 
or RGSE no apoptotic were detected were detected in the lower right.  This 
was true across all the cell lines.  
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Figure 32 Apoptosis in the IPSB-18 glioma cell culture before (a) and after 48hr treatment with the IC50 of RCE (b) or RGSE (c). Data 
highlighted in the square are dead cells. Data highlighted by the ovals shown live cells (left) and apoptotic cells (right). 
(a) (b) (c) 
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Table 20 Summary of the percentage of live, apoptotic and necrotic cells after 48 hour treatment with either micronutrient extract (at the IC50) 
(n=3). Change was measured in comparison to the respective untreated cell culture, using a t-test. No significant differences when compared to 
untreated cells were noted. 
 
CELL LINE 
RCE RGSE 
Live Apoptotic Necrotic Live Apoptotic Necrotic 
MUAB-C* 52.8 10.5 29.7 67.3 12.8 32.4 
IPSB-18 3.02 0.05 84.5 1.75 0.01 95.5 
MUMG-GM 2.04 0.03 79.9 1.25 0.02 89.4 
MUIH-GM 2.14 0.08 85.7 2.01 0.01 91.6 
MUTC-GM 1.95 0.04 90.3 0.95 0.01 89.1 
Note: percentages do not add up to 100%. Cells not included were not viable 
*Control cell line 
IC50 of RCE - IPSB-18, 0.4g/ml; MUMG-GM, 1 g/ml; MUTC-GM, 0.007g/ml; MUIH-GM, 0.98g/ml; MUPK-GM, 0.80g/ml 
IC50 of RGSE - IPSB-18, 0.001g/ml; MUMG-GM, 0.0001g/ml; MUTC-GM, 0.5g/ml; MUIH-GM, 0.4g/ml; MUPK-GM, 0.0000001g/ml
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No early pro-apoptotic effect was noted for any cell lines when compared to 
MUAB-C. Instead, a mass of dead cells were visible in the uppermost 
quadrants and some cells remained in the lower left quadrant (live cells). The 
cells indicated in the uppermost right hand quadrants suggest perhaps the 
occurance of late apoptosis. This indicated that, RCE and RGSE were indeed 
cytotoxic, and perhaps a shorter exposure to the respective IC50s either 
micronutrient extract would illustrate an early pro-apoptotic effect. To ensure 
that this result was not a false negative an additional assay, the TUNEL 
assay, was performed to support the analysis.  
 
4.7 Apoptosis Assays - TUNEL 
 
The TUNEL assay results suggested a similar outcome to that seen in the 
annexin V plots. Apoptotic potential was indicated by the visualization of 
fluorescence in three different fields of the cultures analysed. The 
micrographs illustrated in Figure 34 illustrate that there were no visual 
differences between the untreated glioma cells, which indicated little to no 
fluorescence, and those treated with either RCE or RGSE. The lack of 
fluorescence suggests very little or no apoptotic potential. This result was 
seen across all the glioma cell cultures and the MUAB-C control culture. This 
result suggested that neither RCE nor RGSE affect the apoptotic potential of 
the glioma cells. Furthermore, due to the limited apoptotic potential seen in 
the untreated cultures it may be speculated that these cell cultures do not 
undergo apoptosis as their major pathway of cell death. 
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                                            (a)                                                      (b)                                                        (c) 
 
 
Figure 33 Micrographs representing apoptosis following the TUNEL assay in (a) untreated cells and following treatment with (b) RCE or (c) 
RGSE for IPSB-18 (nuclei = blue, apoptotic cells = green). Magnification x40
IPSB-18 after RCE treatment IPSB-18 after RGSE treatment Untreatment 
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Figure 34 Micrograph representing apoptosis using the TUNEL assay in untreated 
MUAB-C control cells (nuclei = blue, apoptotic cells = green). 
 
The suggestion that neither RCE nor RGSE induce apoptosis, at 
concentrations tested, in GB cell cultures was indicated by the results of the 
two independent assays.  
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Table 21 Mean number of fluorescent cells counted  
CELL LINE Untreated RCE RGSE 
MUAB-C*    
Mean 4 3 1 
SD 3 2 1 
IPSB-18    
Mean 2 1 0 
SD 1 1 0 
MUMG-GM    
Mean 1 0 0 
SD 1 0 0 
MUIH-GM    
Mean 1 1 0 
SD 1 1 0 
MUTC-GM    
Mean 3 0 0 
SD 2 0 0 
Counts across three fields in an average of three experiments totaling nine counts, following 
48hr treatment with the respective micronutrient at the IC50. 
*Control cell line 
IC50 of RCE - IPSB-18, 0.4g/ml; MUMG-GM, 1 g/ml; MUTC-GM, 0.007g/ml; MUIH-GM, 0.98g/ml; 
MUPK-GM, 0.80g/ml 
IC50 of RGSE - IPSB-18, 0.001g/ml; MUMG-GM, 0.0001g/ml; MUTC-GM, 0.5g/ml; MUIH-GM, 
0.4g/ml; MUPK-GM, 0.0000001g/ml
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4.8 Angiogenesis Assays – Tubule Formation Assay 
 
This initial angiogenesis assay was carried out to determine whether either 
micronutrient could be shown to have an anti-angiogenic effect. This was 
achieved by culturing HUVEC cells and incubating these in the presence of 
either RCE or RGSE. During the angiogenesis process HUVEC cells normally 
exhibit tubule formation. In this assay the number of tubules formed after 48 
hour treatment with either of the micronutrients were counted and plotted on a 
histogram. Figure 36 illustrates the findings and suggests a propensity for 
both micronutrient extracts to decrease tubule formation. In particular RCE 
was found to have a greater anti-angiogenic effect when compared to RGSE. 
 
 
 
Figure 35 The average numbers of tubules formed by HUVEC cells were counted in 
three different fields, to examine the extent of the affect of RCE and RGSE on tubule 
formation. The graph illustrates the counts taken as an average of three repetitions of 
the experiment. Significant differences calculated using ANOVA are indicated (* 
p<0.05, ** p<0.001). 
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4.9 Angiogenesis Assays – Co-Culture Assay 
 
The number of tubules counted upon co-culturing HUVECs with each of the 
glioblastoma cell lines were found to increase with time and could be seen to 
protrude towards the GB cells (Fig 37). It was also visually noted that the cell 
viability and the rate of growth of the HUVEC cells also increased upon 
introduction of GB cells. When treated with either of the micronutrient extracts, 
it was found that the number of tubules counted were fewer than those 
counted in the untreated cultures.  
 
 
 
(a) 
 
 
 
(b) 
 
Figure 36 Representative micrographs illustrating tubule development of HUVEC 
cells (a) co-cultured with glioblastoma cells (the dotted line illustrates the delineation 
of the GBs on the left and HUVECs on the right) and (b) not co-cultured with GBs, 
without treatment with RCE or RGSE. Arrows indicate tubule formation. Cells were 
cultured for 48 hours  
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Figure 37  The average number of tubules counted in three different fields, of three 
separate experiments, of treated and untreated HUVEC cells co-cultured and not co-
cultured with GBs. Cells were treated with the IC50 of the either micronutrient. 
Significant differences were measured in comparison to the untreated control using a 
Tukey HSD test (*p<0.05, **p <0.001) 
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4.10 Summary of Results  
 
Analysis of both red clover extract (RCE) and red grape seed extract (RGSE) 
found both micronutrient extracts had an effect on the glioma cell cultures 
investigated, but not the control astrocytic cell culture MUAB-C. It can be seen 
that both micronutrients reduce viability, decrease invasive potential and 
decrease angiogenesis. However this study did not illustrate an effect on the 
apoptotic potential of the glioma cultures or the control cell culture.
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CHAPTER 5: Discussion 
 
High grade gliomas, in particular glioblastoma multiforme (GB), continue to 
have a poor prognosis. Conventional therapies such as radiotherapy and 
chemotherapy have been largely unsuccessful in curing malignant brain 
tumours (Biasoli 2014; Farah 2016). Survival rates for grade IV tumours are 
as little as six to nine months (McKinney 2004; Ho 2014; Farah 2016), and 
significant advances in conventional therapies are also limited (Weathers 
2014 p.1; Tseng 2016). This has encouraged patients to investigate the 
benefits of complementary and/or alternative medicines (Eisele 2014), which 
could potentially alleviate the trauma associated with disease progression and 
side effects of radiation and chemotherapy. 
 
This study investigated the therapeutic effect of two micronutrient extracts, 
specifically red clover extract and red grape seed extract in adult malignant 
brain tumours in vitro. Both these extracts and their individual active 
compounds are known to exhibit anticancer effects and and in some cases 
the individual active compunds have been known to show to affect various 
aspects of brain tumour development and growth, however, to the best of our 
knowledge neither extract has been reported for their to affect biopsy derived 
glioma cell cultures. The investigation of these two extracts analysed their 
effect on cell viability, invasion and angiogenesis. The study also investigated 
both micronutrient extracts for their effect on apoptosis. Both red clover 
extract (RCE) and red grape seed extract (RGSE) were found to affect the 
invasive and angiogenic potential of the glioma cultures but did not appear to 
exhibit early apoptosis in the cells.  
123 | P a g e  
 
5.1 The Effect of Glioma Cell Heterogenity on Cell Culture 
Survival 
 
Initially the study evaluated four biopsy glioblastoma multiforme (GB) cultures 
(grade IV), a primary cell culture (anaplastic astrocytoma grade III), a control 
astrocytic cell culture and a human umbilical vein endothelial cell culture. 
Biopsy cultures were chosen for experimentation as they offer several 
advantages over autopsy-derived materials and animal models. Being 
relatively fresh, the cell viability of the extracted and cultured biopsy cells is 
high, in the range of at least 90% (Totowa 2001), thus providing cultured cells 
of a similar phenotype as those in vivo. In vitro, however, unpredictability of 
biopsy derived cultures is seen with increasing passage (Janus 1992). 
Therefore, biopsy derived glioma cultures at no greater than passage 10 were 
used as part of this study to maintain integrity.  
 
As low passage cultures are extremely sensitive to the freezing and 
resurrection process, unfortunately, the biopsy derived culture MUPK-GM, 
initially used in this study was unable to be sustained. This failure to resurrect 
might be due to the DMSO found in freezing media. DMSO when used as part 
of freezing medium partially solubilizes the membrane of the cells (Yamashita 
2000). It may be that the particular biopsy derived culture (MUPK-GM) was 
particularly sensitive to DMSO in the freezing medium explaining the failed 
resurrection. Further study on the affects of DMSO in freezing medium on 
biopsy derived glioma cells is warranted. 
 
The primary cell culture, IPSB-18 was evaluated at passage 20. IPSB-18 has 
historically been used to assess the affect of other micronutrients on 
characteristic biologic features such as cell viability and invasion (Rooprai 
2001; Rooprai 2007; Rooprai personal communication). To retain consistency 
with previous studies, and allow future comparisons of the various 
micronutrient affects on glioma cell cultures, the therapeutic affects of both 
RCE and RGSE were examined on this primary culture also. 
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5.2 Morphological Heterogeneity of Glioma Cell Cultures 
 
Gliomas are highly heterogeneous and can consist of up to 14 different cell 
sub-populations (Pilkington 2001; Marusyk 2010; Sottoriva 2013; Inda 2014; 
Crespin 2016). Potter et al (2009) reported low passage cultures retain the 
global tumour profile in vivo when compared to higher passage cultures. As a 
result, each tumour is genotypically and phenotypically different from any 
other, thus presenting the initial hurdle in developing a common treatment for 
brain tumours (Rao 2003; Louis 2006; Mason 2008; Sathornsumetee 2008; 
Wen 2008; Weathers 2014). Within this study heterogeneity of the glioma cell 
cultures was seen using phase contrast microscopy. 
 
The IPSB-18 primary GB culture exhibited small cells which grew rapidly in 
small clumps. The biopsy derived cultures; MUMG-GM, MUIH-GM, MUTC-
GM and MUPK-GM exhibited larger, longer spindle like cells, with clear 
differences in the morphology between cell cultures. The differences in the 
morphology of the GB cultures may be assumed to be related to the 
heterogeneous nature of the GB tumour (Bozkurt 2014, p1021). Further study 
into the various cell types found within each of the biopsy cultures is required. 
One such technique to investigate the different subpopulations within the 
cultures is flow cytometry. Studies have shown by measuring the antigenic 
expression of glioma cell cultures a number of different populations may be 
identified (Prestegarden 2010). Flow cytometry assays in this study do 
indicate differing percentages of antigenic expression between the glioma 
cultures (Table 18), though further investigation would be required to 
investigate the different subpopulations which exist between the cultures. 
 
The control astrocytic cell culture, MUAB-C, was the only culture which 
depicted the classical astrocytic ‘star shape’. This result was expected of the 
normal astrocytic cell culture. MUAB-C cells were found to develop at a 
slower rate when compared to the biopsy derived GB cultures, which not only 
grew at a faster rate but only partially presented the classic ‘star shape’ 
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illustrated by the control cell culture. Cancer cells are known to divide and 
grow indefinitely though normal cells will only grow when required, this may 
explain the differences seen between the GB cultures and normal astocytic 
cultures. This was also illustrated by the population doubling times (PDTs). 
 
5.3 Differences between Population Doubling Times of Glioma 
Cultures   
 
Most normal cell lines are only able to undergo a few subcultures, or 
passages. These are called finite cell lines. The limited number of passages is 
dictated by the population doubling time of a particular cell population, before 
it stops growing due to aging (Hayflick 1985; Hayflick 1994). 
The process of doubling the cell population can be described by growth 
curves which show the population doubling time (PDT). The PDT indicates the 
period of time during which the number of cells double in number. The 
traditional curve illustrates three growth phases (as shown in Figure 36). 
Initially the cells enter a latent period which shows no growth, called the lag 
phase. This period allows the cells to recover from trypsinisation, reconstruct 
the cytoskeleton, secrete matrix to aid attachment, and spread out across the 
surface, thus re-entering the cell cycle (Figure 36). Subsequently an 
exponential growth is noted known as the log phase. In this period the cell 
population doubles over a definable period, known as the doubling time and 
characteristic for each cell line. Increased growth results in eventual 
overcrowding such that the entire surface is occupied. Overcrowding 
eventually withdraws the cells from a growth cycle. This is illustrated as a 
plateau or stationary phase. Some cells may differentiate during this phase; 
others simply exit the cell cycle and return to G0 but retain viability. A 
reduction in proliferation in the stationary phase can be attributed to a high 
cell density and exhaustion of growth factors in the growth medium (Stoker 
1973; Westermark 1975). 
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Figure 38 Growth Curve:  Cell growth follows a three phase pattern. Initially the cells 
the cells enter a lag phase during which no growth occurs this is followed by the log 
phase. Here the cells increase exponentially. Finally, the cells enter the latent phase 
where cells are unable to growth and develop any further (Laird 1965, p282). 
 
MUAB-C was found to have a PDT of 72 hours and unlike the biopsy cultures 
this time remained consistent with increasing passage number. IPSB-18 
(passage 29-30) indicated the shortest PDT at 36 hours, when compared to 
the longer PDTs of the lower passage biopsy derived cultures in particular 
MUPK-GM took around two weeks to double its population. The population 
doubling times (PDT) of the glioma cell cultures were statistically analysed to 
compare each glioma culture with the control cell culture (MUAB-C). The 
ANOVA analysis yielded a p value of 0.000 and as such a Tukey’s test was 
performed to identify where the significant difference lay. As summarised in 
Table 23 there appeared to be a statistically significant difference between the 
PDT of each glioma culture compared to the normal astocytic cell culture, 
MUAB-C (p=<0.01) (Table 23).  
 
As previously discussed the differences between the PDTs may be due to the 
greater heterogeneous nature of the biopsy derived cultures (Pilkington 1992). 
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Different cells, with differing phenotypes, may exhibit unique periods of 
growth, which may be affected with increasing passage number. The cultures 
were therefore only investigated at specific passages, to best retain an 
assumed phenotypic consistency, throughout evaluations (Table 22).   
 
Table 22 Summary of population doubling times of the cell cultures used in this 
study. A p value following a Tukey test illustrates the comparison between the glioma 
cultures and the control culture (MUAB-C – PDT = 72hr) 
Cell Line 
Population 
doubling time 
(hr) 
p value 
(when compared to 
MUAB-C) 
Passage 
investigated  
IPSB-18 36 <0.01 29-30 
MUMG-GM 165 <0.01 4-6 
MUIH-GM 210 <0.01 5-7 
MUTC-GM 197 <0.01 4-6 
MUPK-GM 347 <0.01 3-5 
 
5.4 Cell Viability: The Toxic Effects of RCE and RGSE 
5.4.1 DMSO Alters the Effects of Micronutrient Extracts 
 
DMSO is known to permeate the cell membrane and interact with the cell 
metabolism (Violante 2002; He 2012). Peng (2005) has suggested that DMSO 
has no direct effects on the MTT assay and in fact DMSO is used to solubilise 
the deposited tetrazolium salt prior to microtitre plate reading. It was therefore 
assumed these results occurred due to DMSO being used to dissolve the 
flavonoid extracts. DMSO has been known to display a variety of therapeutic 
effects and cytotoxic effects (Santos 2003) and thus it is reasonable to 
suggest DMSO does have an affect on cell viability of brain tumour cell 
cultures investigated as part of this study. As this study showed DMSO had a 
cytotoxic effect on glioma cultures, it is therefore suggested that, prior to 
dissolving any extract in any solvent, the cells being treated should be initially 
investigated for any toxicity the solvent may display towards the cell culture, 
using a suitable viability assay. 
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5.4.2 Pigmentation of Micronutrient Extracts  
 
Despite removing DMSO from the assay and replacing this with clear DMEM, 
the results remained confusing; there was an apparent reduction in viability 
following 48-hour treatment with low concentrations of either extract, followed 
by an apparent increase in viability at higher concentrations, depicting a 
biphasic curve (Figs 18 and 19). This increase in percentage viability at higher 
concentrations, for both RCE and RGSE, suggested that both micronutrients 
were encouraging cell growth and maintenance of cell populations between 
concentrations of 50g/ml and 250g/ml. Similar results were also reported in 
other studies (personal communication) and remain unexplained. Some 
groups suggest a lag within the cell cycle (personal communication) though 
this did not seem plausible as the investigation yielded an end-point result 
rather that a continuous result.  
 
Further analysis into the occurrence of the biphasic curve analysed phase 
contrast micrographs of glioma cells following 48-hour treatment with either of 
the micronutrient extracts. The micrographs have shown that at 
concentrations greater than 10g/ml for RCE and 20g/ml for RGSE, more 
than 90% cell death was induced. The biphasic curve therefore appears to be 
an anomaly. Such a phenomenon has previously been reported using 
concentrations of anthocyanidins (Elisia 2008). In this study, Elisia et al (2008) 
showed that when determining the differences between various viability 
assays, at concentrations of anthocyanidins between 0.4 to 9.4 mg/mL, the 
results yielded were inconsistent.  
 
As reported (Chapter 2) further analysis of the treated 96 well plates found 
residues of the extracts remaining, which despite copious washing, were not 
being entirely removed from the wells. The interference of the pigments in the 
extracts on the viability assay absorbance value was determined by 
measuring the optical density of RCE and RGSE. It was noted that RCE and 
RGSE both interfere with absorbance values at 570nm at concentrations 
higher than 1g/ml, as demonstrated by the peaks on the optical density 
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graphs at 570nm (Fig 24). As the residual colour of both RCE and RGSE 
interfered with the final absorbance at 570nm it was determined that RCE and 
RGSE should not be analysed at high concentrations using the MTT assay. It 
is therefore recommended that prior to any viability investigation, the chosen 
compound be tested for interference, at the desired concentrations, with the 
appropriate wavelength. 
 
Viability assays read at a wavelength of lower than 570nm, such as the MTS 
assay (470nm), should be replaced by viability assays read at higher 
wavelengths. An alternative to both the MTT and MTS assays, is using 
DRAQ7™. This flow cytometry technique accurately differentiates and 
quantifies live and dead/dying cells in a given cell sample, by using the 
fluorescent dye DRAQ7™ (Biostatus). DRAQ7™ is a far-red emitting DNA-
specific dye, having its Exλmax at 488 nm especially for detection by flow 
cytometry. It is impermeant to live cells but rapidly enters any leaky or dead 
cell and stains its nuclear DNA. Unlike some nuclear dyes like PI, DRAQ7™ 
does not stain cytoplasmic RNA of viable cells and thus avoids false positive 
results (Rieger, 2010). The low wavelength at which it is read also does not 
interfere with micronutrient dyes thus alleviating the problem of interference 
with absorbance readings, in the MTT assay.  
 
As a reduced viability had been demonstrated by concentrations of RCE and 
RGSE lower than 10g/ml it could be inferred the IC50 of each micronutrient 
extract may be found at lower concentrations which would not interfere with 
the use of the MTT assay. Table 24 summarizes the IC50 values for all the 
glioma cultures.  
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Table 23 Summary of the IC50s of the micronutrients using various cell cultures 
including primary cultures set up from biopsies, an existing low passage cell line. 
 
Cell Culture Passage 
Number 
IC50 
  RCE RGSE 
IPSB-18 29-30 400ng/ml 1ng/ml 
MUMG-GM 4-6 1 g/ml 0.1ng/ml 
MUTC-GM 5-7 7ng/ml 500ng/ml 
MUIH-GM 4-6 0.98g/ml 400ng/ml 
MUPK-GM 3-5 0.80g/ml 0.1pg/ml 
 
 
The IC50 for RCE and for RGSE for the glioma cultures all differ from one 
another. This may reflect the previously discussed, heterogeneous natures of 
these cultures. Previous researchers have reported that glioma cultures differ 
phenotypically (Pilkington 2001, Sottoriva 2013). Each sub-cell population 
within each culture may respond to a different concentration of micronutrient 
extract. As such, differences in the glioma culture IC50s were expected to be 
seen. This study showed significant differences in viability were seen within 
the glioma cultures, as the concentration or RCE or RGSE was increased.  
 
The glioma culture, IPSB-18 was found to have one of the lowest IC50s, for 
RCE (400ng/ml). Knott et al. (1990) showed IPSB-18 consisted of a low 
number of different cell populations. This reduced heterogenous nature of the 
culture may explain the lower IC50.  The effect of the micronutrients on each 
cell type will be reacted upon in a different way so it can be speculated that 
the more cell variations within a culture, more micronutrient is required to 
target the cells. This is supported by the higher IC50’s seen for some of the 
biopsy cultures which are assumed to be more heterogeneous.  
 
Interestingly MUPK-GM and MUTC-GM did display increased sensitivity to 
RGSE and RCE respectively, when compared to the other cell cultures (Table 
24). Given the decreased cell heterogeneity found within IPSB-18, it may be 
assumed MUPK-GM and MUTC-GM also exhibit a low number of different cell 
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populations. Further characterization of the sub populations within these 
glioma cultures, using flow cytometry is warranted. 
 
Despite limited analysis on the MUPK-GM cell culture this assay indicated a 
reduction in cell viability following treatment with RCE or RGSE. This 
suggested that MUPK-GM was likely to have yielded similar outcomes as the 
other biopsy derived GB cultures. Given the reduction in cell viability of all the 
glioma cultures, further investigation into why this occurred was required. 
 
5.5 Changes in Environment Effect Antigenic Expression of 
Glioma Cultures 
 
Routinely cell biopsies and established cultures are characterised by 
examining the antigenic expression of the cells. In this particular study flow 
cytometry and immunocytochemistry were used to analyse the antigenic 
expression of the glioma cultures and whether treatment with either of the 
micronutrient extracts affected expression. 
 
5.5.1 Changes in Microenvironment affect the Phenotype of the 
Glioma Cells 
 
Prior to evaluating the antigenic profile of the biopsy derived GB cultures, this 
study appraised the microenvironment in which the cells were cultured; 
specifically, serum supplement. Globally, the controversial topic of debate 
around the choice of serum used to supplement growth media has resulted in 
differing use of serum supplementation (Chimenti, 2014). Personal 
communication with labs in Norway, who have adopted the use of newborn 
calf serum instead of foetal calf serum to culture glioma cells in vitro, 
encouraged the investigation into whether the microenvironmental properties, 
of the culture media have an affect on glioma cells.  
 
This study assessed the antigenic expression of seven antigens in five 
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established glioma cell cultures, with particular focus on glial fibrillary acidic 
protein (GFAP) and galactocerbrosicide (Gal C) (Chapter 3). These two 
indicative markers of cells of astrocytic and oligodendrocytic origin 
respectively, were investigated specifically to support studies performed by 
Raff et al. (1983) and Tenenbaum et al. (1996). The culture media in which 
glioma cells were grown, were supplemented with either foetal calf serum 
(FCS); the standard serum supplementation adopted, newborn calf serum 
(NCS); the serum adopted by colleagues in Norway (personal communication) 
and human serum (HS); to mimic glioma cell growth in vivo. 
 
The change of antigenic expression found in this study can be seen in the 
immunocytochemical micrographs of GFAP expression (Fig 13). In particular, 
the expression of GFAP was shown to be down regulated with differing sera 
supplementation, specifically FCS<NCS<HS. Upon analysis of the flow 
cytochemical data (Table 13) statistically significant differences were seen in 
three of the glioma cell cultures when compared to cells cultured in FCS, 
namely A172 (NCS p=0.04), HF66 (NCS p=0.048; HS p=0.029) and U373 
(NCS p=0.02; HS p=0.02). 
 
A similar but opposing, result was seen when analyzing the expression of the 
oligodendrocytic marker galactocerobroside (Gal C). Immunocytochemical 
micrographs indicated altered expression with the antigens being up 
regulated, specifically FCS>NCS>HS. Flow cytochemical results showed 
significant differences in four of the five glioma cell cultures evaluated; IPSB-
18 (HS p=0.02), U251 (HS p=0.004), HF66 (NCS p= 0.0009; HS p= 0.0001) 
and U373 (HS p=0.01). 
 
These findings support similar occurrences reported in previous studies by 
Raff et al (1983) and Tenenbaum et al (1996), reinforcing the notion that 
microenvironmental changes manipulate cells to change phenotype. Studies 
by Raff et al. (1983) explored the influences of external factors the cellular 
environment, such as the presence or absence of foetal calf serum in the 
culture medium, on the developmental pathways of astrocytes and 
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oligodendrocytes. They assessed morphological and immunocytochemical 
criteria of the divergent pathways of cell development in the immature glia of 
the rat optic nerve. They used A2B5 antibody for the detection of Type 2 
astrocytes in this study and proposed that both fibrous astrocytes and 
oligodendrocytes may be derived from a primitive precursor cell (the so-called 
“O-2A” or oligodendrocyte Type 2 astrocyte progenitor cell) dependent upon 
the influence of the environment. Subsequent studies showed that the 
presence of GFAP-negative, A2B5-positive cells and GFAP-positive, A2B5- 
positive cells in a malignant astrocytoma culture (IPSB-18) which provided 
evidence that the O-2A progenitor and Type 2 astrocyte phenotypes occur 
both in human neoplastic cells in vitro and in normal developing rat neural 
tissue (Knott 1990; Pilkington 1992).  
 
Furthermore, Tenebaum et al. (1996) identified the plasticity of 
oligodendroglioma cells by successfully showing that, when taken from a rat 
brain, they could be manipulated in the presence of serum supplementation, 
into losing the expression of oligodendrocytic antigenic markers and acquiring 
astrocytic markers. Upon re-introduction into the rat, these cells were able to 
revert back to their original antigenic expression. They also confirmed that 
human oligodendroglioma cells had a similar fate being induced, by the 
absence or presence of serum, into oligodendrocytes or Type 2 astrocytes, 
respectively. 
 
Conclusions of these studies suggested the optimal use of serum 
supplementation with the growth media for GB cultures was human serum as 
this mimicked conditions in vivo. Unfortunately, as human serum is not readily 
available and/or produced, studies may be subject to delay and it is not an 
economically viable option. As such, to maintain consistency with previous 
studies, investigation into the effects of other micronutrient extracts on IPSB-
18 and other glioma cultures (Rooprai 2007), the remainder of this study grew 
the glioma cells in growth media supplemented with 10% FCS, unless 
otherwise indicated. Further investigation into trans-differentiation of glioma 
cells, cultured in the presence of FCS as the growth supplement of choice, is 
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warranted, with the aim to develop a media supplement able to imitate 
conditions in vivo. 
 
5.5.2 Micronutients Alter Antigenic Expression of Glioma Cell 
Cultures 
 
Evaluation of the glioma cell cultures investigated the expression of five 
antigens; GFAP, CD44, NCAM eric-1, v and 1. These antigens were 
chosen to retain uniformity with studies performed previously on glioma cell 
lines, assessing the effect of other micronutrient extracts (Rooprai, 2007). 
Flow cytochemical data compared the antigenic expression of untreated 
glioma cultures vs. glioma cultures following 48-hour treatment with either 
RCE or RGSE. The immunocytochemical data illustrated the approximate 
percentage expression based on the amount of fluorescence visualized.  
 
GFAP expression 
 
Glial fibrillary acidic protein (GFAP) was first described in 1971 by Eng et al. 
(1971) and is a member of the cytoskeletal protein family and is widely 
expressed in astroglial cells and in neural stem cells (Eng 1971; Doetsch 
2003). It is also expressed in astroglial tumours, such as astrocytomas and 
GB (Jacque, 1978; Hamaya, 1985; Abaza, 1998). The expression of GFAP 
provided a positive control confirming the integrity of the cultures used as 
astrocytic in origin. Flow cytochemical data indicated that GFAP expression in 
IPSB-18 cells treated with RCE was found to be significantly down-regulated 
compared to untreated IPSB-18 cells (p = 0.015). When treated with RGSE 
however, although the expression of GFAP appeared to be down regulated, 
this change did not reach significance (p=0.0439). This change in antigenic 
expression was mimicked by the other glioma cultures (Table 18). 
 
Immunocytochemical data did not however confirm a down regulation in the 
expression of GFAP.  
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CD44 expression 
 
CD44, a cell surface adhesion molecule (Pilkington 1993; Radotra 1998; Ariza 
1995; Li 1995) and a principal receptor for hyaluronan (HA) (Aruffo 1990), is a 
glycosaminoglycan found in the extra cellular matrix (ECM). CD44 has been 
implicated in the invasive process (Merzak 1994) and has been suggested as 
a biomarker of cancer stem like cells (Yan 2015). As part of the evaluation of 
the effects of RCE and RGSE, investigation into the expression of CD44 by 
gliomal cells following treatment with the micronutrients was carried out. 
 
Neither flow cytochemical nor immunocytochemical data indicated a 
significant change in expression of CD44 by the cell lines under investigation 
following treatment with RCE and RGSE (Table 18 and 19). CD44 is 
overexpressed in brain tumours and is involved in the invasive process and 
cell-cell adhesion (Merzak, 1994). Therefore, a down regulation would have 
indicated a possible anti-invasive effect. A slight decrease in CD44 was seen 
in the immunocytochemical micrographs of glioma cultures following 
treatment with RCE and RGSE when compared to the untreated glioma 
cultures, however, analysis of the flow cytochemical data found that this was 
not statistically different (p=>0.05). RCE and RGSE do not appear to affect 
the pathways underlying the invasive process within GBs as indicated by 
expression of this antigen. Although CD44 is known to mediate invasion in 
gliomas (Merzak 1994; Yoshida 2012) and has previously been shown to be 
down regulated following treatment with micronutrient extracts (Rooprai 
2007). Additionally, grape seed extract and its individual components have 
been shown to downregulate CD44 in other cancers, including colon cancer 
(Kumar 2014) and breast cancer (Ouhtit 2014). Curcumin is also amongst one 
of the other micronutrients which has demonstrated a clear down regulation of 
CD44 (Chung 2015). Further investigation into the expression of CD44 is 
required.   
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Eric-1 NCAM expression 
 
Eric-1 NCAM is a cell surface glycoprotein that also mediates cell-cell 
adhesion independent of Ca2+ (Keilhauer 1985), and plays an important role 
in neurite outgrowth and fasciculation (Appel 1993).  Eric-1 NCAM has also 
been found to be involved in migration/invasion (Gratsa 1997). Although no 
significant difference was found in the expression of Eric-1 NCAM between 
the treated and untreated cultures (p=0.06-0.11) (Table 18), 
immunocytochemical micrographs indicated a down regulation. This therefore 
suggested further study may be warranted.  
 
As both CD44 and Eric-1 NCAM exhibited only a slight down regulation in 
expression in immunocytochemical data but analysis of the flow cytochemical 
data did not indicate a significant change, further investigation into the anti-
invasive potential of both micronutrient extracts was required.  
 
V integrin expression 
 
In malignant gliomas, the expression of many integrins, including v and 1 
are reportedly increased, relative to their levels in normal brain tissue 
(Gingras, 1995; Rooprai, 1999; Paulus, 1993).  
 
The expression of v intergrin was found to be down regulated in all the IPSB-
18 cell cultures following treatment with RCE (p<0.001) and RGSE (p<0.001) 
when compared to the untreated cell culture. A similar result was found for the 
biopsy derived glioma cultures (p<0.001) (Table 18). Immunocytochemical 
data also depicted a clear down regulation in the expression of V when 
compared to untreated cell (Fig 28).  
 
v is unique in that it can pair with multiple  subunits to form five recognized 
receptors, v1, v3, v5, v6 and v8 (Nemeth 2007). Integrins v3 
and v5 are consistently overexpressed in GBs in comparison, other 
integrins and play an important role in gliomagenesis, progression, invasion 
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and angiogenesis (Brooks 1994; Friedlander 1995; Hynes 2002; D’Abaco 
2007). Integrin αvβ3 in particular, is necessary for the formation, survival, and 
maturation of newly formed blood vessels (Brooks 1994). Therefore, a down 
regulation in αv suggests that RCE and RGSE have anti-invasive and anti-
angiogenic potential. Blandin et al (2016), suggested a downregulation of αv 
integrin may be useful to reduce invasion of GBs. 
 
1 integrin expression 
 
1 integrin is also highly expressed in glioma cell lines, when compared to 
normal brain tissue (Gingras 1995; Paulus 1993). It has been shown that 
blocking the 1 integrin can reduce invasive potential in glioma cell lines 
(Tysnes, 1996; Friedlander, 1996; Tonn, 1998).  
 
Following 48-hour treatment of IPSB-18 with RCE or RGSE a down regulation 
of 1 integrin was seen. Following comparison of this against the untreated 
cells, the down regulation was found to be statistically significant for both RCE 
(p<0.001) and RGSE (p<0.01) (Table 18).  Down regulation of 1 integrin 
expression was also found following treatment with RCE or RGSE in all the 
biopsy derived cultures (p<0.001). Immunocytochemical micrographs also 
illustrated a clear down regulation in expression of 1 integrin (Fig 28). 
 
1-integrin initiated invasion is likely mediated by the 31 integrin receptor, 
although several subunits can pair with 1 integrin (Tysnes 1996; Knott 1998; 
Fukushima 1998). The data for the expression of integrins supported the anti-
invasive capabilities of both micronutrients.  
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5.6 Diffuse Invasion Reduced After Micronutrient Treatement  
 
Various molecules are implicated in the invasive potential of gliomas, 
including CD44, NCAM and integrins. Investigation into the antigenic 
expression of these molecules may support the suggestion both RCE and 
RGSE may exhibit anti-invasive potential, however the difference in 
expression of CD44 and NCAM were not found to be statistically significant. 
Therefore, to investigate the anti-invasive potential of both micronutrient 
extracts further, modified Boyden chambers were used. This 2-dimensional 
study was performed using all the glioma cultures and the control cell line 
MUAB-C. Cells were seeded into the modified Boyden chamber above a layer 
of extra cellular matrix (ECM). The cells which migrated through the chamber 
and across the ECM were then counted.  
 
When analysed, the normal cell culture MUAB-C, very little invasion.  
Examination of data found that this was based on only 1 or 2 cells migrating 
through the chamber. Given MUAB-C was assumed to have ‘no’ invasive 
potential, incubation with RCE or RGSE would determine if either 
micronutrient promoted the invasive process. Neither of the micronutrient 
extracts was found to have an effect on invasive potential of MUAB-C, with 
the average invasion remaining at 0%. This indicated RCE and RGSE do not 
promote invasion in MUAB-C. 
 
The glioma cultures (Fig 29) did initially display invasive potential. The anti-
invasive effects of both micronutrient extracts are visible in Figures 29, 31 and 
32 where upon treatment with RCE and RGSE, the number of invading glioma 
cells reduced dramatically. Invasion is a multi process biological feature, and 
it may only be speculated which pathway may be affected. Recent research 
has identified several key molecules that regulate GB cell migration and 
invasion, and may serve as attractive targets. Similarly, Zhou et al (2016), 
found that grape seed extract also demonstrated a reduction in invasion in 
luncg cancer.  
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One such explanation for the anti-invasive potential may lie in the down 
regulation of integrins and their interaction with the cells migratory processes. 
Integrins, in particular 1 subunit, play an important role in glioma biology and 
its expression has been correlated with the invasive behavior of glioma 
(Paulus, 1996) It is supported by the observation that inhibition of 1 integrin 
leads to decreased motility while inhibition of v integrin results in increased 
motility. This correlates with data previously depicted by flow cytochemical 
and immunocytochemical data. 
 
Another possible explanation may lie in the effect of the micronutrients on 
matrix metalloproteinanses (MMPs). MMPs play a vital role in invasion by 
paving a pathway for the malignant tissue to migrate or invade along. Down 
regulation of various MMPs in the presence of micronutrients has previously 
been reported (Rooprai 2007). As such, inhibition of MMPs could aid a 
reduction in invasion ultimately preventing recurrence of tumour growth. 
Preliminary flow cytochemical data illustrated a slight down regulation of MMP 
2 and 9 following treatment of glioma cell cultures with either of the 
micronutrients. Initial findings indicated MMP2, an initiator of both invasion 
and angiogenesis, was reduced in treated glioma cells, when compared to 
untreated cells. Recent studies in to the ‘knock-out’ of MircoRNAs for 
membrane type MMPs found that this downregulation suppressed the 
malignancy of gliomas cells in vitro (Sakr 2016), supporting the suggestion 
that targeting MMPs could reduce the likelihood of both invasion and 
angiogenesis. 
Grape seed extract has been shown in breast cancer (Dinicola 2014) to 
downregulate the expression of both MMP2 and MMP9.  Further investigation 
into the expression of MMPs could provide an explanation into the pathways 
interrupted by RCE or RGSE during invasion.  
 
Other possible targets to investigate the affect of the invasive potential include 
tGLI1 (a novel splice variant of GLI1), SDF-1, Pin1, OPN, MGP, ADAM19, 
140 | P a g e  
 
VAT-1, Sema3A-neuropilin-1, and AJAP1. (Nakada, 2010; Mertsch 2009; Lo 
2009; Kenig 2010; Bagci 2009; Atkinson 2009; Lamour 2010; Qi 2009; 
Mertsch 2009). 
 
5.7 Late Pro Apoptotic Potential: A Qualitative Indication  
 
In the normal brain, cells of the CNS exhibit differences in their resistance to 
the automated process of apoptosis, the most resistant of cells being 
microglia and the most vulnerable, neurons. The sensitivity of glial cells lies 
between the two extremes (Salgado 2007). During malignant progression, 
tumour cells acquire an increased resistance to apoptotic agents and 
procedures. In particular the invading cells of GBs are less sensitive to 
apoptosis, resulting in a high frequency of relapse (LeFrank 2005). Two 
assays were performed to determine whether either of the micronutrients 
displayed pro-apoptotic characteristics, annexin V and the TUNEL assay.  
 
The control cell line (MUAB-C) displayed a small number of apoptotic cells 
when analysed with the annexin V assay (an average of 10%). This remained 
consistent following treatment with RCE (10.5%) or RGSE (12.8%). The 
TUNEL assay illustrated apoptotic cells as fluorescent. The number of 
fluorescent cells was then counted in an average of three fields.  The results 
were similar to those in the annexin V assay with only three or four fluorescent 
cells in each field counted (Fig 35).  
 
Untreated IPSB-18 glioma cells displayed a small proportion of apoptotic cells 
(2.9 %) (Fig 33). Following treatment with RCE and RGSE the percentage of 
apoptotic cells decreased (0.05% and 0.01% respectively), though this 
change was not significant.  Instead, the majority of cells appeared in the 
necrosis quadrant of the annexin V plot. The TUNEL assay micrographs also 
showed an average of 0-1 fluorescent cells in each field (Fig 34). This result 
was seen across all the biopsy derived glioma cultures (Table 20). 
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Although a slight reduction in apoptotic potential was illustrated in treated 
glioma cells when compared to untreated cells, this was not a significant 
change with only a difference of around one or two cells. It can therefore be 
suggested that glioma cells do not exhibit an apoptotic affect following 
treatment with either RCE or RGSE, though cell death had occurred.  
 
Apoptosis is rarely seen in glioma cultures, possibly as a result of the 
relationship between rates of apoptosis and tumor grade, not being straight 
forward, though one explanation could be attributed to integrins, in particular 
the expression of v3. As more cells enter an invasive state their sensitivity 
for apoptosis decreases. This phenomenon can be attributed to the enhanced 
expression of v3, in the marginals infiltrating zones (Sarafian 2009). v3 
serves as a basic regulator of proliferation, invasion and angiogenesis (Bogler 
2005). Integrins bind to a variety of ECM ligands including vitronectin, 
fibronectin, fibrinogen, thrombospondin, proteolyzed collagen, von Willebrand 
factor and osteopontin. Such ligation activates intracellular signaling pathways 
that promote cell survival, proliferation, motility and inhibit apoptosis (Bogler 
2005; Horton 1997; Stupack 2002). 
 
As discussed earlier, the expression of the v was found to be down 
regulated in all treated glioma cultures, when compared to the control cell 
culture MUAB-C. Preliminary investigation of the 3 integrin also exhibited a 
very slight upregulation of antigenic expression when compared to the normal 
brain tissue in vitro (Fig 39).This would suggest more cells should be sensitive 
to the apopotic pathway, however, the limited apoptotic potential displayed 
when analysed using both annexin V and TUNEL assays was not significant 
and therefore does not suggest that RCE or RGSE induce apoptosis.  
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Figure 39 The expression of 3 integrin in a) normal brain tissue and b) glioma 
cultures. 3 expression is increased in malignant tissue. When in compound form, 
v3, thus resulting in a resistance to apoptosis and a vulnerability to invasion and 
angiogenesis. 
 
These findings suggest the dominant form of cell death in glioblastoma is 
necrosis rather than apoptosis, and this histological feature is part of the 
definition of this tumor type (Kleihues 2000). This has been verified in recent 
literature which states that despite apoptosis being caspase dependent and 
necrosis caspase independent, both these pathways share common starting 
points such as death domains like p55 TNF receptor (TNF-RI) and Fas and 
the adapter protein FADD. Both micronutrients in particular RGSE exhibit 
antioxidant properties and are thus are known to reduce free radicals (Bagchi 
2000) and induce apoptosis mainly by targeting Fas death domain. However, 
prolonged activation of Fas without phagocytosis of apoptotic cells is seen to 
induce cell death via necrosis in vitro in cell lines (Eisele 2011). In the annexin 
V plots the majority of cells lay in the live or dead quadrants, with one or two 
cells in the apoptotic quadrant, suggesting RCE and RGSE exhibit a possible 
necrotic effect. 
 
An explanation for such an occurrence can be related to defective apoptosis 
signaling. This may be caused by increased expression of anti-apoptotic 
molecules or by impaired function of pro-apoptotic molecules (Igney and 
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Krammer 2002). Examples of such mechanisms are illustrated by inhibitor of 
apoptosis proteins (IAPs) such as survivin. This is expressed at high levels in 
many tumours and has been reported to be associated with noncompliant 
disease and poor prognosis (Salvesen 2002; Altieri 2003). It has been 
reported that glioblastoma cultures are positive for survivin expression 
(Chakravarti A, 2002). A downregulation of survivin combined with 
administration of the chemotherapeutic agents temozolomide or etoposide 
was has been shown to exhibit a synergistic cytotoxic effect on GBs (Cruz 
2016). Such IAPs can inhibit effector caspases, including caspase 3, 6 and 7, 
at the core of the apoptotic pathways. Therefore, therapeutic modulation of 
IAPs could target a key control point in cancer resistance (Goyal 2001). 
 
Although neither RCE nor RGSE instigated apoptosis alone, it could be 
postulated, in the presence of another factor, either micronutrient could 
potentially exhibit pro-apoptotic features. Apoptosis is rarely seen in glioma 
cultures though some studies have increased the affinity for glioma cells to 
undergo apoptosis. It was reported by Gondi et al. (2010) that in the presence 
of human umbilical cord cells, enriched in CD44 and CD133, gliomas cultures, 
underwent apoptosis. This suggests glioma cells have the ability to 
demonstrate apoptotic behavior. Further investigation, therefore, is warranted 
into adjuvant compounds which together with the chosen micronutrients could 
induce apoptosis. 
 
Alternatively, autophagy of glioma cells could have occurred. Autophagy is 
accepted as the mechanism by which glioma cells undergo programmed cell 
death when the apoptotic pathway is inhibited (LeFrank 2005). It operates in 
stress conditions such as low oxygen, commonly found in GBs. 
Proautophagic drugs block the mechanistic target of rapamycin (mTOR) a 
serine/threonine protein kinase that regulates cell growth, cell proliferation, 
cell motility, cell survival, protein synthesis, and transcription (Hay 2004; 
Beevers 2006; Fulda 2015). mTOR belongs to the phosphatidylinositol 3-
kinase-related kinase protein family. Expression of of mTOR in GBs is up 
regulated and results in a resistance to apoptosis and autophagy. Further 
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study is warranted into the effects of RCE or RGSE on the expression of 
mTOR and their ability to induce autophagy. 
 
5.8 Anti-angiogenic potential of the micronutrients 
 
In addition to being highly invasive, GBs are extremely vascular. 
Angiogenesis plays an important role in GB growth. Anti-angiogenesis based 
therapies have been shown to be effective in reducing vascularization in GB 
patients. However, therapeutic resistance can develop in patients, suggesting 
that GB cells are capable of altering their signaling pathway (Soda 2013). 
Therefore, it is important to identify novel angiogenic factors that play 
essential roles in tumor angiogenesis and GB progression.  
 
This study found that RCE and RGSE both exhibit anti-angiogenic activity. 
Though the mechanisms by which they do this, have not been confirmed. It is 
clear that when human umbilical vein endothelial cells (HUVEC) are treated 
with either micronutrient the number of tubules produced decrease when 
compared to untreated HUVECs (Fig 36). The reduction in the percentage 
number of tubules reduced from 100%, in untreated cells to 55% (p=<0.05) 
following treatment RCE and 50% (p=<0.001) when treated with RGSE. This 
suggested both micronutrients do exhibit anti-angiogenic properties. 
 
This phenomenon was also depicted when HUVECs were co-cultured against 
glioma cells (Fig 38). The percentage number of tubules reduced significantly 
(p=<0.05), following treatment with either RCE or RGSE. 
 
These results supported studies by Su et al (2005), who illustrated a reduced 
number of blood vessels in bladder cancer cells both in vitro and in vivo, after 
cells had been treated with genistein, the active compound found in RCE. 
Additionally grape seed extracts have been reported to reduce angiogenesis 
in breast cancer cells and prostate cancer cells in vitro (Kaur 2009). 
Furthermore this study suggested the mechanism by which grape seed 
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extracts inhibit this biological feature, is by inhibiting vascular endothelial 
growth factor (VEGF) (Wen 2008; Kanavi 2014). It is possible, therefore, for 
RCE and/or RGSE to affect any number of factors in the angiogenesis 
pathways including VEGF and MMPs. 
 
In brain tumors, VEGF was shown to be over expressed in gliomas compared 
to normal tissue (Osterberg 2016; Li 2009; Plate 1993; 1992). VEGF has been 
implicated as a central mediator of angiogenesis in GBs. In vitro and in vivo 
studies have confirmed a correlation between tumor grade and VEGF 
expression in gliomas (Kawai 2014). Additionally, studies using animal models 
have shown that inhibiting VEGF function also inhibits growth of glioma cells 
in vivo and causes regression of blood vessels (Maity 2000). Osterberg et al. 
(2016) illustrated myeloid cell-restricted VEGF-A deficiency led growth delays 
in gliomas. VEGF is known to enhance vascular permeability (Nagy 1989) and 
studies have shown that antibodies specific to VEGF reduced angiogenesis 
(Alishekevitz 2014).  
 
In addition some MMPs are thought to mediate angiogenesis (Nuttall 2003). 
MMP-2 and MMP-9 are highly expressed in astrocytic tumours and their 
expression positively correlates with tumour grade, especially those of MMP-9 
(Kargiotis 2006).  MMPs are involved in proteolytic degradation of ECM 
proteins to facilitate invasion and angiogenesis (Binder 2002). MMP-9 in 
particular, has also been shown to activate TGF- (Yu 2000) and to increase 
availability of VEGF (Bergers 2000), in turn promoting angiogenesis. 
 
As this study has shown that both micronutrients have anti-invasive and anti-
angiogenic properties it is possible they are acting through down-regulation of 
MMPs. Another MMP, which belongs to the membrane-type MMPs (MT-
MMPs), MT1-MMP is up-regulated in malignant gliomas with it’s expression is 
associated with tumour invasion and angiogenesis (Forsyth 1999; Nakada 
1998). MT-MMPs play a part in both invasion and angiogenesis (Hotary 2000; 
Hiraoka 1998) by cleaving ECM substrates and cell surface receptors, 
including integrins. MT1-MMP mediates activation of MMP2, which binds to 
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integrin v3 that promotes MMP2 maturation (Deryugina 2001). Interestingly, 
it has been shown that two growth factor-cytokine dependent pathways of 
angiogenesis exist that are promoted by distinct integrins one dependent on 
v3 and the other dependent on v5 (Friedlander 1995). It has been 
reported, that the key role of v3 integrin is in the survival and maturation of 
newly formed blood vessels (Ucuzian 2010). By using antagonists of this 
integrin, after angiogenesis is initiated, such antagonists induce apoptosis of 
the proliferating vascular cells without affecting pre-existing quiescent vessels 
(Brooks 1994), probably because v3 is shown to be selectively up-
regulated in proliferating vascular cells (Brooks 1994). Thus the down 
regulation of v could suggest decreased maturation of MMP2 and thus a 
decrease in the survival of newly formed blood vessels and thus 
angiogenesis.  Additionally over expression of MT1-MMP in glioma cells 
results in up-regulation of VEGF secretion and consequently increased 
invasion of endothelial cells and angiogenesis (Deryngina 2002).  
 
There are many mechanisms and pathways by which RCE and RGSE display 
anti-angiogenic potential, which warrant further investigation. As has been 
illustrated in this study invasion and angiogenesis are both affected by both 
micronutrients and therefore it is probable the mechanism by which they are 
both inhibited relies on the same molecules including integrins, MMPs and 
growth factors such as VEGF. 
147 | P a g e  
 
Conclusion 
 
This study examined the effect of red clover extract and red grape seed 
extract on cell viability, invasive potential, apoptotic potential and angiogenic 
potential in malignant human adult brain tumours in vitro. The evaluation of 
both micronutrient extracts indicated that both micronutrient extracts appear to 
display anti-cancer potential.  
 
It was reported that both micronutrients affect glioma cell viability, although it 
was identified that neither micronutrient exhibits pro-apoptotic properties 
implying cell viability may be resultant of an alternative pathway. The study 
also indicated both micronutrients affect the ability of glioma cells to invade 
across an extracellular matrix in vitro, thus suggesting both micronutrients 
have an effect on invasive potential. Examination of tubule viability and growth 
following treatment with either micronutrient resulted in a reduction of tubules 
when compared to untreated glioma cells, suggesting both micronutrients 
display an anti-angiogenic affect. This study has provided a firm foundation for 
further investigation into, the underlying mechanisms in which both 
micronutrient extracts affect cell viability, invasion and angiogenesis in human 
adult brain tumours.  
 
This novel find strongly suggests the vital need to investigate natural 
compounds such as the micronutrients within red clover extract and red grape 
seed extract for therapeutic roles for brain tumour therapy.  
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